HIV protease inhibitors

ABSTRACT

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. patent application Ser. No.08/190,764, filed on Feb. 2, 1994 now U.S. Pat. No. 5,484,926, which isa continuation-in-part of each of U.S. patent application Ser. Nos. (i)08/133,543 and (ii) 08/133,696, both filed on Oct. 7, 1993 and now bothabandoned, and a continuation-in-part of Ser. No. 08/137,254 filed onOct. 18, 1993, now abandoned which is a continuation-in-part of Ser. No.07/995,621 filed Dec. 22, 1992, now abandoned. The disclosures of thetwo parent applications, Ser. Nos. 08/133,543 and 08/133,696 (includingthe specification and claims as originally filed), are specificallyincorporated by reference herein, except for the "Background of theInvention" section of the specification of each application, with thecaveat that the definitions of preferences, terms, variables, labels andthe like used in each application are applicable only to thecorresponding disclosure from that application.

In particular, since each of the above-identified applicationsincorporated by reference was prepared separately, the originalapplications may use in some instances the same term, label or variableto mean something different. For example, the variable "X" is used ineach application, but each application has its own distinct definitionof the substituent or moiety represented by this variable. It will beapparent to those skilled in the art that the terms, labels andvariables in each application incorporated by reference are limitedsolely to the disclosure from that application, and may be replaced byother suitable terms, labels and variables or the like representing theparticular substituents and moieties. Of course, those skilled in theart will realize that any suitable set of terms, labels and variablesmay be used to generically or more specifically represent the subjectmatter disclosed in the present application, including terms, labels,variables, and the like universally applicable to the incorporateddisclosures of the above-identified applications and the followingdisclosure.

BACKGROUND OF THE INVENTION

This invention relates to a novel series of chemical compounds useful asHIV protease inhibitors and to the use of such compounds as antiviralagents.

Acquired Immune Deficiency Syndrome (AIDS) is a relatively newlyrecognized disease or condition. AIDS causes a gradual breakdown of thebody's immune system as well as progressive deterioration of the centraland peripheral nervous systems. Since its initial recognition in theearly 1980's, AIDS has spread rapidly and has now reached epidemicproportions within a relatively limited segment of the population.Intensive research has led to the discovery of the responsible agent,human T-lymphotropic retrovirus III (HTLV-III), now more commonlyreferred to as the human immunodeficiency virus or HIV.

HIV is a member of the class of viruses known as retroviruses. Theretroviral genome is composed of RNA which is converted to DNA byreverse transcription. This retroviral DNA is then stably integratedinto a host cell's chromosome and, employing the replicative processesof the host cells, produces new retroviral particles and advances theinfection to other cells. HIV appears to have a particular affinity forthe human T-4 lymphocyte cell which plays a vital role in the body'simmune system. HIV infection of these white blood cells depletes thiswhite cell population. Eventually, the immune system is renderedinoperative and ineffective against various opportunistic diseases suchas, among others, pneumocystic carini pneumonia, Karposis sarcoma, andcancer of the lymph system.

Although the exact mechanism of the formation and working of the HIVvirus is not understood, identification of the virus has led to someprogress in controlling the disease. For example, the drugazidothymidine (AZT) has been found effective for inhibiting the reversetranscription of the retroviral genome of the HIV virus, thus giving ameasure of control, though not a cure, for patients afflicted with AIDS.The search continues for drugs that can cure or at least provide animproved measure of control of the deadly HIV virus.

Retroviral replication routinely features post-translational processingof polyproteins. This processing is accomplished by virally encoded HIVprotease enzyme. This yields mature polypeptides that will subsequentlyaid in the formation and function of infectious virus. If this molecularprocessing is stifled, then the normal production of HIV is terminated.Therefore, inhibitors of HIV protease may function as anti-HIV viralagents.

HIV protease is one of the translated produces from the HIV structuralprotein pol gene. This retroviral protease specifically cleaves otherstructural polypeptides at discrete sizes to release these newlyactivated structural proteins and enzymes, thereby rendering the virionreplication-competent. As such, inhibition of the HIV protease by potentcompounds may prevent proviral integration of infected T-lymphocytesduring the early phase of the HIV-1 life cycle, as well as inhibit viralproteolytic processing during its late stage. Additionally, the proteaseinhibitors may have the advantages of being more readily available,longer lived in virus, and less toxic than currently available drugs,possibly due to their specificity for the retroviral protease.

In accordance with this invention, there is provided a novel class ofchemical compounds that can inhibit and/or block the activity of the HIVprotease, which halts the proliferation of HIV virus, pharmaceuticalcompositions containing these compounds, and the use of the compounds asinhibitors of the HIV protease.

SUMMARY OF THE INVENTION

The present invention relates to compounds falling within formula (1)below, and pharmaceutically acceptable salts thereof, that inhibit theprotease encoded by human immunodeficiency virus (HIV) type 1 (HIV-1) ortype 2 (HIV-2). These compounds are useful in the treatment of infectionby HIV and the treatment of the acquired immune deficiency syndrome(AIDS). The compounds, their pharmaceutically acceptable salts, and thepharmaceutical compositions of the present invention can be used aloneor in combination with other antivirals, immunomodulators, antibioticsor vaccines. Compounds of the present invention can also be used asprodrugs. Methods of treating AIDS, methods of treating HIV infectionand methods of inhibiting HIV protease are disclosed.

The compounds of the present invention are of the formula (1): ##STR1##wherein: Q₁ and Q₂ are independently selected from hydrogen andsubstituted and unsubstituted alkyl and aryl, and Q₁ and Q₂ may form aring with G.

Q₃ is selected from mercapto and substituted and unsubstituted alkoxyl,aryloxyl, thioether, amino, alkyl, cycloalkyl, saturated and partiallysaturated heterocycle, and aryl,

Q₄ -Q₈ are independently selected from hydrogen, hydroxyl, mercapto,nitro, halogen, --O--J, wherein J is a substituted or unsubstitutedhydrolyzable group, and substituted and unsubstituted alkoxyl, aryloxyl,thioether, acyl, sulfinyl, sulfonyl, amino, alkyl, cycloalkyl, saturatedand partially saturated heterocycle and aryl, and further wherein anyone of Q₄ -Q₈ may be a member of a spiro ring and any two of Q₄ -Q₈ maytogether be members or a ring,

Y and G are independently selected from oxygen, --NH, --N--alkyl,sulfur, selenium, and two hydrogen atoms,

D is carbon or nitrogen,

E is carbon or nitrogen,

Q₉ is selected from hydrogen, halogen, hydroxyl, mercapto, andsubstituted and unsubstituted alkoxyl, aryloxyl, thioether, amino,alkyl, and aryl, wherein Q₉ may form part of a ring,

A is a carbocycle or heterocycle, which is optionally furthersubstituted,

and B is a carbocycle or heterocycle, which is optionally furthersubstituted,

or a pharmaceutically acceptable salt thereof.

The invention also relates to compounds of formula (1), wherein allvariables are the same as those defined above for formula (1) with theexception of D, which is carbon or nitrogen, and is singly bonded toeach of the adjacent ring atoms.

The invention more particularly relates to preferred compounds offormula (1) wherein:

at least one of Q₁ and Q₂ is substituted or unsubstituted alkyl and theother is as defined above,

Q₃ is selected from thioether and aryl,

Q₄ -Q₈ are independently selected from hydrogen, hydroxyl, halogen,--O--J, wherein J is a substituted or unsubstituted hydrolyzable group,and substituted and unsubstituted acyl, alkoxyl, amino and alkyl, andfurther wherein any one or more of Q₄ -Q₈ may form a part of a ring,

Y and G are each oxygen,

D is nitrogen,

E is carbon or nitrogen,

Q₉ is hydrogen,

A is a carbocycle or heterocycle that is an aromatic or partiallysaturated, 5-7 membered mono-ring, which is optionally furthersubstituted,

and B is a heterocycle that is a saturated or partially saturated, 8-12membered poly-ring, which is optionally further substituted,

or a pharmaceutically acceptable salt thereof.

The invention even more particularly relates to compounds of the formula(1) wherein:

one of Q₁ and Q₂ is substituted or unsubstituted alkyl, preferablyt-butyl, and the other is hydrogen,

Q₃ is selected from thioaryl and aryl, preferably thiophenyl and phenyl,

Q₄ is alkyl, preferably methyl,

Q₅ is hydroxyl or --O--J, wherein J is a hydrolyzable group, orsubstituted or unsubstituted alkoxyl or amino,

Q₆ -Q₈ are independently selected from hydrogen, hydroxyl, halogen,--O--J, wherein J is a substituted or unsubstituted hydrolyzable group,and substituted and unsubstituted alkoxyl, acyl, amino and alkyl, andfurther wherein any one or more of Q₆ -Q₈ may form part of a ring,

Y and G are each oxygen,

D is nitrogen,

E is carbon,

Q₉ is hydrogen,

A is a carbocycle that is an aromatic, 5-6 membered monocyclic ring,preferably phenyl, which is optionally further substituted,

and B is a heterocycle that is a saturated, 6-14 membered monocyclic orpolycyclic ring, which is optionally further substituted, preferably ofthe formula ##STR2## wherein M₁ and M₂ are independently selected fromhydrogen, mercapto, hydroxyl, and substituted and unsubstitutedthioether, alkyl, alkoxyl, aryloxyl, amino, five membered heterocycleand carbocycle, sulfinyl, sulfonyl, and acyl, and wherein M₁ and M₂optionally form a ring having up to 10 members, wherein preferably M₁and M₂ independently have from zero to eight non-hydrogen atoms;

or a pharmaceutically acceptable salt thereof.

Preferred compounds of the formula (1) include those wherein:

one of Q₁ and Q₂ is tertiary alkyl, preferably t-butyl, and the other ishydrogen,

Q₃ is thiophenyl, phenyl, naphthyl, or thionaphthyl,

Q₄ is methyl,

Q₅ is hydroxyl, amino, or --O--J, wherein J is a substituted orunsubstituted hydrolyzable group,

Q₆ -Q₈ are independently selected from hydrogen, hydroxyl, halogen,--O--J, wherein J is a substituted or unsubstituted hydrolyzable group,and substituted and unsubstituted alkoxyl, acyl, amino and alkyl, andfurther wherein any one or more of Q₆ -Q₈ may form part of a ring,

Y and G are each oxygen,

D is nitrogen,

E is carbon,

Q₉ is hydrogen,

A is phenyl, which is optionally further substituted,

and B is a heterocycle that is a saturated, 9-10 membered bi-ring,preferably decahydroisoquinolinyl or octahydrothieno 3,2,-c!pyridinyl,

or a pharmaceutically acceptable salt thereof.

According to certain embodiments, the portion of formula (1): ##STR3##is designated as Z or Z¹, and/or the portion of formula (1): ##STR4## isdesignated as X or X¹.

According to certain of those embodiments, the compounds have theformula 1(A): ##STR5## wherein: Z is a group having the structure:##STR6## where: a is 1, 2, 3, 4, or 5;

b is 1, or 2;

c is 1, or 2;

d is 1, 2, 3, or 4;

each R² is independently hydrogen, hydroxy, thiol, halo, amino, C₁ -C₄alkylamino, di(C₁ -C₄)alkylamino, nitro, carboxy, C₁ -C₆ alkyl, C₁ -C₆alkoxy, C₁ -₆ alkylthio, halo(C₁ -C₄)alkyl, hydroxy(C₁ -C₄)alkyl, C₁ -C₆alkylthio(C₁ -C₆)alkyl, C₁ -C₄ alkoxycarbonyl, carbamoyl, N-(C₁ -C₄)alkylcarbamoyl, C₁ -C₄ alkylsulfonyl, N,N-di(C₁ -C₄)alkylcarbamoyl, orC₁ -C₄ alkylsulfonylamino;

A¹ and A² are independently --CH₂ -- or --N(R⁸)--;

A³ and A⁴ are independently --CH-- or --N--;

A⁵ and A⁶ are independently --CH₂ -- or --N(R⁹)--;

A⁷ and A⁸ are independently --CH-- or --N--;

R⁸ is hydrogen or C₁ -C₄ alkyl;

R⁹ is hydrogen or C₁ -C₄ alkyl;

R¹ is aryl, or --S-aryl;

X is a group having the structure: ##STR7## where: R is hydrogen, C₁ -C₄alkyl, or --CH₂ -pyridyl;

R³ is a group having the structure:

1) --C(O)--NR⁴ R⁴, ##STR8## p is 4 or 5; R⁴ at each occurrence isindependently hydrogen, C₁ -C₆ alkyl or hydroxy(C₁ -C₄)alkyl; and

R⁵ and R⁶ are independently selected from hydrogen, hydroxy, C₁ -C₆alkyl, C₁ -C₆ alkoxy, or hydroxy(C₁ -C₄)alkyl; with the provisos that:

(1) one of A¹ and A² must be --N(R⁸)--;

(2) A¹ and A² cannot both be --N(R⁸)--;

(3) A³ and A⁴ cannot both be --N--;

(4) one of A⁵ and A⁶ must be --N(R⁹)--;

(5) A⁵ and A⁶ cannot both be --N(R⁹)--;

(6) A⁷ and A⁸ cannot both be --N--;

or a pharmaceutically acceptable salt thereof.

Also, according to certain of those embodiments, the compounds have theformula 1(B): ##STR9## wherein: R¹ is aryl, or --S-aryl;

X¹ is a group having the formula: ##STR10## R² is hydrogen, halo, or C₁-C₄ alkyl; R₃ is a group having the structure:

1) --C(O)--NR⁴ R⁴, ##STR11## p is 4 or 5; R⁴ at each occurrence isindependently hydrogen, C₁ -C₆ alkyl or hydroxy (C₁ -C₄) alkyl; and

R⁵ and R⁶ are independently selected from hydrogen, hydroxy, C₁ -C₆alkyl, C₁ -C₆ alkoxy, or hydroxy (C₁ -C₄) alkyl;

Z¹ is a group having the structure: ##STR12## where: a is 1, 2, 3, 4, or5;

b is 1, or 2;

c is 1, or 2;

d is 1, 2, 3, or 4

each R⁷ is independently hydrogen, hydroxy, thiol, halo, amino, C₁ -C₄alkylamino, di(C₁ -C₄) alkylamino, nitro, carboxy, C₁ -C₆ alkyl, C₁ -C₆alkoxy, C₁ -C₄ alkylthio, halo(C₁ -C₄)alkyl, hydroxy(C₁ -C₄)alkyl, C₁-C₄ alkylthio(C₁ -C₄)alkyl, C₁ -C₄ alkoxycarbonyl, carbamoyl, N-(C₁-C₄)alkylcarbamoyl, C₁ -C₄ alkylsulfonyl, N,N-di(C₁ -C₄)alkylcarbamoyl,or C₁ -C₄ alkylsulfonylamino;

A¹ and A² are independently --CH₂ -- or --N(R⁸)--;

A³ and A⁴ are independently --CH-- or --N--;

A⁵ and A⁶ are independently --CH₂ -- or --N(R⁹)--;

A⁷ and A⁸ are independently --CH-- or --N--;

R⁸ is hydrogen or C₁ -C₄ alkyl;

R⁹ is hydrogen or C₁ -C₄ alkyl;

T² is hydrogen, or C₁ -C₄ alkyl;

with the provisos that:

(1) one of A¹ and A² must be --N(R⁸)--;

(2) A¹ and A² cannot both be --N(R⁸)--;

(3) A³ and A⁴ cannot both be --N--;

(4) one of A⁵ and A⁶ must be --N(R⁹)--;

(5) A⁵ and A⁶ cannot both be --N(R⁹)--;

(6) A⁷ and A⁸ cannot both be --N--;

or a pharmaceutically acceptable salt thereof.

Preferred species of the formula (1) are:3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide and its pharmaceuticallyacceptable salts, especially methanesulfonic acid salt, and its prodruganalogs, wherein the 3"hydroxy is converted to --O--J, as defined above,especially the dihydrogen phosphate hydrochloride salt; and6S-(6R*,3aS*,7aR*,2'S*,3'S*)!-2- 2'-hydroxy-3'-phenylthiomethyl-4'aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydro-thieno3,2-c!pyridine-6-N-t-butylcarboxamide and its pharmaceuticallyacceptable salts, especially methanesulfonic acid salt, and its prodruganalogs, wherein the 3" hydroxy is converted to --O--J, as definedabove.

The present invention further provides pharmaceutical formulationscomprising an effective amount of a compound of formula (1) or apharmaceutically acceptable salt thereof, in combination with apharmaceutically acceptable carrier, such as a diluent or excipient.

The present invention further provides a method of treating AIDScomprising administering to a host or patient, such as a primate, aneffective amount of a compound of the present invention.

The present invention further provides a method of inhibiting HIVreplication comprising administering to an HIV infected cell, a cellsusceptible to HIV infection or a host or patient, such as a primate, aneffective amount of a compound of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides new compounds falling within formula (1),as described above, that are useful for treating HIV infection and/orAIDS.

Compounds of the formula (1) may be prodrugs. For example, compoundswherein at least one of Q₄ -Q₈ is --O--J, as defined above, may be usedas prodrugs, which can serve to improve the pharmaceutical properties ofthe compounds, such as pharmacokinetic properties, for example, improvedbioavailability or solubility. The preparation of the prodrugs may becarried out by reacting a compound of the formula (1), wherein at leastone of Q₄ -Q₈ is --O--H, with, for example, an activated amino acyl,phosphoryl or hemisuccinyl derivative.

All temperatures stated herein are in degrees Celsius (°C.). All unitsof measurement employed herein are in weight units except for liquidswhich are in volume units.

The term "alkyl" as used herein refers to straight or branched chaingroups, preferably, having one to eight, more preferably having one tosix, and most preferably having from one to four carbon atoms. The term"C₁ -C₆ alkyl" represents a straight or branched alkyl chain having fromone to six carbon atoms. Exemplary C₁ -C₆ alkyl groups include methyl,ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl,neo-pentyl, hexyl, isohexyl, and the like. The term "C₁ -C₆ alkyl"includes within its definition the term "C₁ -C₄ alkyl".

The term "cycloalkyl" represents a saturated or partially saturated,mono- or poly-carbocylic ring, preferably having 5-14 ring carbon atoms.Exemplary cycloalkyls include monocyclic rings having from 3-7,preferably 3-6, carbon atoms, such as cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cycloheptyl and the like. An exemplarycycloalkyl is a C₅ -C₇ cycloalkyl, which is a saturated hydrocarbon ringstructure containing from five to seven carbon atoms.

The term "alkoxyl" represents --O-alkyl. An example of an alkoxyl is aC₁ -C₆ alkoxyl, which represents a straight or branched alkyl chainhaving from one to six carbon atoms attached to an oxygen atom.Exemplary C₁ -C₆ alkoxyl groups include methoxyl, ethoxyl, propoxyl,isopropoxyl, butoxyl, sec-butoxyl, t-butoxyl, pentoxyl, hexoxyl, and thelike. C₁ -C₆ alkoxyl includes within its definition a C₁ -C₄ alkoxyl.

The term "aryl" as used herein refers to a carbocyclic or heterocyclic,aromatic, 5-14 membered monocyclic or polycyclic ring. Exemplary arylsinclude phenyl, naphthyl, anthryl, phenanthryl, thienyl, pyrrolyl,imidazolyl, pyrazolyl, furyl, isothiazolyl, furazanyl, isoxazolyl,thiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl,benzo b!thienyl, naphtho 2,3-b!thianthrenyl, isobenzofuranyl, chromenyl,xanthenyl, phenoxathienyl, indolizinyl, isoindolyl, indolyl, indazolyl,purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl,quinoxyalinyl, quinzolinyl, benzothiazolyl, benzimidazolyl,tetrahydroquinolinyl, cinnolinyl, pteridinyl, carbazolyl,beta-carbolinyl, phenanthridinyl, acridinyl, perimidinyl,pnenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, andphenoxazinyl.

The term "aryloxyl" represents --O-aryl.

The term "hydrolyzable groupt" is a group, which when bonded to anoxygen, forms an ester, which can be hydrolyzed in vivo to a hydroxylgroup. Exemplary hydrolyzable groups, which are optionally substituted,include acyl function, sulfonate function and phosphate function. Forexample, such hydrolyzable groups include blocked or unblocked aminoacid residue, a hemisuccinate residue, and a nicotinate residue.

The term "halogen" represents chlorine, fluorine, bromine or iodine. Theterm "halo" represents chloro, fluoro, bromo or iodo.

The term "carbocycle" represents an aromatic or a saturated or apartially saturated 5-14 membered monocyclic or polycyclic ring, such asa 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring,wherein all the ring members are carbon atoms.

The term "heterocycle" represents an aromatic or a saturated or apartially saturated, 5-14 membered, monocylic or polycyclic ring, suchas a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring,having from one to three heteroatoms selected from nitrogen, oxygen andsulfur, and wherein any nitrogen and sulfur heteroatoms may optionallybe oxidized, and any nitrogen heteroatom may optionally be quaternized.The heterocyclic ring may be attached at any suitable heteroatom orcarbon atom. Examples of such heterocycles includedecahydroisoquinolinyl, octahydro-thieno 3,2-c!pyridinyl, piperidinyl,piperazinyl, azepinyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl,imidazolyl, isobenzofuranyl, furazanyl, imidazolinyl, imidazolidinyl,pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl,isoxazolyl, thianthrenyl, triazinyl, isoxazolidinyl, morpholinyl,thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl,indolyl, quinolinyl, chromenyl, xanthenyl, isoquinolinyl,benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoazolyl,furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, benzob!thienyl, naphtho 2,3-b!thienyl, thiamorpholinyl,thiamorpholinylsulfoxide, thiamorpholinylsulfone, oxadiazolyl,triazolyl, tetrahydroquinolinyl, tetrahydrisoquinolinyl, phenoxathienyl,indolizinyl, isoindolyl, indazolyl, purinyl, isoquinolyl, quinolyl,phthalazinyl, naphthyridinyl, quinoxyalinyl, quinzolinyl,tetrahydroquinolinyl, cinnolinyl, pteridinyl, carbazolyl,beca-carbolinyl, phenanthridinyl, acridinyl, perimidinyl,phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, andphenoxazinyl.

The term "thioether" includes S-aryl, such as phenylthio andnaphthylthio; S-heterocycle where the heterocycle is saturated orpartially saturated; S-(C₅ -C₇)-cycloalkyl; and S-alkyl, such as C₁ -C₆alkylthio. In the thioether, the -aryl, the -heterocycle, the-cycloalkyl and the -alkyl can optionally be substituted. An example ofa thioether is "C₁ -C₆ alkylthio", which represents a straight orbranched alkyl chain having from one to six carbon atoms attached to asulfur atom. Exemplary C₁ -C₆ alkylthio groups include methylthio,echylthio, propylthio, isopropylthio, butylthio, sec-butylthio,t-butylthio, pentylthio, hexylthio, and the like.

The term "mercapto" represents --SH.

The term "amino" represents --NL₁ L₂, wherein L₁ and L₂ are preferablyindependently selected from oxygen, carbocycle, heterocycle, alkyl,sulfonyl and hydrogen; or NC(O)L₃ wherein L₃ is preferably alkyl,alkoxyl, hydrogen or --NL₁ L₂. The aryl, alkyl and alkoxyl groups canoptionally be substituted. An example of an amino is C₁ -C₄ alkylamino,which represents a straight or branched alkyl chain having from one tofour carbon atoms attached to an amino group. Exemplary C₁ -C₄alkylamino groups include methylamino, ethylamino, propylamino,isopropylamino, butylamino, sec-butylamino, and the like. Anotherexample of an amino is di(C₁ -C₄)alkylamino, which represents twostraight or branched alkyl chains, each having from one to four carbonatoms attached to a common amino group. Exemplary di(C₁ -C₄)alkylaminogroups include dimethylamino, ethylmethylamino, methylpropylamino,ethylisopropylamino, butylmethylamino, sec-butylethylamino, and thelike. An example of an amino is C₁ -C₄ alkylsulfonylamino, which has astraight or branched alkyl chain having from one to four carbon atomsattached to a sulfonylamino moiety. Exemplary C₁ -C₄ alkylsulfonylaminogroups include methylsulfonylamino, ethylsulfonylamino,propylsulfonylamino, isopropylsulfonylamino, butylsulfonylamino,sec-butylsulfonylamino, t-butylsulfonylamino, and the like.

The term "acyl" represents L₆ C(O)L₄, wherein L₆ is a single bond, --Oor --N, and further wherein L₄ is preferably alkyl, amino, hydroxyl,alkoxyl or hydrogen. The alkyl and alkoxyl groups can optionally besubstituted. An exemplary acyl is a C₁ -C₄ alkoxycarbonyl, which is astraight or branched alkoxyl chain having from one to four carbon atomsattached to a carbonyl moiety. Exemplary C₁ -C₄ alkoxycarbonyl groupsinclude methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,isopropoxycarbonyl, butoxycarbonyl, and the like. Another exemplary acylis a carboxy wherein L₆ is a single bond and L₄ is alkoxyl, hydrogen, orhydroxyl. A further exemplary acyl is N-(C₁ -C₄)alkylcarbamoyl (L₆ is asingle bond and L₄ is an amino), which is a straight or branched alkylchain having from one to four carbon atoms attached to the nitrogen atomof a carbamoyl moiety. Exemplary N-(C₁ -C₄)alkylcarbamoyl groups includeN-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl,N-isopropylcarbamoyl, N-butylcarbamoyl, and N-t-butylcarbamoyl, and thelike. Yet another exemplary acyl is N,N-di(C₁ -C₄)alkylcarbamoyl, whichhas two straight or branched alkyl chains, each having from one to fourcarbon atoms attached to the nitrogen atom of a carbamoyl moiety.Exemplary N,N-di(C₁ -C₄)alkylcarbamoyl groups includeN,N-dimethylcarbamoyl, N,N-ethylmethylcarbamoyl,N,N-methylpropylcarbamoyl, N,N-ethylisopropylcarbamoyl,N,N-butylmethylcarbamoyl, N,N-sec-butylethylcarbamoyl, and the like.

The term "sulfinyl" represents --SO-L₅, wherein L₅ is preferably alkyl,amino, aryl, cycloalkyl or heterocycle. The alkyl, aryl, cycloalkyl andheterocycle can all optionally be substituted.

The term "sulfonyl" represents --SO₂ -L₅, wherein L₅ is preferablyalkyl, aryl, cycloalkyl, heterocycle or amino. The alkyl, aryl,cycloalkyl and heterocycle can all optionally be substituted. An exampleof a sulfonyl is a C₁ -C₄ alkylsulfonyl, which is a straight or branchedalkyl chain having from one to four carbon atoms attached to a sulfonylmoiety. Exemplary C₁ -C₄ alkylsulfonyl groups include methylsulfonyl,ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl,sec-butylsulfonyl, t-butylsulfonyl and the like.

As indicated above, many of the groups are optionally substituted.Examples of substituents for alkyl and aryl include mercapto, thioether,nitro (NO₂), amino, aryloxyl, halogen, hydroxyl, alkoxyl, and acyl, aswell as aryl, cycloalkyl and saturated and partially saturatedheterocycles. Examples of substituents for heterocycle and cycloalkylinclude those listed above for alkyl and aryl, as well as aryl andalkyl.

Exemplary substituted aryls include a phenyl or naphthyl ringsubstituted with one or more substituents, preferably one to threesubstituents, independently selected from halo, hydroxy, morpholino(C₁-C₄)alkoxy carbonyl, pyridyl (C₁ -C₄)alkoxycarbonyl, halo (C₁ -C₄)alkyl,C₁ -C₄ alkyl, C₁ -C₄ alkoxy, carboxy, C₁ C₄ alkoxycarbonyl, carbamoyl,N-(C₁ -C₄)alkylcarbamoyl, amino, C₁ -C₄ alkylamino, di(C₁ -C₄)alkylaminoor a group of the formula --(CH₂)_(a) -R⁷ where a is 1, 2, 3 or 4; andR⁷ is hydroxy, C₁ -C₄ alkoxy, carboxy, C₁ -C₄ alkoxycarbonyl, amino,carbamoyl, C₁ -C₄ alkylamino or di(C₁ -C₄)alkylamino.

Another substituted alkyl is halo(C₁ -C₄)alkyl, which represents astraight or branched alkyl chain having from one to four carbon atomswith 1-3 halogen atoms attached to it. Exemplary halo(C₁ -C₄)alkylgroups include chloromethyl, 2-bromoethyl, 1-chloroisopropyl,3-fluoropropyl, 2,3-dibromobutyl, 3-chloroisobutyl, iodo-t-butyl,trifluoromethyl and the like.

Another substituted alkyl is hydroxy(C₁ -C₄)alkyl, which represents astraight or branched alkyl chain having from one to four carbon atomswith a hydroxy group attached to it. Exemplary hydroxy(C₁ -C₄)alkylgroups include hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl,2-hydroxyisopropyl, 4-hydroxybutyl and the like.

Yet another substituted alkyl is C₁ -C₄ alkylthio(C₁ -C₄)alkyl, which isa straight or branched C₁ -C₄ alkyl group with a C₁ -C₄ alkylthio groupattached to it. Exemplary C₁ -C₄ alkylthio(C₁ -C₄)alkyl groups includemethylthiomethyl, ethylthiomethyl, propylthiopropyl,sec-butylthiomethyl, and the like.

Yet another exemplary substituted alkyl is heterocycle(C₁ -C₄ )alkyl,which is a straight or branched alkyl chain having from one to fourcarbon atoms with a heterocycle attached to it. Exemplary heterocycle(C₁-C₄)alkyls include pyrrolylmethyl, quinolinylmethyl, 1-indolylethyl,2-furylethyl, 3-thien-2-ylpropyl, 1-imidazolylisopropyl,4-thiazolylbutyl and the like.

Yet another substituted alkyl is aryl(C₁ -C₄)alkyl, which is a straightor branched alkyl chain having from one to four carbon atoms with anaryl group attached to it. Exemplary aryl(C₁ -C₄)alkyl groups includephenylmethyl, 2-phenylethyl, 3-naphthyl-propyl, 1-naphthylisopropyl,4-phenylbutyl and the like.

The heterocycle can, for example, be substituted with 1, 2 or 3substituents independently selected from halo, halo(C₁ -C₄)alkyl, C₁ -C₄alkyl, C₁ -C₄ alkoxy, carboxy, C₁ -C₄ alkoxycarbonyl, carbamoyl, N-(C₁-C₄)alkylcarbamoyl, amino, C₁ -C₄ alkylamino, di(C₁ -C₄)alkylamino or agroup having the structure --(CH₂)_(a) -R⁷ where a is 1, 2, 3 or 4 andR⁷ is hydroxy, C₁ -C₄ alkoxy, carboxy, C₁ -C₄ alkoxycarbonyl, amino,carbamoyl, C₁ -C₄ alkylamino or di(C₁ -C₄)alkylamino.

Examples of substituted heterocycles include 3-N-t-butyl carboxamidedecahydroisoquinolinyl, 6-N-t-butyl carboxamide octahydro-thieno3,2-c!pyridinyl, 3-methylimidazolyl, 3-methoxypyridyl,4-chloroquinolinyl, 4-aminothiazolyl, 8-methylquinolinyl,6-chloroquinoxalinyl, 3-ethylpyridyl, 6-methoxybenzimidazolyl,4-hydroxyfuryl, 4-methylisoquinolinyl, 6,8-dibromoquinolinyl,4,8-dimethylnaphthyl, 2-methyl-1,2,3,4-tetrahydroisoquinolinyl,N-methyl-quinolin-2-yl, 2-t-butoxycarbonyl-1,2,3,4-isoquinolin-7-yl andthe like.

Exemplary heterocyclic ring systems represented by A or B include (1)5-membered monocyclic ring groups such as thienyl, pyrrolyl, imidazolyl,pyrazolyl, furyl, isothiazolyl, furazanyl, isoxazolyl, thiazolyl and thelike; (2) 6-membered monocyclic groups such as pyridyl, pyrazinyl,pyrimidinyl, pyridazinly, triazinyl and the like; and (3) polycyclicheterocyclic rings groups, such as decahydroisoquinolinyl,octahydro-thieno 3,2-c! pyridinyl, benzo b!thienyl, naphtho2,3-b!thianthrenyl, isobenzofuranyl, chromenyl, xanthenyl, and fully orpartially saturated analogs thereof.

A cycloalkyl may be optionally substituted with 1, 2 or 3 substituentsindependently selected from halo, halo(C₁ -C₄)alkyl, C₁ -C₄ alkyl, C₁-C₄ alkoxy, carboxy, C₁ -C₄ alkoxycarbonyl, carbamoyl, N-(C₁-C₄)alkylcarbamoyl, amino, C₁ -C₄ alkylamino, di(C₁ -C₄ )alkylamino or agroup having the structure --(CH₂)_(a) -R⁷ where a is 1, 2, 3 or 4 andR⁷ is hydroxy, C₁ -C₄ alkoxy, carboxy, C₁ -C₄ alkoxycarbonyl, amino,carbamoyl, C₁ -C₄ alkylamino or di(C₁ -C₄)alkylamino. Exemplarysubstituted cycloalkyl groups include 3-methylcyclooentyl,4-ethoxycyclohexyl, 5-carboxycyclo-heptyl, 6-chlorocyclohexyl and thelike.

Exemplary substituted hydrolyzable groups include N-benzyl glycyl,N-Cbz-L-valyl, and N-methyl nicotinate.

Exemplary compounds of formula (1) include those compounds of formula Iin each of the incorporated applications Ser. Nos. 08/137,254,08/133,696, and 08/133,543 that fall within the scope of formula (1) asdefined herein.

The compounds of the present invention have at least two asymmetriccenters denoted by an asterisk in the formula (1) below: ##STR13##

As a consequence of these asymmetric centers, the compounds of thepresent invention can occur in any of the possible stereoisomeric forms,and can be used in mixtures of stereoisomers, which can be opticallyactive or racemic, or can be used alone as essentially purestereisomers, i.e., at least 95% pure. All asymmetric forms, individualstereoisomers and combinations thereof, are within the scope of thepresent invention.

The individual stereosomers may be prepared from their respectiveprecursors by the procedures described above, by resolving the racemicmixt ures, or by s eparating the diastereomers. The resolution can becarried out in the presence of a resolving agent, by chromatography orby repeated crystallization or by some combination of these techniqueswhich are known in the art. Further details regarding resolutions can befound in Jacques et al., Enantiomers, Racemates, and Resolutions, JohnWiley & Sons 1981.

Preferably, the compounds of the present invention are substantiallypure, i.e, over 50% pure. More preferably, the compounds are at least75% pure. Even more preferably, the compounds are more than 90% pure.Even more preferably, the compounds are at least 95% pure, morepreferably, at least 97% pure, and most preferably at least 99% pure.

As mentioned a bove, the invention includes the pharmaceuticallyacceptable salts of the compounds defined by formula (1). A compound ofthis invent ion may possess a sufficiently acidic, a sufficiently basic,or both functional groups, and accordingly react with any of a number ofinorganic or organic bases, and inorganic and organic acids, to form apharmaceutically acceptable salt.

The term "pharmaceutically acceptable salt", as used herein, refers tosalts of the compounds of the above formula which are substantiallynon-toxic to living organisms. Exemplary pharmaceutically acceptablesalts include those salts prepared by reaction of the compounds of thepresent invention with a mineral or organic acid or an inorganic base.The reactants are generally combined in a mutual solvent such asdiethylether or benzene, for acid addition salts, or water or alcoholsfor base addition salts. The salts normally precipitate out of solutionwithin about one hour to about ten days and can be isolated byfiltration or other conventional methods. Such salts are known as acidaddition and base addition salts.

Acids that may be employed to form acid addition salts are inorganicacids such as hydrochloric acid, hydrobromic acid, hydroiodic acid,sulfuric acid, phosphoric acid, and the like, and organic acids such asp-toluenesulfonic, methanesulfonic acid, oxalic acid,p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid,benzoic acid, acetic acid, and the like.

Examples of pharmaceutically acceptable salts are the sulfate,pyrosulfate, bisulfate, sulfite, bisulfite, phosphate,monohydrogenphosphate, dihydrogenphosphate, metaphosphate,pyrophosphate, chloride, bromide, iodide, acetate, propionate,decanoate, caprylate, acrylate, formate, isobutyrate, caproate,heptanoate, propiolate, oxalate, malonate, succinate, suberate,sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate,benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate,hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate,phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate,g-hydroxybutyrate, glycollate, tartrate, methane-sulfonate,propanesulfonate, naphthalene-1-sulfonate, napththalene-2-sulfonate,mandelate and the like.

Preferred pharmaceutically acceptable acid addition salts are thoseformed with mineral acids such as hydrochloric acid and hydrobromicacid, and those formed with organic acids such as maleic acid andmethanesulfonic acid.

Base addition salts include those derived from inorganic and organicbases, such as ammonium or alkali or alkaline earth metal hydroxides,carbonates, bicarbonates, and the like. Such bases useful in preparingthe salts of this invention thus include sodium hydroxide, potassiumhydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate,sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calciumcarbonate and the like. The potassium and sodium salt forms areparticularly preferred.

It should be recognized that the particular counterion forming a part ofany salt of this invention is not of a critical nature, so long as thesalt as a whole is pharmacologically acceptable and as long as thecounterion does not contribute undesired qualities to the salt as awhole.

Certain compounds are those compounds of formula 1 (A) above wherein:

Z is a group having the structure: ##STR14## R² is hydrogen, hydroxy, C₁-C₄ alkyl, halo, amino, nitro, or trifluoromethyl;

a is 1, 2, or 3;

c is 1; and

R³ is --C(O)NR⁴ R⁴ ;

or a pharmaceutically acceptable salt thereof.

Of these compounds, more preferred are those compounds where:

Z is ##STR15## R² is hydrogen, methyl, ethyl, propyl, chloro, fluoro,hydroxy, or amino;

X is ##STR16## R is --CH₂ -pyridyl; R¹ is phenyl or --S-phenyl; and

R³ is --C(O)NH(R⁴);

or a pharmaceutically acceptable salt thereof.

Of these compounds, especially preferred are those compounds where:

Z is ##STR17## R^(2a) is methyl, ethyl, or propyl; R^(2b) is hydrogen,hydroxy, or amino;

R^(2c) is hydrogen, hydroxy, or amino;

X is ##STR18## and R³ is --C(O)NH(t-butyl);

or a pharmaceutically acceptable salt thereof.

Certain other preferred compounds are those compounds of formula 1 (B)wherein:

X¹ is ##STR19## T² is hydrogen or methyl; Z¹ is a group having thestructure: ##STR20## R⁷ is hydrogen, C₁ -C₄ alkyl, halo, nitro, amino,hydroxy; a is 1, 2, or 3;

c is 1;

or a pharmaceutically acceptable salt thereof.

Of these compounds, more preferred are those compounds where:

Z¹ is ##STR21## R⁷ is hydrogen, methyl, ethyl, hydroxy, amino, chloro;R¹ is --S-phenyl, or --S-naphth-2-yl; and

R³ is --C(O)NR⁴ R⁴ ;

or a pharmacaceutically acceptable salt thereof.

Of these compounds, especially preferred are those compounds where:

Z¹ is ##STR22## R⁷ a is hydrogen, methyl, ethyl, chloro, bromo, orfluoro; R⁷ b is hydrogen, hydroxy, chloro, or amino;

R⁷ c is hydrogen, hydroxy, or amino;

R³ is --C(O)NH(t-butyl);

or a pharmaceutically acceptable salt thereof.

Preferred compounds are:

2-2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide:##STR23## 2-2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamidemethanesulfonic acid salt: ##STR24## 2-2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide3"-dihydrogen phosphate hydrochloride salt: ##STR25## 2-2'-hydroxy-3'-phenylthiomethyl-4'aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydro-thieno3,2-c!pyridine-6-N-t-butylcarboxamide: ##STR26## and 2-2'-hydroxy-3'-phenylthiomethyl-4'aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydro-thieno3,2-c!pyridine-6-N-t-butylcarboxamide methanesulfonic acid salt:##STR27##

Each of the above five formulae has five assymetric centers and thusdefines a compound selected from the group of 32 individualstereoisomers and any mixture of two or more stereoisomers.

Preferred stereoisomers of these compounds are:

3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide:##STR28## 3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamidemethanesulfonic acid salt: ##STR29## 3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide3"-dihydrogen phosphate hydrochloride salt: ##STR30##6S-(6R*,3aS*,7aR*,2'S*,3'S*)!-2-2'-hydroxy-3'-phenylthiomethyl-4'aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydro-thieno3,2-c!pyridine-6-N-t-butylcarboxamide: ##STR31## and6S-(6R*,3aS*,7aR*,2'S*,3'S*)!-2-2'-hydroxy-3'-phenylthiomethyl-4'aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydro-thieno 3,2-c!pyridine-6-N-t-butylcarboxamidemethanesulfonic acid salt: ##STR32## 3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-propyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide;##STR33## 2S-(2R*,2'S*,3'S*)!-1-2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(3"-hydroxy-2"-methylphenyl)pentyl!-4-pyrid-3"-ylmethylpiperazine-2-N-t-butylcarboxamide; ##STR34##3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(1",2",3",4"-tetrahydroquinolin-5"-yl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide; ##STR35##3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide;##STR36## 3S-(3R*,4aR*,8aR*,2'S*,3'*)!-2-2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-ethyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide;##STR37## 2'R-(2'R*,3'S*)!-N-t-butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(1",2",3",4"-tetrahydroquinolin-5"-yl)pentyl!benzamide;

2'R-(2'R*,3'S*)!-N-t-butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!benzamide;

2'R-(2'R*,3'S*)!-N-t-butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3",5"-diaminophenyl)pentyl!benzamide;

2'R-(2'R*,3'S*)!-N-t-butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-1-naphthylamide;and

2'R-(2'R*,3'S*)!-N-t-butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-chloro-3"-aminophenyl)pentyl!-1-naphthylamide;

or a pharmaceutically acceptable salt of any of the foregoing mostpreferred compounds.

The compounds of formula 1 can be prepared according to the followingReaction I. ##STR38## where the variables are as defined for formula 1above.

Reaction I is a standard coupling reaction commonly employed in thesynthesis of amides which is carried out by reacting an appropriatelysubstituted amine of formula IA, with an appropriately substitutedcarboxylic acid reactant of formula IB, in an aprotic solvent or mixtureof solvents. The reaction is carried out in the presence or absence of apromoting agent, preferably in the presence of a promoting agent, and inthe presence of a coupling reagent. Typical aprotic solvents for thisreaction are tetrahydrofuran and dimethylformamide, or a mixture of suchsolvents. The reaction is carried out at a temperature from about -300°C. to about 250° C. The amine reactant is generally employed inequimolar proportions relative to the carboxylic acid reactant, in thepresence of an equimolar quantity to a slight excess of the couplingreagent. Typical coupling reagents include the carbodiimides such asdicyclohexylcarbodiimide (DCC) and N,N'-diethylcarbodiimide; theimidazoles such as carbonyldiimidazole; as well as reagents such asbis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl) orN-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). A preferredcoupling reagent for this reaction is DCC. A promoting agent ispreferably included for this reaction; a preferred promoting agent ishydroxybenzotriazole hydrate (HOBT.H₂ O).

Once the reaction is complete, the compound may be isolated, if desired,by procedures known in the art, for example, the compound may becrystallized and then collected by filtration, or the reaction solventmay be removed by extraction, evaporation or decantation. The compoundmay be further purified, if desired, by common techniques such ascrystallization or chromatography over solid supports such as silica gelor alumina.

The starting compounds of formula IA may be prepared according to theprocedures shown in Reaction Scheme A. ##STR39## where: V^(A) is anamino-protecting group;

B, D, G, Q₁, Q₂, Q₃, and Q₉ are defined the same as they are definedabove for formula (1); and

ZZ is halo.

Reaction Scheme A, above, is accomplished by carrying out reactions 1-7in sequential order. Once a reaction is complete, the intermediatecompound may be isolated, if desired, by procedures known in the art,for example, the compound may be crystallized and then collected byfiltration, or the reaction solvent may be removed by extraction,evaporation or decantation. The intermediate compound may be furtherpurified, if desired, by common techniques such as crystallization orchromatography over solid supports such as silica gel or alumina, beforecarrying out the next step of the reaction scheme.

Reaction A.1 is carried out by converting an amino-protected carboxylicacid reactant having the structure: ##STR40## to the corresponding mixedanhydride under conditions known in the art. For example, theamino-protected carboxylic acid reactant may be reacted with a C₁ -C₆alkylchloroformate, such as isobutylchloroformate preferably in thepresence of an acid scavenger. Preferred acid scavengers are thetrialkylamines, preferably triethylamine. The reaction is typicallycarried out in an aprotic solvent such as ethyl acetate. Solvent choiceis not critical so long as the solvent employed is inert to the ongoingreaction and the reactants are sufficiently solubilized to effect thedesired reaction. The resulting mixed anhydride reactant is preferablyused in Reaction A.2 without further isolation or purification.

Reaction A.2 is accomplished in two steps. First, a solution of sodiumhydroxide, covered with a layer of an ether solvent, preferably diethylether, is reacted with a large excess ofN-methyl-N-nitro-N-nitrosoguanidine to form a diazomethane reactant. Thesodium hydroxide is preferably used as an aqueous solution having aboutfour to six mol/liter of sodium hydroxide. Once this reaction issubstantially complete, the organic layer is dried over a dessicant suchas potassium hydroxide. This solution is then reacted with the mixedanhydride from Reaction A.1, above, to form the correspondingalpha-diazo carbonyl compound. The diazomethane reactant is preferablyused in this reaction without isolation or purification. The reaction istypically carried out at a temperature of from about -50° C. to about-10°C., preferably about -20° C.

In Reaction A.3, the alpha-diazo carbonyl compound prepared in ReactionA.2 is reacted with an acid of the formula H-ZZ where ZZ is halo, in anaprotic solvent such as diethylether to form an alpha-halo carbonylcompound. A preferred acid reactant is hydrochloric acid which providesthe corresponding alpha-chloro carbonyl compound. The reaction istypically carried out at a temperature from about -30° C. to about 0° C.Solvent choice is not critical so long as the solvent employed is inertto the ongoing reaction and the reactants are sufficiently solubilizedto effect the desired reaction. The acid reactant is typically added inthe form of an anhydrous gas in small increments until the reactionappears substantially complete. The reaction can be monitored by thinlayer chromatography.

In Reaction A.4, the carbonyl moiety on the compound prepared inReaction A.3 is reduced using standard conditions known in the art toform the corresponding alpha-chloro hydroxy compound. For example, thecompound prepared in Reaction A.3 is combined with a reducing agent in amixture of solvents. Typical reducing agents include sodium borohydride,lithium borohydride, zinc borohydride, diisobutylaluminum hydride, andsodium bis(2-methoxy-ethoxy) aluminum hydride. A preferred reducingagent is sodium borohydride. Typical solvent mixtures include a proticand aprotic mixture such as tetrahydrofuran/water. Solvent choice is notcritical so long as the solvent employed is inert to the ongoingreaction, and the reactants are sufficiently solubilized to effect thedesired reaction. The reaction is typically carried out at a temperaturefrom about -10° C., preferably about 0° C.

In Reaction A.5, the alpha-chloro hydroxy compound prepared in ReactionA.4 is treated with a strong base to form the corresponding epoxide(which is used above in Reaction II.5) under standard conditions knownin the art. For example, the alpha-chloro hydroxy compound may bereacted with a potassium hydroxide/ethanol mixture in an alcoholicsolvent such as ethanol. The reaction is typically carried out at atemperature from about 0° C. to about the reflux temperature of thesolvent. Preferably the reaction is carried out at room temperature.

In Reaction A.6, the epoxide prepared in Reaction A.5 is reacted with aheterocyclic reactant: ##STR41## in an alcoholic solvent at atemperature of from about 20° C. to 100° C. Solvent choice is notcritical so long as the solvent employed is inert to the ongoingreaction and the reactants are sufficiently solubilized to effect thedesired reaction. Typical solvents for this reaction include thealcohols, preferably isopropanol or ethanol. The reaction is preferablycarried out at a temperature of about 80° C.

Reaction A.7 is a standard amino deprotection reaction using proceduresand methods known in the art to afford the corresponding amine which isused in Reaction I, above. This amine may be reacted withoutpurification, but it is preferably purified first.

The compounds of formula IA, where Q₃ is --S-aryl, are prepared by firstreacting amino-protected serine with triphenylphosphine anddiethylazodicarboxylate (DEAD) in an aprotic solvent at a temperature offrom about -80° C. to 0° C. to form the corresponding beta-lactone. Thereaction is typically carried out in an ether, such as tetrahydrofuranat a temperature of from about -80° C. to -50° C. Next, the lactone ringis opened to provide a compound having the structure: ##STR42## byreacting the lactone with an appropriately substituted thioanion havingthe structure, --S-aryl. The thioanion compound is preferably formed byreacting the corresponding thiol with a strong base, such as sodiumhydride or potassium hydride. This reaction is typically carried out inan aprotic solvent at a temperature from about 0° C. to about 40° C. andunder an inert atmosphere, such as nitrogen. Typical solvents for thisreaction include ethers, preferably tetrahydrofuran.

Alternatively, the compounds of formula IA, where Q₃ is --S-aryl, may beprepared using the procedures detailed in Photaki, JACS, 85, 1123(1963), and Sasaki, N. A. et al, Tetrahedron Letters, 28, 6069 (1987).For example, the compounds may be prepared by reacting doubly protectedserine (carboxy-protected and amino-orotected) with toluenesulfonylchloride in the presence of dimethylaminopyridine (DMAP) and an acidscavenger such as pyridine in an aprotic solvent such as methylenechloride to form the corresponding toluenesulfonate which may then bereacted with an appropriately substituted thioanion having thestructure, --S-aryl. The thioanion compound is preferably formed byreacting the corresponding thiol with a strong base as described above.The carboxy-protecting group may be removed from the resulting doublyprotected arylthioalanine using conditions known in the art.

The heterocyclic reactants of the formula ##STR43## used in ReactionA.6, may be prepared using procedures and methods known in the art. Forexample, the heterocyclic reactants were typically prepared from thecorresponding amino-protected amino acids by a cid activation followedby treatment with an alkylamine. This reaction is typically carried outin the presence of an acid scavenger, such as N-methylmorpholine.Removal of the amino-protecting group using standard chemicaldeprotecting techniques then provides the desired heterocyclicreactants. Specifically, the3S-(3R*,4aR*,8aR*)!-decahydroisoquinoline-3-N-t-butylcarboxamide wasprepared using 2S-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid bythe following procedure:

1) amino-protection (t-Boc);

2) acid activation/reaction with t-butylamine;

3) catalytic hydrogenation;

4) amino-deprotection.

The piperazine reactants may be prepared by converting an appropriatelysubstituted pyrazine compound to the corresponding piperazine compoundusing procedures known in the art, preferably using catalytichydrogenation. For example, the hydrogenation may be accomplished bycombining the pyrazine reactant with a catalyst under a hydrogenatmosphere in an aprotic solvent at a temperature from about 0° C. toabout 60° C. Suitable catalysts include palladium-on-carbon, platinummetal, platinum oxide and the like. A preferred catalyst is platinumoxide. Typical solvents for this reaction include tetrahydrofuran,dimethylformamide or a mixture of tetrahydrofuran and dimethylformamide.

The nitrogen atom on the resultant piperazine reactant may be alkylatedusing procedures known in the art. For example, the piperazine reactantmay be reacted with a halo(C₁ -C₄)alkyl, or halomethylpyridine, such asmethyl iodide or chloromethylpyridine. Preferred halo substituentsinclude chloro, bromo and iodo. The reaction is carried out attemperatures of from about 0° C. to 60° C. in a mutually inert solventand in the presence of an acid scavenger. A preferred acid scavenger ispotassium carbonate. Typical solvents include a mixture of a protic andaprotic solvents such as acetonitrile and water. Solvent choice is notcritical so long as the solvent employed is inert to the ongoingreaction and the reactants are sufficiently solubilized to effect thedesired reaction.

Alternatively, the alkylated piperazine reactant may be prepared usingreductive amination. For example, the piperazine reactant prepared abovemay be reacted with an aldehyde (for example, 3-pyridine carboxylicaldehyde, ethanal, propanal) or a ketone in the presence of a reducingagent and an acid. The reaction is typically carried out in an alcoholicsolvent such as methanol, ethanol or isopropanol. Typical reducingagents include sodium borohydride, lithium cyanoborohydride, sodiumcyanoborohydride, and the like. A preferred reducing agent is sodiumcyanoborohydride. Typical acids include any protic acid such ashydrochloric acid, sulfuric acid, methanesulfonic acid, or acetic acid.A preferred acid is acetic acid.

The intermediate reactant ##STR44## can also be prepared that has theformula 2: ##STR45## wherein: V⁰ and V¹ are independently hydrogen, C₁-C₆ alkyl, or hydroxy (C₁ -C₆) alkyl;

V² is hydrogen, an amino-protecting group, or a group of the formula:##STR46## V³ is --(CH₂)_(t) --V^(3') ; t is 0, 1, 2, 3, or 4;

V^(3') is aryl, --O-aryl, or --S-aryl;

V⁴ is hydrogen or an amino-protecting group; f, h and j are eachindependently 0, 1 or 2; g and i are each independently 0 or 1;

V⁵ is --CH₂ --, --CHV⁵ --, or --CV^(5') V^(5') --;

V⁶ is --CH₂ --, --CHV^(6'), --CV^(6') V^(6') --;

V⁷ is --CH₂ --, --CHV^(7'), or --CV^(7') V^(7') --;

each of V^(5'), V^(6'), and V^(7') is independently selected from thegroup consisting of halo, hydroxy, C₁ -C₆ alkyl, halo(C₁ -C₆)alkyl,hydroxy(C₁ -C₆)alkyl, C₁ -C₆ alkoxy, C₁ -C₆ alkylthio, amino, or cyano;

T and W are independently --S--, --S(O)--, --S(O)₂ --, --O--, --NH--, or--(V⁹)--; and

V⁹ is C₁ -C₆ alkyl, aryl(C₁ -C₆)alkyl, aryl, or acyl; with the provisosthat:

g and i cannot both be 0;

the sum of f, g, h, i and j must be 2, 3, 4, or 5;

if V⁵ is --CV^(5') V^(5') --, then V⁶ must be --CH₂ -- or --CHV^(6') --;and V⁷ must be --CH₂ -- or --CHV^(7') --;

if V⁶ is --CV^(6') V^(6') --, then V⁵ must be --CH₂ -- or --CHV^(5') --;and V⁷ must be --CH₂ -- or --CHV^(7') --;

if V⁷ is --CV^(7') V^(7') --, then V⁵ must be --CH₂ -- or --CHV^(5') --;and V⁶ must be --CH₂ -- or --CHV^(6') --;

or a pharmaceutically acceptable salt thereof. ##STR47## wherein V⁴, V³,V⁰, V¹, V⁵, T, V⁶, W, V⁷, f, g, h, i, j, are defined above for formula2;

V^(A) is an amino-protecting group; and

U on the bicyclic ring in reaction 1-3 above represents the presence ofdouble bonds between, for example, V_(f) and V_(h), V_(f) and V_(f), orV_(j) and V_(h) and the like, where b, c, or d is 0, respectively.

Reaction Scheme II, above, is accomplished by carrying out reactions 1-3(or 1-5) in sequential order. Once a reaction is complete, theintermediate compound may be isolated, if desired, by procedures knownin the art, for example, the compound may be crystallized and thencollected by filtration, or the reaction solvent may be removed byextraction, evaporation or decantation. The intermediate compound may befurther purified, if desired, by common techniques such ascrystallization or chromatography over solid supports such as silica gelor alumina, before carrying out the next step of the reaction scheme.

Reaction II.1 is typically carried out by activating the carboxylic acidmoiety using, for example, DCC or a mixed anhydride such as isobutyl,followed by reaction with a primary or secondary amine having theformula NV⁰ V¹ where V⁰ and V¹ are as defined above for formula (2). Thereaction is typically carried out in a nonpolar aprotic solvent ormixture of solvents in the presence or absence of an acid scavenger at atemperature of from about -20° C. to about 25° C. to afford thecorresponding amide. Suitable solvents for this reaction include ethersand chlorinated hydrocarbons, preferably diethyl ether, chloroform, ormethylene chloride. Preferably, this reaction is carried out in thepresence of an acid scavenger such as a tertiary amine, preferablytriethylamine. The amide afforded by this reaction may be isolated orfurther reacted as shown in Reaction II.2.

Reaction II.2 is typically carried out by reacting the compound obtainedfrom Reaction II.1 using the procedures detailed in ComprehensiveOrganic Synthesis, "Heteroatom Manipulation", Barry M. Trost, ed.,volume 6, pages 736-746, (1991). In general, an appropriatelysubstituted monocyclic ring is reacted with an aldehyde, such asformaldehyde or trichloroacetaldehyde, in the presence of an acid. Theacid may be used as a solvent. Typical acids include hydrochloric acid,hydrobromic acid, sulfuric acid, acetic acid, trifluoroacetic acid, andthe like. A co-solvent may optionally be added to the reaction mixture.The co-solvent choice is not critical so long as the co-solvent employedis inert to the ongoing reaction, and the reactants are sufficientlysolubilized to effect the desired reaction. Typical solvents for thisreaction include halogenated solvents such as methylene chloride,trichloroethane, carbontetrachloride, and the like. Alternatively, thealdehyde may be produced in situ using for example, dimethoxymethane anda suitable acid.

In reaction II.3, the compound isolated from reaction II.2 is reduced toprovide a saturated heterocyclic compound as depicted above. Catalytichydrogenation is a preferred method of reduction. Typical catalystsinclude palladium catalysts, rhodium catalysts (for example rhodium onaluminum) and rhenium catalysts. Preferred catalysts includepalladium-on-carbon. Suitable solvents for this reaction include the C₁-C₄ alcohols, tetrahydrofuran, acetic acid in alcohol, ethyl acetate andthe like. A preferred solvent is ethanol. The reaction is typicallycarried out under an atmosphere of hydrogen from about 1000 to about4000 psi at a temperature of from about 25° C. to about 150° C.Preferably, the reaction is carried out under an atmosphere of hydrogenfrom about 2000 to about 3000 psi at a temperature of from about 50° C.to 100° C. The catalyst is generally employed in a amount ranging fromabout equimolar proportions to about a twelve-fold excess (by weight) ofthe reactant, preferably in about a six- to ten-fold excess (by weight)of the catalyst relative to the substrate.

Reactions II.4 and II.5 may be used to prepare compounds of formula (3)which correspond to compounds of formula (2) where ##STR48## and V³ andV⁴ are as defined above for formula (2), including their definitions ofV³ and t.

Reaction II.4 is a standard amino deprotection reaction using proceduresand methods known in the art to afford the corresponding amine which isthen used in Reaction II.5. Chemicai deprotection procedures arepreferred. For example, the compound isolated from II.3 may bedeprotected using trimethylsilyliodide (TMSI) in an aprotic solvent ormixture of solvents at a temperature of from about 10° C. to 60° C.,preferably at a temperature of from about 20° C. to 40° C. Typicalsolvents include methylene chloride, acetonitrile trichloroethane, andthe like.

In Reaction II.5, the epoxide prepared in Reaction A.5, above, in whichQ₃ of Reaction A.5 is replaced by V³, is reacted with the compoundisolated from Reaction II.4 in an alcoholic solvent at a temperature offrom about 20° C. to 100° C. Solvent choice is not critical so long asthe solvent employed is inert to the ongoing reaction, and the reactantsare sufficiently solubilized to effect the desired reaction. Typicalsolvents for this reaction include the alcohols, preferably isopropanolor ethanol. The reaction is preferably carried out at a temperature ofabout 80° C.

The compound isolated from reaction II.5 may optionally be deprotectedto provide a compound of formula (3) where V^(A) is hydrogen.

The epoxide used in Reaction II.5 may be synthesized using ReactionScheme A above.

The carboxylic acid reactant of formula (IB) ##STR49## used in ReactionScheme I, to the extent not commercially available, can be preparedusing known procedures. More particularly, this reactant may be preparedby further substitution and/or oxidation of a commercially availablearyl or heterocyclic compound. For example, aryl or heterocycliccompounds of the formula ##STR50## may be oxidized using proceduresknown in the art. Specifically, the compound of the formula ##STR51##may be reacted with an oxidizing agent such as selenium dioxide orpotassium permanganate at temperatures of from about 0° C. to 200° C. ina mutually inert solvent, such as water or diphenylether.

A second method for preparing compounds of the formula (IB) involvesprotecting an appropriately substituted carboxylated aryl orheterocyclic with a carboxy-protecting group, and then furthersubstituting the aryl or heterocyclic group using procedures known inthe art. The carboxy-protecting group may then be removed usingprocedures known in the art to provide the desired carboxylic acidreactant of formula (IB).

The term "carboxy-protecting group" as used in the specification refersto substituents of the carboxy group commonly employed to block orprotect the carboxy functionality while reacting other functional groupson the compound. Examples of such carboxy-protecting groups includemethyl, p-nitrobenzyl, p-methylbenzyl, p-methoxybenzyl,3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl,2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl,benzhydryl, 4,4'-dimethoxybenzhydryl, 2,2',4,4'-tetramethoxybenzhydryl,t-butyl, t-amyl, trityl, 4-methoxytrityl, 4,4'-dimethoxy-trityl,4,4',4"-trimethoxytrityl, 2-phenylprop-2-yl, trimethylsilyl,t-butyldimethylsilyl, phenacyl, 2,2,2-trichloroethyl,b-(di(n-butyl)methylsilyl)ethyl, p-toluenesulfonylethyl,4-nitrobenzylsulfonylethyl, allyl, cinnamyl,1-(trimethylsilylmethyl)prop-1-en-3-yl and like moieties. A preferredmethod of protecting the carboxy group involves converting the carboxymoiety to an amide moiety and then hydrolyzing the amide back to providethe desired carboxy substituent. Further examples of these groups arefound in E. Haslam, "Protective Groups in Organic Chemistry", J. G. W.McOmie, Ed., Plenum Press, New York, N.Y., 1973, Chapter 5, and T. W.Greene, "Protective Groups in Organic Synthesis", John Wiley and Sons,New York, N.Y., 1981, Chapter 5.

A preferred procedure for protecting the carboxy moiety involves theacid activation of the carboxy moiety, followed by the formation of anamide. For example, the carboxy moiety may be converted to an acylhalide, acyl anhydride, acyl imidazole and the like, preferably in thepresence of an acid scavenger to form an activated carboxy moiety. Acommercially available acid chloride is typically employed, obviatingthe need for further acid activation. Preferred acid scavengers are thetrialkylamines, preferably triethylamine. The reaction is typicallycarried out in an aprotic solvent such as diethylether, methylenechloride or the like. A preferred solvent is methylene chloride. Solventchoice is not critical so long as the solvent employed is inert to theongoing reaction and the reactants are sufficiently solubilized toeffect the desired reaction. The activated carboxy moiety is thenreacted with an amine, R¹¹ -NH₂, for example aniline, in an aproticsolvent to provide an amide reactant ##STR52## which may then be furthersubstituted according to known procedures.

The amide reactant ##STR53## may be further substituted by orthodeprotonation of the heterocyclic or aryl group ##STR54## to provide thecorresponding anion followed by reaction with a variety of reagents suchas alkyl halides, or halogenating agents such as bromine. The amidereactant is generally deprotonated twice using two equivalents of astrong base such as n-butyl lithium or sec-butyl lithium relative to theamide reactant, optionally in the presence of a metal coordinating agentsuch as tetramethylethylenediamine (TMEDA). The reaction is typicallycarried out in an aprotic solvent, preferably an ether such asdiethylether, tetrahydrofuran or the like at a temperature from about-78° C. to about 25° C.

The resultant compound may then be hydrolyzed using procedures known inthe art to provide the desired, substituted carboxylic acid reactant offormula (IB). For example, a suitable hydrolysis involves exposing theamide reactant to a strong mineral acid, organic acid, or a mineralacid/organic mixture at a temperature from about 100° C. to about 160°C. Typical acids which may be used in this reaction include hydrobromicacid, acetic acid, hydrochloric acid and the like. A sealed tube mayoptionally be employed to accelerate the reaction rate.

A third method for preparing the substituted carboxylic acid reactant offormula (IB) involves diazotization of an aniline, followed by aquenching of the resultant diazonium salt. Specifically, the aminomoiety of the aniline reactant is converted to a diazonium salt byreaction with nitrous acid. Nitrous acid may be produced in situ bytreating sodium nitrite with an aqueous solution of a strong acid suchas hydrochloric acid, or sulfuric acid. This reaction is typicallycarried out at or below 5° C. The diazonium salt is then quenched byreaction with suitable reagent to provide the desired substitutedaromatic system. Representative quenching reagents include water,cyanide, halide, aqueous sulfuric acid, and the like. Typically, thereaction will be heated to facilitate the desired reaction.

There are a variety of reactions that are known in the art which may beused to produce the desired substitutions on the aryl or heterocyclicrings. For example, there are a variety of aromatic electrophilic andnucleophilic substitution reactions oulined in chapters 11 and 13 ofMarch, J., "Advanced Organic Chemistry," 3rd edition, Wiley, 1985.

In addition, the compounds of the formula (IB) may be prepared bycarboxylating an appropriately substituted aryl of heterocycliccompound. The carboxylation may be accomplished using a number ofdifferent reagents. For example, the aryl or heterocyclic reagent may bereacted with phosgene, oxalyl chloride, urea hydrochloride, orN,N-diethylcarbamoyl chloride in the presence of Friedel-Craftscatalysts. A variation of this method involves reacting the aryl orheterocyclic reagent with an alkyl thiolchloroformate (RSCOCl), or acarbamoyl chloride (H₂ NCOCl) to provide an amide and a thiol ester,respectively. The amide and thiol ester may then be hydrolyzed toprovide the desired carboxy group. March, at 491.

Examples of Friedel-Crafts catalysts include the Lewis acids, such asaluminum bromide (AlBr₃), aluminum chloride (AlCl₃), iron (III) chloride(FeCl₃), boron trichloride (BCl₃), boron trifluoride (BF₃), and thelike. See also, March, J., "Advanced Organic Chemistry," 3rd edition,Wiley, 1985; Olah, "Friedel-Crafts and Related Reactions," Interscience,New York, 1963-1965; and Olah, "Friedel-Crafts Chemistry," Wiley, NewYork, 1973.

Additionally, the quinoline carboxylic acid reactants may be prepared byreacting an appropriately substituted aniline with glycerol using theSkraup reaction disclosed in Bradford, L et al, J. Chem. Soc., 1947, p437. For example, 3-amino benzoic acid may be reacted with glycerol inthe presence of an oxidizing agent such as m-nitro benzene sulfonic acidor sodium m-nitro benzene sulfonate in a 60-75% aqueous solution ofsulfuric acid to provide the desired carboxy-substituted quinoline. Thereaction is typically carried out at a temperature from about 35° C. toreflux temperature for one to six hours, preferably from about 50° C. toreflux temperature for two to four hours.

The resultant reactants may then be reduced or hydrogenated usingprocedures known in the art. See e.g., March, at 700. A preferredprocedure involves catalytic hydrogenation, for examole by combining thequinoline carboxylic acid reactant with hydrogen gas in the presence ofa catalyst. A preferred catalyst is palladium-on-carbon. Typicalsolvents suitable for use in this reaction include any organic solventsuch as ethyl acetate. Solvent choice is not critical so long as thesolvent employed is inert to the ongoing reaction. The reaction isgenerally substantially complete after about 1 to 24 hours whenconducted at a temperature in the range of from about 25° C. to about100° C.

According to other embodiments, the compounds of formula IA, in which Q₃is replaced by R¹, can be prepared according to the following ReactionScheme B. ##STR55## where: R^(b) is an amino-protecting group; and

R¹, and R³ are as defined above for formula 1(B)

Reaction Scheme B, above, is accomplished by carrying out reactions 1-6in sequential order. once a reaction is complete, the intermediatecompound may be isolated, if desired by procedures known in the art, forexample, the compound may be crystallized and then collected byfiltration, or the reaction solvent may be removed by extraction,evaporation or decantation. The intermediate compound may be furtherpurified, if desired, by common techniques such as crystallization orchromatography over solid supports such as silica gel or alumina, beforecarrying out the next step of the reaction scheme.

In Reaction B.1, the reaction is typically carried out by activating,that is, converting, a suitably substituted aryl or unsaturatedheterocycle carboxylic acid to the corresponding acyl chloride or acylbromide by reaction with thionyl chloride, thionyl bromide, phosphoroustrichloride, phosphorous tribromide, phosphorous pentabromide orphosphorous pentachloride according to procedures and under conditionsknown in the art. Suitable aryl, heterocycle or unsaturated heterocyclecarboxylic acid compounds are commercially available or prepared bystandard procedures known in the art.

In Reaction B.2, the acyl chloride or acyl bromide, prepared in ReactionB.1, is reacted with ammonia or a primary or secondary amine having theformula ##STR56## where R⁴, R⁵, R⁶ and p are as defined above forformula 1(B), in a nonpolar aprotic solvent or mixture of solvents inthe presence or absence of an acid scavenger to afford the correspondingamide. The reaction is typically carried out at a temperature of fromabout -20° C. to about 25° C. Typical solvents for this reaction includeethers and chlorinated hydrocarbons, preferably diethylether, chloroformor methylene chloride. Preferably, this reaction is carried out in thepresence of an acid scavenger such as a tertiary amine, preferablytriethylamine.

In Reaction B.3, the amide prepared in Reaction B.2, is reacted with astrong base in the presence of a solubilizing agent to afford thecorresponding anion which is then reacted in Reaction B.4 with a Weinrebamide to afford a ketone. Reaction B.3 is carried out in an aproticsolvent at a temperature of from about -78° C. to about 0° C. Typicalbases used in Reaction B.3 include lithium amide bases and alkyl lithiumbases, preferably C₁ -C₄ alkyl lithium bases and lithium di (C₁ -C₄)alkylamide bases. Typical solubilizing agents for Reaction 3 aretetramethyl(C₁ -C₄)alkylenediamines, preferablytetramethylethylenediamine. Reaction B.4 is carried out in an aproticsolvent at a temperature from about -80° C. to about -40° C. Typicalsolvents for Reactions B.3 and B.4 include ethers, preferablytetrahydrofuran. In Reaction B.4, the anion is generally employed in anamount ranging from about equimolar proportions to about a three molarexcess of the anion, preferably in about a two molar excess of the anionrelative to the Weinreb amide reactant.

In Reaction B.5, the ketone prepared in Reaction B.3, is reduced to thecorresponding alcohol using a suitable reducing agent. The reaction iscarried out in a protic solvent at a temperature of from about -25° C.to about 25° C. Typical reducing agents for this reaction include sodiumborohydride, lithium borohydride, diisobutylaluminum hydride, and sodiumbis(2-methoxyethoxy)aluminum hydride. A preferred reducing agent issodium borohydride. Typical protic solvents for this reaction includealcohols, preferably ethanol.

Reaction B.6 is a standard amino deprotection reaction using proceduresand methods known in the art to afford the corresponding amine which isused in Reaction I above. This amine may be reacted withoutpurification, but it is preferably purified first.

The Weinreb amide used as a reactant in Reaction B.4 is prepared byreacting an amino-protected amino acid with N-methoxy-N-methyl-amine inthe presence of a promoting agent, an acid scavenger, and a couplingagent. The reaction is carried out in an aprotic solvent or mixture ofsolvents at a temperature of from about -25° C. to 25° C. A preferredpromoting agent for this reaction is HOBT.H₂ O. Preferred acidscavengers are the tertiary alkylamines, preferably triethylamine orN-methyl-morpholine. A preferred coupling reagent is ethyldimethylaminopropylcarbodiimide hydrochloride. The Weinreb amideafforded by this reaction is preferably isolated prior to its use inReaction B.4.

The compounds of formula IA, where R¹ replaces Q₃ and where R¹ is--S-aryl, are prepared in Scheme B by first reacting amino-protectedserine with triphenylphosphine and diethylazodicarboxylate (DEAD) in anaprotic solvent at a temperature of from about -80° C. to 0° C. to formthe corresponding beta-lactone. The reaction is typically carried out inan ether, such as tetrahydrofuran at a temperature of from about -80° C.to -50° C. Next, the lactone ring is opened to provide a compound havingthe structure: ##STR57## by reacting the lactone with an appropriatelysubstituted thioanion having the structure, --S-aryl. The thioanioncompound is preferably formed by reacting the corresponding thiol with astrong base, such as sodium hydride or potassium hydride. This reactionis typically carried out in an aprotic solvent at a temperature fromabout 0° C. to about 40° C. and under an inert atmosphere, such asnitrogen. Typical solvents for this reaction include ethers, preferablytetrahydrofuran. The desired amide reactant is then formed by reactingthe resulting carboxylic acid reactant with N-methoxy-N-methyl-amine inthe presence of a promoting agent, an acid scavenger and a couplingagent substantially as described above.

Alternatively, the compounds of formula (IA), where R¹ replaces Q₃ andwhere R¹ is --S-aryl, may be prepared in Scheme B using the proceduresdetailed in Photaki, JACS, 85, 1123 (1963), and Sasaki, N. A. et al.,Tetrahedron Letters, 28, 6069 (1987). For example, the compounds may beprepared by reacting doubly protected serine (carboxy-protected andamino-protected) with toluenesulfonyl chloride in the presence ofdimethylaminopyridine (DMAP) and an acid scavenger such as pyridine inan aprotic solvent such as methylene chloride to form the correspondingtoluenesulfonate compound which may then be reacted with anappropriately substituted thioanion having the structure, --S-aryl. Thethioanion compound is preferably formed by reacting the correspondingthiol with a strong base as described above. The carboxy-protectinggroup may then be removed from the resulting doubly protectedarylthioalanine using conditions known in the art.

According to certain embodiments, an intermediate for making compoundsof the present invention is prepared as follows. The intermediate hasthe formula 4: ##STR58## wherein: R¹ is aryl, or --S-aryl;

R¹⁰ is hydrogen or an amino-protecting group;

R⁰ is C₁ -C₄ alkyl or --CH₂ -pyridyl;

R³ is a group having the structure:

1) --C(O)--NR⁴ R⁴ ##STR59## p is 4 or 5; R⁴ at each occurrence isindependently hydrogen, C₁ -C₆ alkyl or hydroxy(C₁ -C₄)alkyl; and

R⁵ and R⁶ are independently selected from hydrogen, hydroxy, C₁ -C₆alkyl, C₁ -C₆ alkoxy, or hydroxy(C₁ -C₄)alkyl; or a pharmaceuticallyacceptable salt thereof; comprising:

(a) reducing a compound of the formula ##STR60## to provide a piperazinecompound; (b) alkylating the piperazine compound to provide a compoundof the formula ##STR61## (c) reacting the piperazine compound of step(b) with an epoxide of the formula ##STR62## where R^(b) is an aminoprotecting group; in an alcoholic solvent at a temperature of from about20° C. to 100° C. to form a compound of formula II wherein R10 is anamino-protecting group; and

d) optionally removing the amino-protecting group to form a compound offormula 4 wherein R¹⁰ is hydrogen.

The following Preparations and Examples illustrate aspects of theinvention. These examples are for illustrative purposes and are notintended to limit the scope of the invention.

Abbreviations for the terms melting point, nuclear magnetic resonancespectra, electron impact mass spectra, field desorption mass spectra,fast atom bombardment mass spectra, infrared spectra, ultravioletspectra, elemental analysis, high performance liquid chromatography, andthin layer chromatography are, respectively, m.p., NMR, EIMS, MS(FD),MS(FAB), IR, UV, Analysis, HPLC, and TLC. In addition, the absorptionmaxima listed for the IR spectra are those of interest, not all maximaobserved.

In conjunction with the NMR spectra, the following abbreviations areused: singlet (s), doublet (d), doublet of doublets (dd), triplet (t),quartet (q), multiplet (m), doublet of multiplets (dm), broad singlet(br.s), broad doublet (br.s), broad triplet (br.t), and broad multiplet(br.m). J indicates the coupling constant in Hertz (Hz). Unlessotherwise noted, NMR data refer to the free base of the subjectcompound.

The NMR spectra were obtained on a Bruker Corp. 270 MHz instrument or ona General Electric QE-300 300 MHz instrument. The chemical shifts areexpressed in delta values (ppm downfield from tetramethylsilane). MS(FD)spectra were taken on a Varian-MAT 731 Spectrometer using carbondendrite emitters. EIMS spectra were obtained on a CEC 21-110 instrumentfrom Consolidated Electrodynamics Corporation. MS(FAB) spectra wereobtained on a VG ZAB-3 Spectrometer. IR spectra were obtained on aPerkin-Elmer 281 instrument. UV spectra were obtained on a Cary 118instrument. TLC was carried out on E. Merck silica gel plates. Meltingpoints are uncorrected.

Preparation 1

A. 3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-3'-N-(Benzyloxycarbonyl)amino-2'-hydroxy-4'-phenyl!butyldecahydroisoquinoline-3-N-t-butylcarboxamide

A solution of 1'S-(1'R*,1R*)!-1-1'-N-(benzyloxycarbonyl)amino-2'-(phenyl)ethyl!oxirane and3S-(3R*,4aR*,8aR*)!-decahydroisoquinoline-3-N-t-butylcarboxamide inabsolute ethanol was heated at 80° C. overnight. The reaction mixturewas reduced to dryness under reduced pressure to provide a residue. Thisresidue was purified using flash chromatography (gradient eluent of10-50% ethyl acetate in methylene chloride) to provide 6.47 g of anoff-white foam.

Yield: 75%. ¹ H NMR (CDCl₃): δ 1.29 (s, 9H), 1.25-2.05 (m, 2H),2.20-2.35 (m, 2H), 2.55-2.70 (m, 11H), 2.85-3.10 (m, 3H), 3.24 (br.s,1H), 3.82 (br.s, 1H), 3.98 (br.s, 1H), 4.99 (br.s, 2H), 5.16-5.18 (m,1H), 5.80 (br.s, 1H), 7.05-7.38 (m, 10H). IR (CHCl₃): 3600-3100 (br.),3031, 2929, 1714, 1673, 1512, 1455, 1368, 1232, 1199, 1047 cm⁻¹. MS(FD):m/e 536 (M⁺).

B. 3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2- 3 '-Amino-2'-hydroxy-4'-phenyl!butyldecahydroisoquinoline-3-N-t-butylcarboxamide

A rapidly stirring suspension of 6.37 g (11.91 mmol) of the subtitledcompound of Preparation 1A and 1.2 g of 10% palladium-on-carbon in 200mL of absolute ethanol was placed under an atmosphere of hydrogen. Afterapproximately 48 hours, the reaction mixture was filtered through celiteand reduced to dryness under reduced pressure to provide 5.09 g of thedesired subtitled compound. This compound was used without furtherpurification.

NMR (CDCl₃) δ 1.33 (s, 9H), 1.40-1.95 (m, 10H), 2.25-2.48 (m, 2H),2.59-2.75 (m, 3H), 2.80-3.40 (m, 7H), 3.75-3.90 (m, 1H), 6.19 (br.s,1H)d, 7.18-7.35 (m, 5H). IR (CHCl₃): 3600-3100 (br.), 2929, 2865, 1671,1515, 1455, 1367, 1245, 1047 cm⁻¹. MS(FD): m/e 402 (M⁺, 100).

Preparation 2

A. 2R-N(Benzyloxycarbonyl)amino-3-naphth-2-ylthio propanoic acid

To a solution of 1.28 g (8.00 mmol) of naphthalene-2-thiol in 30 mL oftetrahydrofuran, was slowly added 1.77 g (8.16 g) of 60% sodium hydride,under nitrogen. After stirring for approximately 15 minutes, a solutionof N(benzyloxycarbonyl)serine-β-lactone in 20 mL of tetrahydrofuran wasslowly added. The reaction mixture was allowed to react at roomtemperature for approximately one hour, and then was concentrated underreduced pressure to provide a residue. This residue was dissolved inethyl acetate and washed sequentially with 0.5N sodium bisulfate and asaturated brine solution. The resulting layers were separated and theorganic layer was dried over sodium sulfate, filtered, and thenconcentrated under reduced pressure to provide a residue. This residuewas purified using flash chromatography to provide 2.08 g of a paleyellow solid.

Yield: ⁻ 68%. ¹ H NMR (CDCl₃): δ 3.42-3.61 (br.m, 2H), 5.53-5.76 (br.s,1H), 4.85-5.08 (br.m, 2H), 5.54-5.76 (br.s, 1H), 7.06-7.97 (m, 12H).α!_(D) -55.72° (c 1.0, MeOH). IR (KBr): 3348, 3048, 1746, 1715, 1674,1560, 1550, 1269, 1200, 1060 cm ⁻¹. MS(FD): m/e 381 (M⁺), 381 (100).Analysis for C₂₀ H₁₉ NO₄ S: Calcd: C, 66.12; H, 5.02; N, 3.67; Found: C,66.22; H, 5.04; N, 3.86.

B. 3R-1-Diazo-2-oxo-3-N-(benzyloxycarbonyl)amino-4-(naphth-2-ylthio)butane

To a cold (-30° C.) solution of 15.38 g (40.3 mmol) of the subtitledcompound of Preparation 2A in 230 mL of ethyl acetate, was slowly added5.62 mL (40.3 mmol) of triethylamine, under nitrogen via syringe. To theresulting solution was then added 7.84 mL (60.5 mmol) of isobutylchloroformate, via syringe. In a separate flask, 10 g ofN(methyl)-N(nitro)-N(nitroso)-guanidine was carefully added to a bilayermixture of 170 mL of diethylether and 170 mL of a 5N sodium hydroxidesolution, resulting in a large evolution of gas. When this reaction wassubstantially complete, the organic layer was decanted from the aqueouslayer onto potassium hydroxide and dried. This diazomethane formationand addition was repeated using identical quantities of diethylether andsodium hydroxide and 30 g of N(methyl)-N(nitro)-N(nitroso)-guanidine.The resultant diazomethane reactant was then added to the mixedanhydride solution prepared above and the reaction mixture was allowedto react cold (-30° C.) for approximately 20 minutes. When the reactionwas substantially complete, as indicated by TLC, nitrogen was bubbledthrough the solution using a fire polished Pasteur pipet to remove anyexcess diazomechane and then the solution was concentrated under reducedpressure to orovide a residue. This residue was purified using flashchromatography (eluent of 10% ethyl acetate in methylene chloride) toprovide 13.62 g of a yellow oil.

Yield: 83%. ¹ H NMR (CDCl₃) δ 3.32-3.46 (m, 2H), 4.40-4.67 (m, 1H),5.00-5.09 (m, 2H), 5.44 (s, 1H), 5.76 (d, J=7.8 Hz, 1H), 7.25-7.86 (m,12H).

C. 3R-1-Chloro-2-oxo-3-N-(benzyloxycarbonyl)amino-4-(naphth-2-ylthio)butane

A short burst (about 2 seconds) of anhydrous hydrochloric acid (gas) waspassed through a cold (-20° C.) solution of 13.62 g (33.59 mmol) of thesubtitled compound of Preparation 2B in 230 mL of diethylether,resulting in the evolution of a gas. This procedure was repeated takingcare not to add excess hydrochloric acid. When the reaction wassubstantially complete, as indicated by TLC, the solution wasconcentrated under reduced pressure to provide a residue. This residuewas purified using flash chromatography (eluent of 10% ethyl acetate inmethylene chloride) to provide 12.05 g of a pale tan solid.

Yield: 87%. ¹ H NMR (CDCl₃): δ 3.41 (dd, J=12,6 Hz, 1H), 3.53 (dd,J=12,6 Hz, 1H), 4.18 (AB q, J=41.9 Hz, J=15.9 Hz, 2H), 4.77 (dd, J=9, 3Hz, 1H), 5.04 (AB q, J=12 Hz, J=10.4 Hz, 2H), 5.59 (d, J=7 Hz, 1H),7.24-7.85 (m, 12H). α!_(D) -80.00° (c 1.0, MeOH). IR (CHCl₃): 3426,3031, 3012, 1717, 1502, 1340, 1230, 1228, 1045 cm⁻¹. MS(FD): m/e 413(M⁺), 413 (100). Analysis for C₂₂ H₂₀ NO₃ SCl: Calcd: C, 63.84; H, 4.87;N, 3.38; Found: C, 64.12; H, 4.95; N, 3.54.

D.3R-(3R*,4S*)!-1-Chloro-2-hydroxy-3-N-(benzyloxycarbonyl)amino-4-(naphth-2-ylthio)butane

To a cold (0° C.) solution of 530 mg (1.28 mmol) of the subtitledcompound of Preparation 2C, in 10 mL of tetrahydrofuran and 1 mL ofwater, was added 73 mg (1.92 mmol) of sodium borohydride. When thereaction was substantially complete as indicated by TLC, the solutionwas adjusted to pH 3 using 10 mL of an aqueous saturated ammoniumchloride solution and 500 μL of a 5N hydrochloric acid solution. Theresultant solution was extracted-twice with methylene chloride and thecombined organic layers were washed with water, dried over sodiumsulfate, filtered and then concentrated under reduced pressure toprovide a residue. This residue was purified using radial chromatography(eluent of methylene chloride) to provide 212 mg of a tan solid.

Yield: 40%. ¹ H NMR (CDCl₃): δ 3.40 (s, 2H), 3.61-3.71 (m, 2H),3.97-3.99 (m, 2H), 4.99 (s, 2H), 5.16 (br.s, 1H), 7.21-7.83 (complex,12H). MS(FD): m/e 415 (M⁺), 415 (100). α!_(D) -47.67° (c 0.86, MeOH). IR(CHCl₃): 3630, 3412, 3011, 1720, 1502, 1236, 1044 cm⁻¹. Analysis for C₂₂H₂₂ NO₃ ClS: Calcd: C, 63.53; H, 5.33; N, 3.37; Found: C, 63.72; H.5.60; N, 3.64.

E. 1'R-(1'R*,1S*)!-1- (1'-N-(Benzyloxycarbonyl)amino-2'-(naphth-2-ylthio)ethyl! oxirane

A solution of 31 mg (0.55 mmol) of potassium hydroxide in 1 mL ofethanol was added to a solution of 190 mg (0.46 mmol) of the subtitledcompound of Preparation 2D, in 6 mL of a 1:2 ethanol/ethyl acetatesolution. When the reaction was substantially complete, as indicated byTLC, the reaction mixture was poured into a water/methylene chloridemixture. The resulting layers were separated, and the organic layer waswashed with water, dried over sodium sulfate, filtered and thenconcentrated under reduced pressure to provide a residue. This residuewas purified using radial chromatography (eluent of 10% ethyl acetate inmethylene chloride) to provide 172 mg of a light tan solid.

Yield: 99%. ¹ H NMR (CDCl₃): δ 2.76 (br.s, 2H) 3.01 (br.s, 1H), 3.31 (d,J=5 Hz, 2H), 3.77 (br.s, 1H), 5.05 (s, 2H), 5.22 (d, J=6 Hz, 1H),7.25-7.85 (complex, 12H). α!_(D) -125.42° (c 0.59, MeOH). MS(FD): m/e379 (M⁺), 379 (100). IR (CHCl₃): 3640, 3022, 2976, 1720, 1502, 1235,1045 cm⁻¹. Analysis for C₂₂ H₂₁ NO₃ S: Calcd: C, 69.63; H, 5.58; N,3.69; Found: C, 69.41; H, 5.53; N, 3.64.

F. 2S-(2R*,2'R*,3'S*)!-1- 2'-Hydroxy-3'-(N-benzyloxycarbonyl)amino-4'-(naphth-2-ylthio)butyl!piperidine-2-N-(t-butyl)carboxamide

A solution of 0.51 g (1.34 mmol) of the subtitled compound ofPreparation 2E and 0.26 g (1.41 mmol) of the subtitled compound ofPreparation 4C in 25 mL of isopropanol was heated to 55° C. forapproximately forty eight hours. The resultant reaction mixture wascooled and then concentrated under reduced pressure to provide a crudematerial. This material was purified using radial chromatography (4 mmplate; eluent of 10% acetone in methylene chloride) to provide 104 mg ofa white foam.

Yield: 14%. ¹ H NMR (CDCl₃): δ 1.29 (s, 9H), 1.44-1.82 (m, 6H), 2.19 (m,1H), 2.40 (m, 1H), 2.68 (m, 2H), 3.09 (m, 1H), 3.46 (m, 2H), 4.00 (m,2H), 5.01 (s, 2H), 5.73 (d, 1H), 6.01 (br.s, 1H), 7.23-7.34 (m, 5H),7.45 (m, 3H), 7.72-7.83 (m, 4H). MS(FD): m/e 563 (M⁺, 100).

G. 2S-(2R*,2'S*,3'S*)!-1- 2'-Hydroxy-3'-amino-4'-(naphth-2-ylthio)butyl!piperidine-2-N-(t-butyl)carboxamide

A solution containing 1.05 g (0.18 mmol) of the subtitled compound ofPreparation 2F in 10 mL of 30% hydrobromic acid in acetic acid wasreacted for approximately one hour. The resultant reaction mixture wasconcentrated, azeotroped three times with toluene, redissolved inmethanol containing 4.5 mL each of diethylamine and ammonium hydroxideand then concentrated under reduced pressure to provide a residue. Thisresidue was Durified using radial chromatography (1 mm plate; eluent of3% methanol in methylene chloride containing 1% acetic acid) to provide64 mg of a white foam.

Yield: 80%. ¹ H NMR (CDCl₃): δ 1.29 (s, 9H), 1.52-1.73 (m, 6H), 1.84 (m,1H), 2.31-2.43 (m, 2H), 2.75-3.04 (m, 5H), 3.17 (m, 1H), 3.41 (m, 1H),3.71 (m, 1H), 6.22 (br.s, 1H), 7.47 (m, 3H), 7.73-7.82 (m, 4H). MS(FD):m/e 430 (M⁺, 100).

Preparation 3

A. 2S-N-(Benzyloxycarbonyl)-2-pyrrolidinecarboxylate pentafluorophenylester

To a cold (0° C.) solution of 30 g (0.12 mol) of2S-N(benzyloxycarbonyl)-2-pyrrolidinecarboxylic acid and 25.8 g (0.14mol) of pentafluorophenol in 450 mL of tetrahydrofuran, was added 27.7 g(0.14 mol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) in oneportion, followed by 150 mL of methylene chloride. The resultantreaction mixture was warmed to room temperature and reacted forapproximately four hours. When the reaction was substantially complete,as indicated by TLC, the reaction mixture was concentrated under reducedpressure to provide a residue. This residue was dissolved in 500 mL ofethyl acetate and washed sequentially with water, potassium carbonate,1N hydrochloric acid and brine, dried over sodium sulfate, filtered andthen reduced to dryness under reduced pressure to provide a solid. Thissolid was redissolved in hexane and washed with potassium carbonate,dried over sodium sulfate, filtered and reduced to dryness under reducedpressure to provide 45.95 g of the desired subtitled compound.

Yield: 92%. ¹ H NMR (CDCl₃): δ 1.95-2.15 (m, 2H), 2.20-2.35 (m, 1H),2.35-2.50 (m, 1H), 3.50-3.75 (m, 2H), 4.65-4.75 (m, 1H), 5.02-5.30 (m,2H), 7.20-7.45 (m, 5H).

B. 2S-N-(Benzyloxycarbonyl)pyrrolidine-2-N(t-butyl)carboxamide

To a cold (0° C.) solution of 45.90 g (0.111 mmol) of the subtitledcompound of Preparation 3A in 100 mL of anhydrous methylene chloride,was slowly added 100 mL (0.952 mmol) of t-butylamine. The reactionmixture was warmed to room temperature and reacted for approximately onehour and then diluted with 1000 mL of methylene chloride and then washedsequentially with 1N potassium carbonate, 1N hydrochloric acid, 1Npotassium carbonate, and brine, dried over sodium sulfate, and then plugfiltered using 50% ethyl acetate in hexane to provide 37.74 g of thedesired compound which was used without further purification.

¹ N NMR (CDCl₃): δ 0.95-1.50 (m, 9H), 1.70-2.40 (m, 4H), 3.30-3.60 (m,2H), 4.10-4.30 (m, 1H), 4.95-5.35 (m, 2H), 5.65 (br.s, 0.5H), 6.55(br.s, 1H), 7.20-7.50 (m, 5.5H).

C. 2S-Pyrrolidine-2-N-(t-Butyl)carboxamide

The subtitled compound of Preparation 3B (2.71 g, 8.9 mmol) wasdeprotected substantially as detailed in Preparation 1B, using 500 mg of10% palladium-on-carbon and hydrogen gas (1atmosphere) in 200 mL ofethanol.

Yield: 1.53 g (100%). ¹ H NMR (CDCl₃): δ 1.35 (s, 9H), 1.60-1.75 (m,2H), 1.76-1.90 (m, 1H), 2.00-2.15 (m, 1H), 2.58 (br.s, 1H), 2.80-3.05(m, 2H), 3.55-3.65 (m, 1H), 7.45 (br.s, 1H).

D. 2S-(2R*,2'S*,3'R*)!-1-3'-N(Benzyloxycarbonyl)-amino-2'-hydroxy-4'-phenylbutyl!pyrrolidine-2-N-(t-butyl)carboxamide

A solution containing 122 mg (0.72 mmol) of the subtitled compound ofPreparation 3C and 200 mg (0.68 mmol) of 1S-(1R*,1'R*)!-1-(1'-N-(benzyloxycarbonyl)amino-2'-phenyl)ethyl)oxirane in 10 mL ofmethanol was stirred overnight. When the reaction was substantiallycomplete, as indicated by TLC, the reaction mixture was concentratedunder reduced pressure. The desired compound was purified using columnchromatography (gradient eluent of 2-4% methanol in methylene chloride)to provide 232.2 mg of a clear amorphous solid.

Yield: 55%. α!_(D) -56.97° (c=0.27, MeOH). ¹ H NMR ⁻ (CDCl₃): δ 1.33 (s,9H), 1.55-1.95 (m, 4H), 2.05-2.25 (m, 1H), 2.40-2.55 (m, 1H), 2.65-2.75(m, 2H), 2.80-3.00 (m, 3H), 3.15-3.30 (m, 1H), 3.65-3.75 (m, 1H),3.85-3.95 (m, 1H), 4.86 (br.d, J=1.1 Hz, 1H), 5.03 (s, 2H), 6.95 (m,1H), 7.15-7.40 (m, 10H). IR (CHCl₃): 3700-3100 (br.), 3434, 3031, 2976,1720, 1664, 1604, 1512, 1455, 1394, 1367, 1343, 1233, 1156, 1107, 1063,1028, 911 cm⁻¹. MS(FD): m/e 468 (M⁺, 100)

E. 2S-(2R*,2'S*,3'R*)!-1-3'-Amino-2'-hydroxy-4'-phenylbutyl!pyrrolidine-2-N-t-butylcarboxamide

The subtitled compound of Preparation 3D (222 mg, 0.47 mmol) wasdeprotected substantially as detailed in Preparation 1B, using 67 mg of10% palladium-on-carbon and hydrogen gas (1 atmosphere) in 15 mL ofethanol. The desired compound was purified using column chromatography(eluent of 10% isopropanol in methylene chloride containing 0.75%ammonium hydroxide) to provide 80 mg of an off-white solid.

Yield: 51%. α!_(D) -55.26° (c=0.23, MeOH). ¹ H NMR (CDCl₃): δ 0.80-3.70(m, 25H), 6.90-7.40 (m, 6H). IR (CHCl₃): 3692, 3600-3200 (br.), 2975,1657, 1603, 1522, 1497, 1479, 1455, 1393, 1366, 1232, 1198, 1137, 1049,882 cm⁻¹. MS(FD): m/e 334 (M⁺, 100).

Preparation 4

A. 2S-N-(t-Butoxycarbonyl)pideridine-2-carboxylic acid

A solution of 1.64 g of sodium carbonate in 15 ml of water was added toa cold (0° C.) solution of 2.0 g (15.5 mol) of 2S-piperidinecarboxylicacid in 50 mL of dioxane. After approximately ten minutes, 3.7 g (17.0mol) of di-t-butyl dicarbonate was added to the mixture. The resultantreaction mixture was reacted for approximately six hours, concentratedto one fourth of the original volume and then acidified to pH 2 using 1Msodiumhydrogen sulfate and ethyl acetate. The resulting layers wereseparated, and the organic layers were washed with a saturated brinesolution, dried over sodium sulfate, filtered and then reduced todryness under reduced pressure to provide 2.67 g of a white crystallinesolid.

Yield: 75%. α!_(D) -55.26° (c=0.23, MeOH). ¹ H NMR (CDCl₃): δ 1.20-1.80(m, 15H), 2.15-2.30 (m, 1H), 2.85-3.10 (m, 1H), 3.90-4.10 (m, 2H),4.70-5.00 (m, 1H). IR (CHCl₃): 3700-1800 (br.), 3025, 3018, 3011, 2980,2947, 2865, 1716, 1685, 1449, 1394, 1368, 1280, 1252, 1162, 1147, 1129cm⁻¹. MS(FD): m/e 229 (M⁺, 100). Analysis for C₂₇ H ₃₇ N₃ O₄ : Calcd: C,57.63; H, 8.35; N, 6.11; Found: C, 57.90; H, 8.35; N, 6.19.

B. 2S-N-(t-Butoxycarbonyl)piperidine-2-carboxylate,pentafluorophenylester

To a cold (0° C.) solution of 2.53 g (11.03 mol) of the subtitledcompound of Preparation 4A and 2.34 g (12.7 mol) of pentafluorobenzoicacid in 50 mL of tetrahydrofuran, was added 2.42 g (12.7 mol) of EDC.The resultant reaction mixture was warmed to room temperature andreacted for approximately two hours. The mixture was then concentratedunder reduced pressure to provide a solid. This solid was redissolved inmethylene chloride and washed sequentially with potassium carbonate andbrine, dried over sodium sulfate, filtered and then reduced to drynessunder reduced pressure to provide 3.85 g of a clear oil which solidifiedon standing.

Yield: 88%. ¹ H NMR (CDCl₃): δ 1.20-1.90 (m, 15H), 2.30-2.40 (m, 1H),2.90-3.15 (m, 1H), 3.90-4.15 (m, 1H), 5.05-5.35 (m, 1H).

C. 2S-N-(t-Butoxycarbonyl)piperidine-2-N-t-butylcarboxamide

To a cold (0° C.) solution of 3.8 g (9.6 mmol) of the subtitled compoundof Preparation 4B in 200 mL of methylene chloride, was slowly added 2.53mL (24.0 mmol) of t-butylamine. The reaction mixture was reacted forapproximately four hours and then concentrated under reduced pressure toprovide a residue. This residue was redissolved in methylene chlorideand then washed sequentially with 1M potassium carbonate and brine,dried over sodium sulfate, filtered and then purified using columnchromatography (gradient eluent of 10-20% ethyl acetate in hexane) toprovide 2.52 g of a white solid.

Yield: 92%. α!_(D) -41.47° (c=0.506, MeOH). ¹ H NMR (CDCl₃): δ 1.10-1.70(m, 15H), 2.20-2.35 (m, 1H), 2.65-2.82 (m, 1H), 3.90-4.10 (m, 1H), 4.62(br.s, 1H). IR (CHCl₃): 3600-3300 (br.), 2978, 2945, 2869, 1677, 1512,1455, 1413, 1394, 1367, 1317, 1280, 1255, 1162, 1144, 1127, 1078, 1042,868 cm ⁻¹. MS(FD): m/e 284 (M⁺, 100). Analysis for C₁₅ H₂₈ N₂ O₃ :Calcd: C, 63.35; H, 9.92; N, 9.85; Found: C, 63.10; H, 9.66; N, 9.92.

D. 2S-Piperidine-2-N-t-butylcarboxamide

A solution containing 1.0 g (3.5 mol) of the subtitled compound ofPreparation 4C and 3.5 mL of trifluoroacetic acid in 25 mL of methylenechloride was stirred at room temperature for approximately two hours.The reaction mixture was concentrated and azeotroped once with toluene.The resultant reaction mixture was then partitioned between methylenechloride and sodium bicarbonate. The resulting layers were separated andthe organic layer was dried over sodium sulfate, filtered and reduced todryness under reduced pressure to provide 641 mg of the subtitledcompound.

Yield: 99%. α!_(D) -22.45° (c=0.95, MeOH). ¹ H NMR ⁻ (CDCl₃): δ1.20-1.50 (m, 12H), 1.51-1.62 (m, 1H), 1.64 (s, 1H), 1.75-1.88 (m, 1H),1.90-2.00 (m, 1H), 2.60-2.72 (m, 1H), 2.98-3.10 (m, 2H), 6.63 (br.s,1H). IR (CHCl₃): 3363, 3002, 2969, 2940, 2860, 1738, 1660, 1522, 1480,1455, 1398, 1367, 1324, 1295, 1230, 1129, 1110, 852 cm⁻¹. MS(FD): m/e184 (M⁺, 100).

E. 2S-(2R*,2'S*,3'R*)!-N-3'-(N-Benzyloxycarbonyl)amino-2'-hydroxy-4'-phenyl!butylpiperidine-2-N-t-butylcarboxamide

A solution containing 195 mg (1.06 mmol) of the subtitled compound ofPreparation 4D and 300 mg (1.01 mmol) of 1S-(1R*,1'R*)!-1-(1'-N(benzyloxycarbonyl)amino-2'-phenyl)ethyl!oxirane in 10 mL ofisopropanol was stirred at 55° C. for approximately forty eight hours.When the reaction was substantially complete, as indicated by TLC, thereaction mixture was concentrated under reduced pressure. The desiredcompound was purified using column chromatography (gradient eluent of1-5% isopropanol in methylene chloride).

Yield: 395 mg (81%). α!_(D) -55.64° (c=0.22, MeOH). ¹ H NMR (CDCl₃): δ1.32 (s, 9H), 1.45-1.90 (m, 6H), 2.25-2.50 (m, 2H), 2.70-3.20 (m, 5H),3.30-3.40 (m, 1H), 3.75-4.05 (m, 2H), 4.95-5.10 (m 3H), 6.15 (br.s, 1H),7.18-7.40 (m, 10H). IR (CHCl₃): 3700-3100 (br.), 3623, 3021, 2976, 1668,1603, 1511, 1456, 1313, 1047, 878 cm⁻¹. MS(FD) m/e 482 (M⁺, 100).

F.2S-(2R*,2'S*,3'R*)!-N-(3'-Amino-2'-hydroxy-4'-phenyl!butylpiperidine-2-N-t-butylcarboxamide

The subtitled compound of Preparation 4E (371 mg, 0.77 mmol) wasdeprotected substantially as detailed in Preparation 1B using 110 mg of10% palladium-on-carbon and hydrogen gas in 20 mL of ethanol to provide260 mg of a white foam.

Yield: 97%. α!_(D) -64.92° (c=0.39, MeOH). ¹ H NMR (CDCl₃): δ 1.35 (s,9H), 1.45-1.90 (m, 6H), 2.25-2.35 (m, 1H), 2.50-2.90 (m, 5H), 3.00-3.40(m, 3H), 3.85-3.98 (m, 1H), 6.29 (s, 1H), 7.15-7.38 (m, 5H). IR (CHCl₃):3693, 3650-3100 (br.), 2943, 2862, 1671, 1603, 1517, 1497, 1455, 1394,1367, 1233, 1185, 1049, 887 cm ⁻¹. MS(FD): m/e 348 (M⁺, 100).

Preparation 5

A. Pyrazine-2-N-(t-butyl)carboxamide

To a slurry of 50 g (0.403 mol) pyrazine-2-carboxylic acid in 600 mL oftetrahydrofuran and 100 mL of dimethylformamide, was added 65.9 g (0.407mol) of carbonyldiimidazole. The resultant reaction mixture was reactedat 50° C. until gas evolution ceased. After the reaction mixture cooled,73.5 g (1.00 mol) of t-butylamine was slowly added. The reaction mixturewas reacted for approximately thirty minutes, concentrated under reducedpressure, redissolved in 500 mL of methylene chloride and then washedsequentially with water, hydrochloric acid (pH 2), saturated sodiumbicarbonate, water, 1M potassium hydroxide, and brine, dried over sodiumsulfate, and concentrated to provide 68.5 g of a white solid.

Yield: 95%. ¹ H NMR (CDCl₃): δ 1.51 (s, 9H) 7.73 (br.s, 1H), 8.49 (m,1H), 8.72 (m, 1H), 9.38 (s, 1H).

B. (+/-)-Piperazine-2-N-(t-butyl)carboxamide

A mixture of 68.5 g (0.382 mol) of the subtitled compound of Preparation5A, 70 g (0.308mol) of platinum oxide in 186 mL of ethanol was heatedovernight at 40° C. under a hydrogen atmosphere (60 psi). The resultantcrude material was filtered and the filtrate was concentrated to provide65 g of white solid.

Yield: 95%. MS(FD): m/e 185 (M⁺, 100).

C. (+/-)-4-(Pyrid-3'-ylmethyl)piperazine-2-N-(t-butyl)carboxamide

To a solution of 5.0 g (0.027 mol) of the subtitled compound ofPreparation 5B in 160 mL of a 1:1 mixture of water and acetonitrile, wasadded 18.65 g (0.135 mol) of potassium carbonate. The resultant mixturewas vigorously stirred during the addition of 4.43 g (0.027 mol) of3-chloromethylpyridine hydrochloride and then allowed to reactovernight. The resultant reaction mixture was concentrated under reducedpressure, slurried in a solution of 20% isopropanol in chloroform andwashed sequentially with water and brine, dried over sodium sulfate,filtered and then concentrated to provide a residue. This residue waspurified using flash chromatography (eluent of 5% methanol in methylenechloride containing 1% ammonium hydroxide) to provide 1.34 g of a clearyellow oil.

Yield: 18%. ¹ H NMR (CDCl₃): δ 1.10 (s, 9H), 1.89-2.01 (m, 2H), 2.35 (m,1H), 2.57-2.74 (m, 4H), 3.09 (m, 1H) 3.27 (s, 2H), 6.71 (br.s, 1H), 7.03(m, 1H), 7.44 (m, 1H) 8.26 (m, 2H). IR (KBr): 3691, 3611, 3366, 2974,1666, 1602, 1521, 1479, 1456, 1427, 1393, 1366, 1324, 1139, 1047, 839 cm⁻¹. MS(FD): m/e 276 (M⁺, 100).

D. 2S-(2R*,2'S*,3'R*)!-1-2'-Hydroxy-3'-(N-benzyloxycarbonyl)amino-4'-phenylbutyl!-4-(pyrid-3''-ylmethyl)piperazine-2-N-(t-butyl)carboxamide

A solution containing 0.377 g (1.27 mmol) of 1S-(1R*,1'R*)!-1-(1-N-Benzyloxycarbonyl)amino-2'-phenyl)ethyl!oxirane and 0.350 g (1.27mmol) of the subtitled compound of Preparation 5C in 12 mL ofisopropanol was reacted at 45° C. for approximately forty eight hours.The reaction mixture was cooled and then concentrated under reducedpressure to provide a crude material. This material was purified usingradial chromatography (6 mm plate; gradient eluent of 5-10% isopropanolin methylene chloride) to provide 120 mg of isomer A and 68 mg of isomerB.

Yield: 26% overall. Isomer A: ¹ H NMR ⁻ (CDCl₃): δ 1.33 (s, 9H),2.26-2.89 (m, 13H), 3.29 (m, 1H), 3.45 (s, 2H), 3.79-3.95 (m, 3H), 4.73(br.s, 1H), 4.97 (br.s, 2H), 5.20 (m, 1H), 7.14-7.29 (m, 6H) 7.57 (m,1H), 7.82 (br.s, 1H), 8.53 (m, 2H). IR (KBr): 3692, 3434, 2970, 2829,1714, 1661, 1604, 1579, 1512, 1455, 1427, 1393, 1365, 1231, 1149, 1029,909 cm⁻¹. MS(FD): m/e 573 (M⁺, 100).

E. 2S-(2R*,2'S*,3'R*)!-1-2'-Hydroxy-3'-amino-4'-phenyl!butyl-4-(pyrid-3''-ylmethyl)piperazine-2-N-(t-butyl)carboxamide

A solution containing 0.062 g (0.11 mmol) of the subtitled compound ofPreparation 5D (isomer A) was stirred for approximately ninety minutesin 1.5 mL of a solution of 30% hydrobromic acid in acetic acid. Theresultant mixture was concentrated, azeotroped three times with toluene,redissolved in methanol containing 1 mL each of diethylamine andammonium hydroxide and then concentrated under reduced pressure toprovide a residue. This residue was purified using radial chromatography(2 mm plate; gradient eluent of 15-25% methanol in methylene chloridecontaining 1% ammonium hydroxide) to provide 13 mg of a white solid.

Yield: 28%. ¹ H NMR (CDCl₃): δ 1.33 (s, 9H), 2.36-3.21 (m, 15H), 3.47(d, 2H), 3.75 (m, 1H), 7.19-7.30 (m, 6H) 7.57 (m, 2H), 8.52 (m, 2H).MS(FD): m/e 440 (M⁺, 100).

Preparation 6

A. 2S-(2R*,2'S*,3'S*)!-1-3'-N-(Benzyloxycarbonyl)amino-2'-hydroxy-4'-phenylthiobutyl!-4-pyrid-3''-ylmethyl!piperazine-2-N-t-butylcarboxamide isomer B!

A solution of 596 mg (1.81 mmol) of 1S-(1R*,1'S*)!-1-1-N-(benzyloxycarbonyl)amino-2'-(phenylthio)ethyl!oxirane and 500 mg(1.81 mmol) of the subtitled compound of Preparation 5C in 15 mL ofisopropanol were heated at 43° C. for approximately forty-eight hours.The reaction was monitored using TLC (10% isopropanol in methylenechloride containing 1% ammonium hydroxide; Isomer A R_(f) =0.7; Isomer BR_(f) =0.6). When the reaction was substantially complete, the reactionmixture was concentrated under reduced pressure to provide a residue.This residue was purified using radial chromatography (6 mm plate;gradient eluent of 5-15% isopropanol in methylene chloride containing 1%ammonium hydroxide) to provide 200 mg of isomer A as a light tan foamand 191 mg of an off-white foam (isomer B).

Isomer A: Yield: 18%. ¹ H NMR (CDCl₃): δ 1.31 (s, 9H), 2.25-2.62 (m,7H), 2.78-2.95 (m, 2H), 2.98-3.08 (m, 1H), 3.10-3.25 (m, 2H), 3.40-3.55(m, 2H), 3.72-3.85 (m, 1H), 3.90-4.00(m, 1H), 5.05 (s, 2H), 7.01 (br.s,1H) 7.10-7.40. (m, 11H), 7.62 (d, J=7.8 Hz, 1H), 8.49 (s, 2H). MS(FD):m/e 606 (M⁺, 100). Analysis for C₃₃ H₄₃ N₅ O₄ S: Calcd: C, 65.42; H,7.15; N, 11.56; Found: C, 65.38; H, 7.27; N, 11.36.

Isomer B: Yield: 11%. ¹ NMR (CDCl₃): δ 1.33 (s, 9H), 2.25-2.85 (m, 8H),3.20-3.32 (m, 3H), 3.47 (s, 2H), 3.78-3.95 (m, 2H), 5.06 (s, 2H),5.30-5.38 (m, 1H), 7.10-7.42 (m, 12H), 7.55-7.85 (m, 2H), 8.50-8.60 (m,2H). MS (FD): m/e 606 (M), 497 (100). HR MS(FAB) for C₃₃ H₄₄ N₅ O₄ S:Calcd: 606.3114; Found: 606.3141.

B. 2S-(2R*,2'S*,3'S*)!-1- 2'-Hydroxy-3'-amino-4'-phenylthiobutyl!-4-pyrid-3''-ylmethyl!-piperazine-2-N-t-butylcarboxamide

A solution of 110 mg (0.18 mmol) of isomer B from Preparation 6A in 5 mLof 30% hydrobromic acid in acetic acid was stirred at room temperaturefor approximately 1 hour. The reaction mixture was concentrated underreduced pressure to provide a residue. This residue was redissolved in 4mL of ammonium hydroxide. The resultant solution was extracted fourtimes with 10 mL portions of a 10% solution of isopropanol inchloroform. The combined organic layers were dried over sodium sulfate,filtered and concentrated under reduced pressure to provide a residue.This residue was purified using radial chromatograghy (2 mm plate;gradient eluent of 10-30% methanol in methylene chloride containing 1%ammonium hydroxide) to provide 65 mg of a light yellow foam.

Yield: 72%. ¹ H NMR (CDCl₃): δ 1.25 (s, 9H), 2.25-2.78 (m, 7H),3.00-3.32 (m, 4H), 3.47 (s, 2H), 3.60-3.75 (m, 1H), 4.18-4.35 (m, 1H),6.90-7.65 (m, 9H), 8.40-8.60 (m, 2H). MS(FD): m/e 473 (M⁺, 100).

Preparation 7

A. 3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-3'-N-(Benzyloxycarbonyl)amino-2'-hydroxy-4'-(naphth-2-ylthio)!butyldecahydroisoquinoline-3-N-(t-butyl)carboxamide

A solution was prepared containing 165 mg (0.40 mmol) of the subtitledintermediate of Preparation 2E and 94 mg (0.43 mmol) of3-(1-N(t-butyl)amino-1-oxomethyl)octahydro-(2H)-isoquinoline in 5 mL ofethanol. The resulting reaction mixture was allowed to react at 80° C.for approximately 19 hours. The solution was then cooled to roomtemperature and concentrated under reduced pressure to provide aresidue. This residue was purified using radial chromatography (eluentof 10% ethyl acetate in methylene chloride) to provide 103 mg of anoff-white foam.

Yield: 42%. ¹ H NMR (CDCl₃): δ 1.10-1.73 (m, 20H), 2.13-2.31 (m, 2H),2.44-2.53 (m, 1H), 2.56-2.68 (m, 1H), 2.86-2.97 (m, 1H), 3.52 (br.s,2H), 4.02 (br.s, 2H), 4.98 (s, 2H), 5.65 (s, 1H), 5.94 (s, 1H),7.25-7.83 (complex, 13H). MS (FD): m/e 629 (M⁺), 138 (100). α!_(D)-92.45° (c 1.06, MeOH). IR (CHCl₃): 3429, 3010, 2929, 1713, 1670, 1514,1455, 1047 cm⁻¹. Analysis for C₃₅ H₄₇ N₃ O4S: Calcd: C, 69.98; H, 7.67;N, 6.80; Found: C, 69.86; H, 7.78; N, 6.58.

B. 3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-3'-amino-2'-hydroxy-4'-(naphth-2-ylthio)!butyldecahydroisoquinoline-3-N-(t-butyl)carboxamide

A solution was prepared containing 50 mg (0.081 mmol) of the subtitledintermediate of Preparation 7A and 1 mL of a 38% aqueous hydrobromicacid solution in acetic acid. The resultant reaction mixture was allowedto react at room temperature for approximately 1 hour and then wasconcentrated under reduced pressure to provide a residue. This residuewas slurried with toluene and then concentrated under reduced pressureto provide 61 mg of the desired subtitled intermediate. This compoundwas used crude without purification in Example 9.

¹ H NMR (CDCl₃): δ 1.14 (s, 1H), 1.17-2.07 (complex, 15H), 2.66-2.87 (m,2H), 3.21-3.25 (m, 2H), 3.75 (d, J=12 Hz, 1H), 3.85 (d, J=6 Hz, 1H),4.36-4.47 (m, 1H), 6.73 (s, 1H), 7.39-7.90 (complex, 7H). MS (FD): 483(M⁺), 483 (100).

Preparation 8

A. 2R-2-N(Benzyloxycarbonyl)amino-3-phenylthio propanoic acid

The desired subtitled intermediate was prepared substantially inaccordance with the procedure detailed in Procedure 2A, using 13.1 mL(127 mmol) of thiophenol, 4.6 g (117 mmol) of a 60% sodium hydridesolution and 25.6 g (116 mmol) of L-N(benzyloxycarbonyl)-serineβ-lactone in 450 mL of tetrahydrofuran to provide a residue. Thisresidue was purified using flash chromatography (gradient eluent of 0-2%acetic acid in a 4:1 methylene chloride/ethyl acetate mixture) toprovide 27.9 g of a white solid.

Yield: 72%. ¹ H NMR (CDCl₃): δ 7.55-7.18 (m, 10H), 5.55 (d, J=7 Hz, 1H),5.08 (s, 2H), 4.73-4.60 (m, 1H), 3.55-3.30 (m, 2H). IR (KBr): 3304,3035, 1687, 1532, 736 cm ⁻¹. MS(FD): m/e 332, 288, 271, 181. Analysisfor C₁₇ H₁₇ NO₄ S: Calcd: C, 61.61; H, 5.17; N, 4.23; Found: C, 61.69;H, 5.22; N, 4.47.

B. 3S-1-Diazo-2-oxo-3-N-(benlzyloxycarbonyl)amino-4-phenylthio butane

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Procedure 2B, using 12.1 g (37 mmol) ofthe subtitled compound of Preparation 8A, 5.09 mL (37 mmol) oftriethylamine, 7.13 mL (55 mmol) isobutyl chloroformate, 146 mmol of adiazomethane solution to provide a residue. The diazomethane solutionwas prepared using 100 mL of diethylether, 150 mL of a 5N sodiumhydroxide solution and 21 g (146 mmol) ofN(methyl)-N(nitro)-N(nitroso)-guanidine as described in Preparation 2B.This residue was purified using flash chromatography (gradient eluent of0-5% ethyl acetate in methylene chloride) to provide a yellow oil.

Yield: 73%. ¹ H NMR (CDCl₃) δ 7.50-7.19 (m, 10H), 5.62 (d, J=7 Hz, 1H),5.47 (br.s, 1H), 5.11 (s, 2H), 4.50-4.32 (m, 1H), 3.33 (d, J=6 Hz, 1H).IR (KBr): 3012, 2115, 1720, 1501, 1367, 1228 cm⁻¹. MS (FD): m/e 356,328, 242.

C. 3R-1-Chloro-2-oxo-3-N-(benzyloxycarbonyl)amino-4-phenylthio butane

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Procedure 2C, using 22.3 g (63 mmol) ofthe subtitled compound of Preparation 8B and small quantities ofhydrochloric acid (gas) in 400 mL of diethylether to provide 21 g of awhite solid. This solid was used without further purification.

¹ H NMR (CDCl₃): δ 7.50-7.15 (m, 10H), 5.56 (dd, J=2,6.7 Hz, 1H), 5.11(s, 2H), 4.78-4.67 (m, 1H), 4.20 (d, J=15.9 Hz, 1H), 4.12 (d, J=15.9 Hz,1H), 3.48-3.23 (m, 2H). IR (KBr): 3349, 1732, 1684, 1515, 1266 cm⁻¹. MS(FD): m/e 363 (M⁺). Analysis for C₁₈ H₁₈ NO₃ SCl: Calcd: C, 59.42; H,4.99; N, 3.85; Found: C, 59.57; H, 5.09; N, 4.13.

D.2S-(2R*,3S*)!-1-Chloro-2-hydroxy-3-N-(benzyoxycarbonyl)amino-4-phenylthiobutane

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Procedure 2D, using 21 g (58 mmol) of thesubtitled compound of Preparation 8C, and 2.4 g (63 mmol) of sodiumborohydride in 300 mL of tetrahydrofuran to provide a residue. Thisresidue was purified using flash chromatography (gradient eluent of 0-2%methanol in methylene chloride) followed by flash chromatography(gradient eluent of 0-2% ethyl acetate in chloroform) and thenrecrystallized from methylene chloride at -78° C. to provide 8.3 g ofthe subtitled compound.

Yield: 39%. ¹ H NMR (CDCl₃): δ 7.47-7.19 (m, 10H), 5.22-5.03 (m, 1H),5.09 (s, 2H), 4.01-3.89 (m, 2H), 3.75-3.58 (m, 2H), 3.32 (d, J=4 Hz,2H). IR (KBr): 3321, 2951, 1688, 1542, 1246, 738 cm⁻¹. MS (FD): m/e 366(M⁺), 119. Analysis for C₁₈ H₂₀ NO₃ SCl: Calcd: C, 59.09; H, 5.51; N,3.83; Found: C, 59.03; H, 5.50; N, 3.96.

E. 1'R- (1'R*,1S*)!-1-(1'-N-(benzyloxycarbonyl)amino-2'-phenylthio)ethyl oxirane

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Procedure 2E, using 8.3 g (23 mmol) ofthe subtitled compound of Preparation 8D, 1.4 g (25 mmol) of potassiumhydroxide in 400 mL of ethanol to provide a residue. This residue waspurified using flash chromatography (gradient eluent of 0-2% ethylacetate in methylene chloride) to provide 6.4 g of a white solid.

Yield: 85%. ¹ H NMR (CDCl₃): δ 7.45-7.15 (m, 10H), 5.12 (s, 1H), 5.08(s, 2H), 3.77-3.62 (m, 1H), 3.21 (d, J=6 Hz, 2H), 2.99 (m, 1H), 2.77 (m,2H). IR (KBr): 3303, 3067, 1694, 1538, 1257, 741 cm⁻¹. MS (FD) m/e 329.Analysis for C₃₂ H₄₅ N₃ O₄ S: Calcd: C, 65.63; H, 5.81; N, 4.25; Found:C, 65.48; H, 5.82; N, 4.29.

F. 3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-3'-N-(benzyloxycarbonyl)amino-2'-hydroxy-4'-(phenyl)thio!butyldecahydroisoquinoline-3-N-t-butyl carboxamide

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Procedure 2F, using 6.3 g (19 mmol) ofthe subtitled compound of Preparation 8E, 5 g (21 mmol) of3S-(3R*,4aR*,8aR*)!-decahydroisoquinoline-3-N-t-butylcarboxamide in 300mL of ethanol to provide a residue. This residue was purified usingflash chromatography (gradient eluent of 0-20% ethyl acetate inmethylene chloride) to provide 4.3 g of a white solid.

Yield: 40%. ¹ H NMR (CDCl₃): δ 7.41-7.11 (m, 10H), 5.90 (d, J=5 Hz, 1H),5.64 (s, 1H), 5.05 (d, J=4 Hz, 2H), 4.08-3.90 (m, 2H), 3.40 (d, J=6,2H), 3.05 (s, 1H), 2.95-2.85 (m, 1H), 2.62-2.45 (m, 2H), 2.28-2.15 (m,2H), 2.05-1.88 (m, 2H), 1.78-1.10 (m, 7H), 1.29 (s, 9H). IR(KBr): 3330,2925, 2862, 1706, 1661, 1520, 1454, 1246, 738, 694 cm⁻¹. MS (FD): m/e568 (M⁺), 467. Analysis for C₃₂ H₄₅ N₃ O₄ S: Calcd: C, 67.69; H, 7.99;N, 7.40; Found: C, 67.64; H, 8.20; N, 7.45.

G. 3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-3'-amino-2'-hydroxy-4'-(phenyl)thio!butyldecahydroisoquinoline-3-N-t-butyl carboxamide

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Procedure 2G using 1 g (1.8 mmol) of thesubtitled compound of Preparation 8F and 40 mL of a 30% hydrobromic acidin acetic acid solution, with the exception that the crude material wasdissolved in 30 mL of methanol. To the resulting solution, was added 2mL of diethylamine and 2 mL of concentrated ammonium hydroxide and thenthe mixture was concentrated under reduced pressure to provide aresidue. This residue was redissolved in water and ethyl acetate. Theresulting layers were separated and the organic layer was washedsequentially with an aqueous sodium bicarbonate solution and brine,dried over sodium sulfate, filtered and then reduced to dryness underreduced pressure to provide a residue. This residue was purified usingflash chromatography (gradient eluent of 0-10% methanol in chloroform(containing 3 drops of ammonium hydroxide per 1000 mL of chloroform) toprovide 0.54 g of a white foam.

Yield: 71%. separate ¹ H NMR (CDCl₃): δ 7.41-7.16 (m, 5H), 6.07 (s, 1H),3.78-3.70 (m, 1H), 3.45-3.38 (m, 1H), 3.03-2.84 (m, 3H), 2.38-2.20 (m,3H), 2.00-1.05 (m, 12H), 1.33 (s, 9H). IR (KBr): 2924, 2862, 1660, 1517,1454, 1439, 737, 691 cm⁻¹. MS (FD): m/e 434 (M⁺), 293.

Preparation 9

A. 3-Methoxy-N-phenylbenzamide

A solution of 13.4 mL (147 mmol) of aniline in 30.7 mL of triethylaminewas slowly added to a solution containing 25.1 g (147 mmol) of3-methoxybenzoyl chloride in methylene chloride. The resulting reactionmixture was reacted for approximately thirty minutes and then dilutedwith 1N sodium bicarbonate. The resultant layers were separated and theorganic layer was washed sequentially with water, 1M sodium hydroxideand then brine, dried over sodium sulfate, filtered and then reduced todryness under reduced pressure to provide 31.5 9 of an off-white solid.

Yield: 95%.

B. 3-Methoxy-2-methyl-N-phenylbenzamide

To a cold (-70° C.) solution of 4.54 g (20 mmol) of the subtitledcompound of Preparation 9A and 5.11 g (44 mmol) of TMEDA in 70 mL ofanhydrous tetrahydrofuran, was added 26.9 mL of a 1.56M solution ofn-butyl lithium in hexane. The resultant reaction mixture was warmed to-15° C. and stirred for approximately 45 minutes to provide a yellowslurry. The slurry was then recooled to -70° C. and 2.89 g (20 mmol) ofmethyl iodide was added, resulting in the formation of a whiteprecipitate. The reaction mixture was stirred overnight at roomtemperature, quenched with saturated ammonium chloride and diluted withdiethylether. The resulting layers were separated and the organic phasewashed sequentially with saturated ammonium chloride, water, saturatedsodium bicarbonate and brine solutions. The organic extracts were thendried over sodium sulfate and concentrated to provide a white solidwhich was purified by recrystallization from a 2:1 ethyl acetate/hexanesolution to provide 4.00 g of needles.

Yield: 99%. ¹ H NMR (CDCl₃): δ 2.36 (s, 3H), 3.88 (s, 3H), 3.89 (s, 1H),6.90-7.70 (m, 8H). IR (CHCl₃): 3424, 3013, 2963, 2943, 2840, 1678, 1597,1585, 1519, 1463, 1438, 1383, 1321, 1264, 1240, 1178, 1083, 1069 cm⁻¹.MS(FD): m/e 241 (M⁺, 100). Analysis for C₁₅ H₁₅ NO₂ : Calcd: C, 74.67;H, 6.27; N, 5.80; Found: C, 74.65; H, 6.29; N, 5.82.

C. 3-Hydroxy-2-methylbenzoic acid

A mixture of 1.21 g (5.00 mmol) of the subtitled compound of Preparation9B, 35 mL of 5N hydrochloric acid and 20 mL of a 30% solution ofhydrobromic acid in acetic acid were heated at reflux for 24 hours.After cooling, the reaction mixture was diluted with 100 mL of ethylacetate and 100 mL of water. The resulting layers were separated and theorganic layer was washed once with water and then basified to pH 11using 0.5N sodium hydroxide The resulting layers were separated and theaqueous layer reacidified to pH 1 using 5N hydrochloric acid. Thedesired compound was then extracted from this aqueous layer using ethylacetate. The ethyl acetate extracts were then washed with brine, driedover sodium sulfate, filtered, and then concentrated to provide aresidue which after two concentrations from hexane yielded 750 mg of awhite solid.

Yield: 98%. ¹ H NMR (DMSO-d₆): δ 2.26 (s, 3H), 6.98 (d, J=8.03 Hz, 1H),7.02 (t, J=7.69 Hz, 1H), 7.15 (d, J=7.37 Hz, 1H), 9.55 (br.s, 1H). IR(CHCl₃): 3600-2100 (br.), 3602, 2983, 1696, 1588, 1462, 1406, 1338,1279, 1174, 1154, 1075, 1038, 920, 892, 854, 816 cm⁻¹. MS(FD): m/e 152(M⁺, 100). Analysis for C₈ H₈ O₃ : Calcd: C, 63.15; H, 5.30; Found: C,63.18; H, 5.21.

Alternatively, the desired subtitled compound was prepared by adding22.6 g (0.33 mol) of sodium nitrite in small portions to a cooled (-10°C.) solution of 45 g (0.30 mol) of 3-amino-2-methylbenzoic acid and 106g (58 mL; 1.08 mol) of concentrated sulfuric acid in 400 mL of water,while maintaining the temperature below 7° C. The resultant reactionmixture was stirred for approximately 30 minutes at -10° C., poured intoa solution of 240 mL of concentrated sulfuric acid in 1.2 L water, andthen slowly heated to 80° C. (heavy gas evolution occurs between thetemperatures of 40°-60° C.). When the gas evolution stopped, thereaction mixture was cooled to room temperature and the subtitledcompound was extracted five times with ethyl acetate (600 mL). Thecombined organic phases were combined with 500 mL of an aqueoussaturated sodium carbonate solution. The resultant layers were separatedand the aqueous layer was acidified to pH 2 with concentratedhydrochloric acid. The titled compound was then extracted using ethylacetate (500 mL) and the combined organic phases were washed with brine,dried over sodium sulfate, filtered and then concentrated under reducedpressure to provide a crude material. This material was purified usingtwo recrystallizations from a ethyl acetate/chloroform mixture toprovide 23.2 g of a light orange powder.

Yield: 52%.

Preparation 10

A. 2-Ethyl-3-methoxy-N-phenylbenzamide

The subtitled compound was prepared substantially in accordance with theprocedure detailed in Preparation 9B, using 13.5 mL (21 mmol) of 1.56Mn-butyl lithium, 2.27 g (10.0 mmol) of the subtitled compound ofPreparation 9A, 2.56 g (22.0 mmol) of TMEDA and 1.56 g (10.0 mmol) ofethyl iodide in 50 mL of anhydrous tetrahydrofuran. The resultant crudematerial was purified by recrystallization from a 3:1 solution of ethylacetate/hexane to provide 1.57 g of needles.

Yield: 62%. ¹ H NMR (CDCl₃): δ 1.22 (t, J=7.4 Hz, 3H), 2.81 (q, J=7.4Hz, 2H), 3.88 (s, 3H), 6.96 (d, J=8.2 Hz, 1H), 7.05 (d, J=7.6 Hz, 1H),7.10-7.45 (m, 4H), 7.50 (s, 1H), 7.62 (d, J=7.95 Hz, 1H). MS(FD): m/e255 (M+, 100). Analysis for C₁₆ H₁₇ NO₂ : Calcd: C, 75.27; H, 6.71; N,5.49; Found: C, 75.39; H, 6.72; N, 5.43.

B. 2-Ethyl-3-hydroxybenzoic Acid

A solution containing 180 mg (0.71 mmol) of the subtitled compound ofPreparation 10A, 3 mL of 5N hydrochloric acid and 3 mL of a 30% solutionof hydrobromic acid/acetic acid were heated for 20 hours in a sealedtube at 155° C. After cooling, the reaction mixture was diluted withethyl acetate and water. The resulting layers were separated and theorganic layer was extracted once with water and then basified to pH 11using 0.5N sodium hydroxide. The resulting layers were separated and theaqueous layer reacidified to pH 1 using 5N hydrochloric acid. Thedesired compound was then extracted from this aqueous layer using ethylacetate. The ethyl acetate extracts were washed with brine, dried oversodium sulfate, filtered and then concentrated to provide 103 mg of apale red solid.

Yield: 88. ¹ H NMR (acetone-d₆): δ 1.16 (t, J=7.4 Hz, 3H), 2.98 (q,J=7.4 Hz, 2H), 7.00-7.15 (m, 2H), 7.32-7.36 (m, 1H), 8.48 (br.s, 1H).MS(FD): m/e 166 (M⁺, 100).

Preparation 11

A. 2-Fluoro-3-methoxy-N-phenylbenzamide

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 9B, by adding a solution of3.15 g (10.0 mmol) of N-fluorobenzenesulfonimide in 5 mL oftetrahydrofuran to a solution containing 13.5 mL (21.0 mmol) of 1.56Mn-butyl lithium, 2.27 g (10.0 mmol) of the subtitled compound ofPreparation 9A and 2.56 g (22.0 mmol) of TMEDA in 50 mL of anhydroustetrahydrofuran. The resultant crude material was recrystallized twicefrom a 2:1 solution of ethyl acetate/hexane and then further purifiedusing radial chromatography (6 mm, 0.5% ethyl acetate in methylenechloride) to provide 540 mg of an off-white solid.

Yield: 22%. ¹ H NMR (CDCl₃) δ 3.94 (s, 3H), 7.05-7.80 (m, 8H), 8.35-8.50(m, 1H). MS(FD): m/e 245 (M⁺, 100).

B. 2-Fluoro-3-hydroxybenzoic Acid

The subtitled compound was prepared substantially in accordance with theprocedure detailed in Preparation 9C, using a solution of 255 mg (1.02mmol) of the subtitled compound of Preparation 11A, 3 mL of 5Nhydrochloric acid and 5 mL of a 30% solution of hydrobromic acid inacetic acid to provide 134 mg of a white solid.

Yield: 86%. ¹ H NMR (acetone-d₆): δ 7.05-7.50 (m, 5H). MS (FD): m/e 156(M⁺, 100).

Preparation 12

A. 4-N-(Phenyl)carbamoyl pyridine

A solution of 22.8 mL (250 mmol) of aniline in 104.5 mL (750 mmol) oftriethylamine was slowly added to a solution of 44.5 g (250 mmol) of4-chloroformyl pyridinium hydrochloride in 500 mL of chloroform. Theresulting reaction mixture was stirred overnight and then refluxed for 2hours. After cooling, the reaction mixture was diluted with 600 mL ofwater which resulted in the formation of a precipitate. After adding 200mL of isopropanol to the mixture, the resultant layers were separatedand the organic layer was washed sequentially with 0.1N sodiumhydroxide, water and then brine, dried over sodium sulfate, filtered andthen concentrated under reduced pressure at 70° C. to provide a whitesolid with a brown tinge. This solid was washed with 200 mL of ethylacetate to provide 38.9 g of the desired subtitled compound.

Yield: 78%.

B. 4-N-(Phenyl)carbamoyl pyridine N-oxide

To a hot (85°-90° C.) solution of 19.8 g (100 mmol) of the subtitledcompound of Preparation 12A in 60 mL of glacial acetic acid, was slowlyadded 51 mL of hydrogen peroxide behind a blast shield. The resultantreaction mixture was reacted for approximately four hours at 90° C.,cooled to room temperature, diluted in about 60 mL of a mixture ofisopropanol and chloroform and then basified to pH 12. The resultantlayers were separated and the combined organic extracts were dried oversodium sulfate, filtered and concentrated under reduced pressure toprovide a pale yellow solid. This solid was triturated with 250 mL ofmethylene chloride and reduced to dryness to provide 15.95 g of anoff-white solid.

Yield: 75%.

C. 2-Chloro-4-N-(phenyl)carbamoyl pyridine

To a solution of 20.2 g (97.0 mmol) of phosphorus pentachloride in 27 mL(289 mmol) of phosphorous oxychloride, was added 14.4 g (67.2 mmol) ofthe subtitled compound of Preparation 12B. The resultant reactionmixture was slowly heated to 130° C. and reacted for approximately 40minutes. The reaction mixture was cooled to room temperature and thenconcentrated under reduced pressure to provide a residue. This residuewas redissolved in 80 mL of water and then diluted with 80 mL of aqueouspotassium carbonate resulting in the formation of a yellow precipitate.The precipitate was isolated by filtration, dissolved in 250 mL of hotethanol and then hot filtered to provide a dark yellow solution. Thissolution was concentrated under reduced pressure to approximately 160 mLand then hot filtered again before the addition of about 50-60 mL ofwater. The resultant solution was cooled and the desired compound wasisolated by recrystallization to provide 8.0 g of pale yellow and whiteneedles.

Yield: 51%.

D. 2-Methoxy-4-N-(phenyl)carbamoyl pyridine

To a slurry of 4.09 g (18.0 mmol) of the subtitled compound ofPreparation 12C in 30 mL of methanol, was added 2.92 g (42.0 mmol) ofsodium methoxide. The resultant reaction mixture was refluxed forapproximately eighteen hours, cooled and concentrated under reducedpressure to provide a solid. This solid was washed with water andtriturated with cold benzene to provide 1.8 g of a solid. Analysis ofthis solid indicated that the reaction was not complete, so anadditional 10.01 g (144 mmol) of sodium methoxide was added to the solidin methanol. The resultant reaction mixture was refluxed in methanol forfifteen hours and worked up identically to provide 300 mg of a solid.This solid was purified using column chromatography (2 mm plate; eluentof 40% ethyl acetate in hexane) followed by recrystallization from hothexane to provide 140 mg of the desired compound.

Yield: 3%.

E. 2-Methoxy-3-methyl-4-N-(phenyl)carbamoyl pyridine

The subtitled compound was prepared substantially in accordance with theprocedure detailed in Preparation 9B, using 260 mg (1.17 mmol) of thesubtitled compound of Preparation 12D, 404 μL (2.68 mmol) of TMEDA, 1.78mL (2.68 mmol) of n-butyl lithium, and 329 μL (5.61 mmol) of methyliodide in 2 mL of tetrahydrofuran. The crude material was purified usingradial chromatography (2 mm plate; eluent of 40% ethyl acetate inhexane) followed by recrystallization from hot hexane to provide 140 mgof the desired subtitled compound.

F. 3-methyl-2-pyridone-4-carboxylic acid

A slurry of 150 mg (0.598 mmol) of the subtitled compound of Preparation12E in 4 mL of 5N hydrochloric acid (aqueous) was refluxed forapproximately five hours. After cooling, the reaction mixture wasconcentrated under reduced pressure to provide a yellow oil. This oilwas dissolved in 15 mL of water and the resultant solution was adjustedto pH 8 using potassium hydroxide and then diluted with 10 mL oftoluene. The resulting layers were separated and the aqueous layer wasacidified to pH 3.5 using a 5N hydrochloric acid solution and thenconcentrated under reduced pressure to provide a yellow solid. Thissolid was slurried in 2 mL of hot ethanol and filtered through a cottonplug. The filtrate was then reduced to dryness under reduced pressure toprovide 130 mg of a solid. This solid was washed with 5 mL of hot 10%acetic acid in ethyl acetate to provide 17 mg of a solid which was thencrystallized in ethanol to provide 6.8 mg of the desired subtitledcompound.

Yield: 6%.

Preparation 13

2.6-Dichloro-3-hydroxy benzoic acid

Chlorine gas (20 g; 282 mmol) was slowly bubbled through a cold (-70°C.) solution of 20 g (145 mmol) of 3-hydroxy benzoic acid in 100 mL ofmethanol, under nitrogen, resulting in a temperature increase to about-5° C. The reaction mixture was recooled and after approximately thirtyminutes, the chlorine gas was flushed out with nitrogen. The reactionmixture was then warmed to room temperature and diluted with 100 mL ofwater. The desired titled compound was isolated by recrystallization toprovide a white solid. This solid was purified by recrystallization from90 mL of water followed by recrystallization from 250 mL of benzenecontaining 10 mL of acetone to provide 4.8 g of the desired titledcompound.

Yield: 16%.

Preparation 14

2-Chloro-3-hydroxy benzoic acid

Chlorine gas (10.3 g; 147 mmol) was slowly bubbled through a coldsolution of 20 g (145 mmol) of 3-hydroxy benzoic acid in 100 mL ofmethanol, under nitrogen, while maintaining the temperature below -60°C. After approximately thirty minutes, the chlorine gas was flushed outwith nitrogen and the reaction mixture was allowed to warm to roomtemperature and diluted with 100 mL of water. The desired titledcompound was isolated by recrystallization to provide a white solid.This solid was purified by recrystallization from 50 mL of waterfollowed by recrystallization from 130 mL of benzene containing 10 mL ofacetone to provide the desired titled compound.

Preparation 15

A. 2-Methyl-3-methoxy benzoate methyl ester

A slurry of 306 mg (2.00 mmol) of the subtitled compound of Preparation9C, 1.06 mL (20.0 mmol) of methyl iodide and 1.38 g (10.0 mmol) ofpotassium carbonate in 8 mL of acetone was refluxed for approximately 3hours. Since the reaction was not complete, an additional 2 mL (37.7mmol) of methyl iodide, 2 g (14.5 mmol) of potassium carbonate and 10 mLof acetone were added to the reaction mixture. After refluxing themixture for approximately sixteen hours, the mixture was filtered. Thefiltrate was then concentrated under reduced pressure to provide aresidue. This residue was dissolved in ethyl acetate and washed withwater and then reduced to dryness under reduced pressure to provide 188mg of material which was 88% desired product.

B. 2-Methyl-3-methoxy benzoic acid

A solution of 116 mg (4.86 mmol) of lithium hydroxide in 1 mL of waterwas added to a solution of 175 mg (0.97 mmol) of the subtitled compoundof Preparation 15A in 3 mL of tetrahydrofuran. The resultant reactionmixture was stirred rapidly. When the reaction was substantiallycomplete, as indicated by TLC, the reaction mixture was concentratedunder reduced pressure to provide a residue. This residue wasredissolved with 10 mL of hexane, 25 mL of water and 3 mL of 1N sodiumhydroxide. The resulting layers were separated and the aqueous layer wasdiluted with ethyl acetate and then acidifed to pH 1 using 1Mhydrochloric acid. The resulting layers were separated and the ethylacetate layer was washed with brine, dried over sodium sulfate, filteredand reduced to dryness under reduced pressure to provide 73 mg of thedesired subtitled compound.

Preparation 16

A. 2-Butyl-3-methoxy-N-phenylbenzamide

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 9B, using 11.95 mL of 1.51Mof n-butyl lithium in hexanes (18.04 mmol), 1.95 g (8.95 mmol) of thesubtitled compound of Preparation 9A, 2.19 g (18.89 mmol) of TMEDA and1.60 g (9.45 mmol) butyl iodide in 30 mL of anhydrous tetrahydrofuran.The resultant crude material was purified using radial chromatography (4mm plate; eluent of 15% ethyl acetate in hexane) to provide 83 mg of aclear, colorless oil.

Yield: 3.5%. ¹ H NMR (CDCl₃): δ 0.89 (t, J=7.27 Hz, 3H), 1.36 (m, 2H),1.56 (m, 2H), 2.78 (m, 2H), 3.84 (s, 3H), 6.92 (d, J=7.98 Hz, 1H), 7.00(d, J=7.36 Hz, 1H), 7.11-7.22 (m, 2H), 7.35 (t, 2H), 7.59 (m 2H). IR(CHCl₃): 3691, 3619, 3424, 3024, 3010, 2963, 2874, 1679, 1602, 1580,1517, 1459, 1437, 1315, 1265, 1177, 1055, 877 cm⁻¹. MS(FD) : m/e 283(M⁺, 100).

B. 2-Butyl-3-hydroxybenzoic Acid

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 10B, using 80 mg (0.28 mmol)of the subtitled compound of Preparation 16A in 2 mL of 5N hydrochloricacid, and 2 mL of 30% hydrobromic acid in acetic acid to provide 44 mgof crude material which was used without further purification.

Yield: 60% (by ¹ H NMR). ¹ H NMR (CDCl₃): δ 0.96 (t, J=8.09 Hz, 3H),1.44 (m, 2H), 1.59 (m, 2H), 3.03 (m, 2H), 6.99 (d, J=8.03 Hz, 1H), 7.15(t, J=7.77 Hz, 1H), 7.59 (d, J=6.85 Hz, 1H).

Preparation 17

A. 3-Methoxy-2-propyl-N-phenylbenzamide

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 9B, using 2.5 g (11.0 mmol)of the subtitled compound of Preparation 9A, 2.81 g (24.2 mmol) ofTMEDA, 15.23 mL (23.13 mmol) of n-butyl lithium and 1.33 g (11.0 mmol)of allyl bromide in 30 mL of tetrahydrofuran to provide 2.5 g of crudematerial. This material was dissolved in 30 mL of absolute ethanol inthe presence of 0.5 g of 10% palladium-on-carbon and the resultingmixture was reacted under a hydrogen atmosphere for approximately twelvehours. The mixture was then filtered over celite and the filtrate wasconcentrated under reduced pressure to provide an orange oil. This oilwas purified using radial chromatography (6 mm plate; eluent of 10%ethyl acetate in hexane) to provide 438 mg of a white foam.

Yield: 15%. ¹ H NMR (CDCl₃): δ 0.94 (t, J=7.35 Hz, 3H), 1.62 (m, 2H),2.75 (m, 2H), 3.84 (s, 3H), 6.92 (d, J=8.06 Hz, 1H), 7.00 (d, J=7.39 Hz,1H), 7.16 (m, 2H), 7.34 (t, 2H), 7.59 (d, 2H), 7.69 (br.s, 1H).

B. 3-Hydroxy-2-propylbenzoic Acid

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 10B, using 438 mg (1.62 mmol)of the subtitled compound of Preparation 17A in 7 mL of 5N hydrochloricacid and 7 mL of 30% hydrobromic acid in acetic acid to provide a tansolid. This solid was purified by recrystallization from hot toluene toprovide 84 mg of a tan solid.

Yield: 29%. ¹ H NMR (CDCl₃): δ 1.01 (t, J=7.33 Hz, 3H), 1.63 (m, 2H),2.98 (m, 2H), 6.98 (d, J=7.97 Hz, 1H), 7.14 (t, J=7.86 Hz, 1H), 7.57 (d,J=7.28 Hz, 1H). IR (KBr) 3383, 3047, 2962, 2872, 2641, 1698, 1458, 1412,1341, 1296, 1278, 1223, 1174, 1086, 929, 815, 752 cm⁻¹. MS(FD): m/e 180(M⁺, 100).

Preparation 18

A. 2-Isopropyl-3-methoxybenzonitrile

To a mixture of 2.76 g (0.115 mol) of magnesium in 75 mL ofdiethylether, was slowly added 24.31 g (0.143 mol) isopropyl iodide. Theresulting reaction mixture was allowed to react until all of themagnesium was consumed. Then, a solution of 15.0 g (0.92 mol) of2,3-dimethoxy benzonitrile in 75 mL of diethylether was added overninety minutes. The resulting reaction mixture was reacted overnight atroom temperature and then refluxed for four hours. The resultantreaction mixture was then cooled to 0° C., and the top layer wasdecanted into saturated ammonium chloride and ice. The resultant layerswere separated and the organic layer was washed sequentially with adilute sodium hydroxide solution, water, and a dilute hydrochloric acidsolution, dried over sodium sulfate, filtered and then concentrated toprovide an orange oil. This oil was distilled under reduced pressure (5inch vigreux column; 0.2 mm Hg) to provide 6.25 g of an orange oil.

Yield: 39%. ¹ NMR (CDCl₃): δ 1.37 (d, J=6.7 Hz, 6H), 3.55 (m, 1H), 3.83(s, 3H), 7.04 (d, J=7.79 Hz, 1H), 7.18 (m, 2H). IR (CHCl₃): 3690, 3617,3019, 2968, 2939, 2841, 2228, 1577, 1470, 1457, 1440, 1387, 1363, 1265,1100, 1070, 1045, 878 cm⁻¹. MS(FD): m/e 175 (M⁺, 100).

B. 3-Hydroxy-2-isopropyl benzoic acid

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 10B, using 330 mg (1.88 mmol)of the subtitled compound of Preparation 18A in 2 mL of 5N hydrochloricacid and 30% hydrobromic acid in acetic acid. The crude product waspurified using radial chromatography (2 mm plate; eluent of 3% methanolin methylene chloride containing 1% acetic acid) to provide 125 mg of arose colored solid.

Yield: 37%. ¹ H NMR (CDCl₃): δ 1.40 (d, J=6.92 Hz, 6H), 3.62 (m, 1H),6.83 (d, J=7.86 Hz, 1H), 7.06 (t, J=7.89 Hz, 1H), 7.24 (d, J=7.55 Hz,1H). IR (CHCl₃): 3599, 3025, 2965, 2876, 1695, 1603, 1584, 1466, 1454,1404, 1360, 1275, 1234, 1166, 1148, 1086, 1057, 926 cm⁻¹. MS(FD): m/e180 (M⁺, 100). Analysis for C₁₀ H₁₂ O₃ : Calcd: C, 66.65; H, 6.71;Found: C, 66.53; H, 6.84.

Preparation 19

3-methylisonicotinic acid

To a hot (155° C.) solution of 10.7 g (0.1 mol) of 3,4-lutidine in 100mL diphenylether, was added 18 g (0.16 mol) selenium dioxide inportions. After about 20 minutes, the reaction was heated to 185° C. andallowed to react for approximately thirty minutes. After cooling, thereaction mixture was diluted with water and filtered. The filtrate wasextracted with chloroform and the chloroform extracts were thenconcentrated under reduced pressure to provide 6.0 g of a pale brownsolid.

Yield: 44%. ¹ H NMR (CDCl₃): δ 2.43 (s, 3H), 7.61 (d, J=4.98 Hz, 1H),8.49 (d, J=4.99 Hz, 1H), 8.53 (s, 1H). ¹³ C NMR (CDCl₃): δ 17.91,123.21, 132.81, 138.15, 148.12, 152.71, 167.89 ppm. IR (KBr): 3425,2418, 1724, 1606, 1445, 1387, 1303, 1278, 1235, 1100, 1072, 850 cm⁻¹.MS(FD): m/e 138 (M⁺, 100).

Preparation 20

5-quinolinecarboxylic acid

To a solution containing 15 g (0.1 mol) of m-aminobenzoic acid, 27 g(0.13 mol) of m-nitrobenzene sulfonate and 25 g (0.4 mol) of glycerol,was added 125 g of 70% sulfuric acid. The resultant reaction mixture wasrefluxed for about 2.5 hours, diluted with 125 mL of water, basified topH 9 using ammonium hydroxide, stirred overnight with 5 g of charcoal,and then filtered. The filtrate was then boiled with 5 g charcoal,filtered, and then cooled to 50° C., acidified to pH 5 with glacialacetic acid (15 mL), and filtered to provide a brown solid. This solidwas boiled in 300 mL of water containing 10 mL of acetic acid and hotfiltered to provide crude material. This material was purified usingrecrystallization from boiling acetic acid to provide 6.1 g of a palebrown solid.

Yield: 32%. ¹ H NMR (CDCl₃): δ 7.62 (m, 1H), 7.81 (t, J=7.82 Hz, 1H),8.20 (m, 2H), 8.93 (d, J=3.79 Hz, 1H), 9.24 (d, J=8.58 Hz, 1H). IR(KBr): 2772, 2431, 1906, 1708, 1610, 1589, 1507, 1363, 1323, 1269, 1235,1211, 1141, 1076, 1034, 999, 866, 807 cm⁻¹. MS(FD): m/e 173 (M⁺, 100).

Preparation 21

1,2,3,4-tetrahydro-5-quinolinecarboxylic acid

A solution containing 1.03 g (5.95 mmol) of the titled compound ofPreparation 20, 1.87 g (29.77 mmol) of ammonium formate in 100 mL ofethanol was purged with nitrogen for 10 minutes. To this solution wasadded 0.5 g of palladium black and the resultant reaction mixture washeated to 65° C. After approximately three hours, the reaction mixturewas filtered; the resultant filtrate was concentrated under reducedpressure to provide a residue. This residue was partitioned betweenwater (pH 4) and a solution of 10% isopropanol in chloroform. Theresulting layers were separated, and the organic layer was washed withwater (pH=4), dried over sodium sulfate, filtered, and concentrated toprovide crude material. This material was purified using radialchromatography (2 mm plate; gradient eluent of 5-10% methanol inmethylene chloride containing 1% acetic acid) to provide 87 mg of a tansolid.

Yield: 8%. ¹ H NMR (CDCl₃): δ 1.04 (m, 2H), 2.16 (t, 2H), 2.40 (m, 2H),5.81 (d, J=8.05 Hz, 1H), 6.09 (t, J=7.78 Hz, 1H), 6.23 (d, J=7.96 Hz,1H). IR(KBr): 3296, 2965, 2929, 1691, 1597, 1474, 1461, 1443, 1350,1305, 1279, 1236, 1184, 1159, 1106, 1073, 1022, 827 cm⁻¹. MS(FD): m/e177 (M⁺, 100). Analysis for C₁₀ H₁₁ NO₂ : Calcd: C, 67.78; H, 6.26; N,7.90; Found: C, 67.96; H, 6.10; N, 7.88.

Preparation 22

A. 3-Amino-2-methyl benzoate methyl ester

A solution of 10 g (66.2 mmol) of 3-amino-2-methyl benzoic acid and 20 gof p-toluenesulfonic acid monohydrate in 400 mL of methanol was refluxedovernight and then diluted with a mixture of ethyl acetate and 1Mpotassium carbonate. The resulting layers were cooled and thenseparated. The organic layer was then washed sequentially with 1Mpotassium carbonate, and brine, dried over sodium sulfate, filtered andthen concentrated to provide 9.23 g of an orange oil.

Yield: 85%. ¹ H NMR (CDCl₃): δ 2.34 (s, 3H), 3.73 (br.s, 2H), 3.88 (s,3H), 6.81 (d, J=7.96 Hz, 1H), 7.05 (t, J=7.78 Hz, 1H), 7.19-7.30 (m,1H). IR (CHCl₃): 3406, 3027, 3012, 2978, 2953, 1718, 1621, 1467, 1435,1315, 1301, 1265, 1196, 1159, 1108, 1066, 1045, 810 cm⁻¹. MS(FD): m/e165 (M⁺, 100).

B. 3-N-(Methylsulfonyl)amino-2-methyl benzoate methyl ester

To a cold (0° C.) solution of 1.07 g (6.48 mmol) of the subtitledcompound of Preparation 22A in 50 mL of anhydrous methylene chloride,was added 1.18 g (6.80 mmol) of methylsulfonic anhydride. The resultantreaction mixture was reacted overnight at room temperature and thendiluted with 100 mL of methylene chloride, washed twice with a sodiumbicarbonate solution, dried over sodium sulfate, filtered, concentrated,redissolved in hexane and then concentrated again to provide a residue.This residue was then triturated three times in hexane and then reducedto dryness under reduced pressure to provide 1.46 g of a pink solid.This solid was then recrystallized using 20 mL of a 30% hexane/50% ethylacetate/20% methanol mixture.

Yield: 57%. ¹ H NMR (DMSO-d₆): δ 2.25-2.45 (m, 4.5H), 2.97 (s, 1.5H),3.80 (s, 3H), 7.23-7.63 (m, 3H), 9.24 (s, 1H). IR (KBr): 3900-2400(br.), 3298, 1713, 1466, 1320, 1290, 1265, 1248, 1210, 1183, 1156, 1047,971, 964, 752, 563, 519 cm⁻¹. MS(FD): m/e 243 (M⁺, 100). Analysis forC₁₀ H₁₃ NO₄ S: Calcd: C, 49.37; H, 5.39; N, 5.76; Found: C, 49.15; H,5.54; N, 5.80.

C. 3-N-(Methylsulfonyl)amino-2-methyl benzoic acid

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 15B, using 400 mg (1.64 mmol)of the subtitled compound of Preparation 22B, and 118 mg (4.93 mmol) oflithium hydroxide in 20 mL of tetrahydrofuran and 8 mL of water, toprovide 206 mg of a white solid.

Yield: 55%. ¹ H NMR (DMSO-d₆): δ 2.43 (s, 3H), 2.97 (s, 3H), 7.26 (t,J=7.87 Hz, 1H), 7.43 (d, J=7.79 Hz, 1H), 7.60 (d, J=7.17 Hz, 1H). IR(KBr): 3800-2200 (br.), 3252, 1685, 1404, 1334, 1309, 1277, 1149, 982,965, 914, 780, 763, 748, 632, 518, 498 cm⁻¹. MS(FD): m/e 243 (M⁺, 100).

Preparation 23

A. 3-methoxy-N-phenylbenzamide

A solution of 13.4 mL (147 mmol) of aniline in 30.7 mL of triethylaminewas slowly added to a solution containing 25.1 g (147 mmol) of3-methoxybenzoyl chloride in methylene chloride. The resulting reactionmixture was reacted for approximately thirty minutes and then dilutedwith 1N sodium bicarbonate. The resultant layers were separated and theorganic layer was washed sequentially with water, 1M sodium hydroxideand then brine, dried over sodium sulfate, filtered and then reduced todryness under reduced pressure to provide 31.6 g of an off-white solid.

Yield: 95%.

B. 3-Methoxy-2-methyl-N-phenylbenzamide

To a cold (-70° C.) solution of 4.54 g (20 mmol) of the subtitledcompound of Preparation 23A and 5.11 g (44 mmol) of TMEDA in 70 mL ofanhydrous tetrahydrofuran, was added 26.9 mL of a 1.56M solution ofn-butyl lithium in hexane. The resultant reaction mixture was warmed to-15° C. and stirred for approximately 45 minutes to provide a yellowslurry. The slurry was then recooled to -70° C. and 2.89 g (20 mmol) ofmethyl iodide was added, resulting in the formation of a whiteprecipitate. The reaction mixture was stirred overnight at roomtemperature, quenched with saturated ammonium chloride and diluted withdiethylether. The resulting layers were separated and the organic phasewashed sequentially with saturated ammonium chloride, water, saturatedsodium bicarbonate and brine solutions. The organic extracts were thendried over sodium sulfate and concentrated to provide a white solidwhich was purified by recrystallization from a 2:1 ethyl acetate/hexanesolution to provide 4.00 g of needles.

Yield: 99%. ¹ H NMR (CDCl₃): δ 2.36 (s, 3H), 3.88 (s, 3H), 3.89 (s, 1H),6.90-7.70 (m, 8H). IR (CHCl₃): 3424, 3013, 2963, 2943, 2840, 1678, 1597,1585, 1519, 1463, 1438, 1383, 1321, 1264, 1240, 1178, 1083, 1069 cm⁻¹.MS(FD): m/e 241 (M⁺, 100). Analysis for C₁₅ H₁₅ NO₂ : Calcd: C, 74.67;H, 6.27; N, 5.80; Found: C, 74.65; H, 6.29; N, 5.82.

C. 2-Methyl-3-hydroxybenzoic acid

A mixture of 1.21 g (5.00 mmol) of the subtitled compound of Preparation23B, 35 mL of 5N hydrochloric acid and 20 mL of a 30% solution ofhydrobromic acid in acetic acid were heated at reflux for 24 hours.After cooling, the reaction mixture was diluted with 100 mL of ethylacetate and 100 mL of water. The resulting layers were separated and theorganic layer was washed once with water and then basified to pH 11using 0.5N sodium hydroxide The resulting layers were separated and theaqueous layer reacidified to pH 1 using 5N hydrochloric acid. Thedesired compound was then extracted from this aqueous layer using ethylacetate. The ethyl acetate extracts were then washed with brine, driedover sodium sulfate, filtered, and then concentrated to provide aresidue which after two concentrations from hexane yielded 750 mg of awhite solid.

Yield: 98%. ¹ H NMR (DMSO-d₆): δ 2.26 (s, 3H), 6.98 (d, J=8.03 Hz, 1H),7.02 (t, J=7.69 Hz, 1H), 7.15 (d, J=7.37 Hz, 1H), 9.55 (br.s, 1H). IR(CHCl3): 3600-2100 (br.), 3602, 2983, 1696, 1588, 1462, 1406, 1338,1279, 1174, 1154, 1075, 1038, 920, 892, 854, 816 cm⁻¹. MS(FD): m/e 152(M⁺, 100). Analysis for C₈ H₈ O₃ : Calcd: C, 63.15; H, 5.30; Found: C,63.18; H, 5.21.

Alternative Preparation for 2-Methyl-3-hydroxybenzoic acid

To a cold (0° C.) suspension of 0.54 g (3.3 mmol) of2-methyl-3-aminobenzoic acid in 5 mL of water containing 0.65 mL ofconcentrated sulfuric acid, was added 0.25 g (3.6 mmol) of solid sodiumnitrite. After approximately 15 minutes the reaction mixture was pouredinto 20 mL of warm water containing 4 mL of concentrated sulfuric acid.The resultant reaction mixture was heated slowly to 90° C., resulting ingas evolution. After the gas evolution ceased, the solution was cooledto room temperature and extracted with ethyl acetate. The organic layerswere combined, washed with 0.5N hydrochloric acid, dried andconcentrated under reduced pressure. The crude residue was purified byrapid filtration through silica gel (eluent of 5% methanol in methylenechloride) to yield 350 mg of a white solid (m.p. 137°-138° C.).

Yield: 69%. ¹ NMR (CDCl₃): δ 8.18 (br.s, 1H), 7.42 (d, J=7.7 Hz, 1H),7.13 (t, J=7.9 Hz, 1H), 6.93 (d, J=7.9 Hz, 1H), 2.46 (s, 3H). Analysisfor C₈ H₈ O₃ : Calcd: C, 63.15; H, 5.29; Found: C, 63.32; H, 5.36.

Preparation 24

A. N-(t-Butyl)-2-methylbenzamide

To a cold (0° C.) solution of 139.2 g (0.9 mol) of o-toluoyl chloride in1200 mL of methylene chloride at 25° C., under nitrogen, was slowlyadded 180.0 g (1.8 mol) of triethylamine followed by the dropwiseaddition of a solution containing 73.14 g (1.0 mol) of t-butylamine in200 mL of methylene chloride. The resulting reaction mixture was warmedto room temperature and allowed to react for 2.5 hours. The reactionmixture was then diluted with 1800 mL of water. The resulting organicand aqueous layers were separated, and the organic layer was washedsequentially with 2N sodium hydroxide, 1.0N hydrochloric acid and brine,dried over magnesium sulfate, filtered and then reduced to dryness underreduced pressure to provide 167.6 g of the desired subtitled compound asan off-white solid (mp 77°-78° C.).

Yield: 97%. ¹ H NMR (CDCl₃): δ 1.41 (s, 9H), 2.41 (s, 3H), 5.54 (br.s,1H), 7.13-7.30 (m, 4H). IR (CHCl₃): 3430, 3011, 2971, 2932, 1661, 1510,1484, 1452, 1393, 1366, 1304, 1216, 876 cm⁻¹. MS(FD): m/e 191 (M⁺), 191(100). Analysis for C₁₂ H₁₇ NO: Calcd: C, 75.35; H, 8.76; N, 7.32;Found: C, 75.10; H, 9.11; N, 7.20.

B.S-N-t-Butyl-2-(3-(N-benzyloxycarbonyl)amino-2-oxo-4-phenylbutyl)benzamide

To a solution of 7.0 g (36.5 mmol) of the subtitled compound ofPreparation 24A in 200 mL of anhydrous tetrahydrofuran, was added 12.1mL (80.3 mmol) of N,N,N',N'-tetramethylethylenediamine (TMEDA) was addedvia syringe. The resulting solution was cooled to -78° C. and then 55.9mL of sec-butyllithium was added dropwise via syringe while maintainingthe temperature of the reaction under -60° C. The resulting reactionsolution was then allowed to stir for approximately 1 hour at -78° C.before the addition of a solution containing 5.00 g (14.6 mmol) ofS-N-methoxy-N-methyl-2-(N-benzyloxycarbonyl)amino-3-phenylpropanamide in50 mL of anhydrous tetrahydrofuran was added via cannula whilemaintaining the reaction temperature below -65° C. The resultingreaction mixture was warmed to -20° C., quenched using 20 mL ofsaturated ammonium chloride and then diluted with 200 mL ofdiethylether. The organic and aqeous layers were separated and theorganic layer was washed sequentially with water, 0.2Nsodiumhydrogensulfate and brine, dried over sodium sulfate, filtered andthen reduced to dryness under reduced pressure to provide a colorlessoil. This oil was purified using flash chromatography (eluent of 25%ethyl acetate in methylene chloride) to provide 6.08 g of a colorlessfoam.

Yield: 88%. α!_(D) -289.26° (c 0.12, MeOH). ¹ H NMR (CDCl₃) δ 1.38 (s,9H), 2.99 (dd, J=15; 6 Hz, 1H), 3.24 (dd, J=15; 6 Hz, 1H), 3.89 (d, J=18Hz, 1H), 4.16 (d, J=18 Hz, 1H), 4.72 (dd, J=15, 6 Hz, 1H), 5.00-5.09 (m,2H), 5.56 (d, J=6 Hz, 1H), 5.93 (br.s, 1H), 7.03-7.40 (m, 14H). IR(CHCl₃): 3431, 3027, 3012, 2973, 1713, 1658, 1511, 1454, 1383, 1366,1307, 1231, 1046 cm⁻¹. MS(FD) m/e 472 (M⁺), 218 (100). Analysis for C₂₉H₃₂ N₂ O₄ : Calcd: C, 73.70; H, 6.82; N, 5.93; Found: C, 73.41; H, 6.98;N, 5.83.

C.2R-(2R*,3S*)!-N-t-Butyl-2-(3-(N-benzyloxycarbonyl)amino-2-hydroxy-4-phenylbutyl)benzamide

To a solution of 6.96 g (14.7 mmol) of the subtitled compound ofPreparation 24B in 200 mL of absolute ethanol, under nitrogen, was added2.78 g (73.5 mmol) of sodium borohydride. When the reaction wassubstantially complete, as indicated by thin layer chromatography (TLC),the reaction mixture was diluted with 200 mL of ethyl acetate andquenched by the dropwise addition of 20 mL of saturated ammoniumchloride. The organic and aqueous layers were then separated and theorganic layer was washed sequentially with 1N hydrochloric acid,saturated sodium bicarbonate solution and brine, dried over sodiumsulfate, filtered and then reduced to dryness under reduced pressure toprovide 6.4 g of a colorless oil. This oil was purified using flashchromatography (gradient eluent of 2-10% methylene chloride in ethylacetate) to provide 5.12 g of the subtitled compound.

Yield: 74%. α!_(D) -10.38° (c 0.10, MeOH). ¹ H NMR (CDCl₃): δ 1.40 (s,9H), 2.79 (dd, J=12; 3 Hz, 1H) 2.90-2.98 (m, 2H), 3.04 (44, J=12, 3 Hz,1H), 3.70-3.81 (m, 1H), 3.97 (m, 1H), 4.96-5.08 (m, 2H), 5.10 (d, J=9Hz, 1H), 5.88 (d, J=6 Hz, 1H), 5.93 (s, 1H), 7.13-7.42 (m, 14H). IR(CHCl₃): 3431, 3028, 3012, 2971, 1773, 1643, 1515, 1454, 1367, 1229,1028 cm⁻¹. MS(FD): m/e 475 (M⁺), 475 (100). Analysis for C₂₉ H₃₄ N₂ O₄ :Calcd: C, 73.39; H, 7.22; N, 5.99; Found: C, 73.12; H, 7.48; N, 5.62.

D. 2R-(2R*,3S*)!-N-t-Butyl-2-(3-amino-2-hydroxy-4-phenylbutyl) benzamide

A suspension was prepared containing 41.0 g (120 mmol) of the subtitledcompound of Preparation 24C and 500 mg of 10% palladium-on-carbon in 150mL of absolute ethanol. This suspension was shaken under 60 psi hydrogenin a Parr shaker apparatus. The 10% palladium-on-carbon catalyst wasthen removed by filtration. The resultant filtrate was reduced todryness under reduced pressure to provide 31.1 g of a light yellow foam.This compound was used without further purification.

Yield: 96%. a!_(D) +34.68° (c 1.0, MeOH). ¹ H NMR (CDCl₃) δ 1.46 (s, 9H)2.71 (dd, J=13.7; 9.5 Hz, 1H), 2.84 (dd, J=13.3; 2.51 Hz, 1H), 2.95-3.06(m, 2H), 3.23-3.29 (m, 1H), 3.84-3.90 (m, 1H), 6.23 (s, 1H), 7.19-7.37(m, 12H). IR (CHCl₃): 3440, 3382, 3007, 2970, 2934, 1643, 1516, 1454,1367, 1213 cm⁻¹. MS(FD): m/e 341 (M⁺), 341 (100).

Preparation 25

A. 2R-2-N(t-Butoxycarbonyl)amino-3-naphth-2-ylthio propanoic acid

To a solution of 2.14 g (13.4 mmol) 2-naphthalene thiol in 40 mL ofanhydrous tetrahydrofuran at room temperature, was added a suspension of0.54 g (13.5 mmol) of sodium hydride in mineral oil. After approximately15 minutes, a solution of 2.5 g (13.4 mmol) ofS-N(t-butoxycarbonyl)-serine-β-lactone in 30 mL of tetrahydrofuran wasadded dropwise. The resultant reaction mixture was allowed to react forapproximately one hour and then was concentrated under reduced pressureto provide a gummy solid. This solid was purified using flashchromatograph (eluent of 1% methanol in ethyl acetate) to provide 4.35 gof a white solid.

Yield: 94%. ¹ H NMR (CDCl₃): δ 10.25 (s, 1H), 7.89 (s, 1H), 7.78 (m,3H), 7.46 (m, 3H), 5.39 (d, 1H), 4.61 (m, 1H), 3.49 (m, 2H), 1.37 (s,9H).

B. 2R-N(Methoxy)-N(methyl)2-N(t-butoxycarbonyl)amino-3-naphth-2-ylthio!propanamide

To a cold (0° C.) solution containing 4.3 g (12.4 mmol) of the subtitledintermediate of Preparation 25A, 1.58 g (16.15 mmol) ofN,O-dimethylhydroxylamine hydrochloride, 2.18 g (16.15 mmol) of1-hydroxybenzotriazole hydrate (HOBT.H₂ O), 2.24 mL (16.15 mmol) oftriethylamine and 2.73 mL (24.86 mmol) N-methylmorpholine in 100 mL ofmethylene chloride, was added 2.62 g (13.67 mmol) of1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). Theresulting reaction mixture was allowed to react at room temperatureovernight. The reaction mixture was diluted with 100 mL of hexane,washed sequentially with 200 mL of a saturated sodium bicarbonatesolution and 200 mL of brine. The resulting layers were separated andthe organic layer was dried over sodium sulfate, filtered and thenconcentrated under reduced pressure to provide a clear yellow oil. ¹ HNMR (CDCl₃): δ 7.90 (s, 1H), 7.80 (m, 3H), 7.49 (m, 3H), 5.41 (d, 1H),4.92 (m, 1H), 3.59 (s, 3H), 3.18-3.46 (m, 2H), 3.05 (s, 3H), 1.42 (s,9H). MS (FD): m/e 391 (M⁺), 390 (100).

C. 3R-N(t-Butyl)-2-2'-oxo-3'-N(t-butoxycarbonyl)amino-4'-naphth-2-ylthio!butyl benzamide

To a cold (-78° C.) solution containing 8.60 g (45 mmol) of thesubtitled compound of Preparation 24A, and 14.2 mL (95 mmol) of TMEDA in100 mL of anhydrous tetrahydrofuran and under an inert atmosphere, wasslowly added 111 mL (95 mmol) of a 0.85M solution of sec-butyllithium inhexanes, via syringe. The internal temperature of the reaction vesselwas monitored during the addition of the sec-butyllithium to ensure thatthe temperature did not exceed -57° C. After allowing the resultantreaction mixture to react for approximately one hour at -78° C., asolution of 7.90 g (20 mmol) of the subtitled intermediate ofPreparation 2B in 80 mL of tetrahydrofuran was added dropwise. When theaddition was complete, the reaction was warmed to -20° C. and then wasquenched by the addition of a saturated ammonium chloride solution. Theresulting mixture was then diluted with 600 mL of diethylether. Theresulting layers were separated and the organic layer was washedsequentially with a 1M sodium bisulfate solution and a brine solution,dried over sodium sulfate, filtered and then concentrated under reducedpressure to provide a yellow oil. This oil was purified using flashchromatography (gradient eluent of 10-50% ethyl acetate in hexane) toprovide 8.5 g of the desired subtitled intermediate.

Yield: (82%). ¹ H NMR (CDCl₃): δ 7.90 (s, 1H), 7.79 (t, 3H), 7.48 (m,3H), 7.40 (d, 1H), 7.29 (m, 2H), 7.05 (d, 1H), 5.94 (br.s, 1H), 5.65 (m,1H), 4.65 (d, 1H), 4.24 (d, J=17 Hz, 1H), 3.86 (d, J=17 Hz, 1H), 3.66(m, 1H), 3.40 (m, 1H), 1.42 (s, 9H), 1.39 (s, 9H). MS (FD): m/e 521(M⁺),521(100).

D. (2R-(2R*,3R*)!-N(t-Butyl)-2-2'-hydroxy-3'-N(t-butoxycarbonyl)amino-4'-naphth-2-ylthio!butylbenzamide

To a solution of 3.49 g (6.7 mmol) of the subtitled intermediate ofPreparation 25C in 150 mL of absolute ethanol, was added 0.51 g (13mmol) of sodium borohydride and the resulting reaction mixture wasallowed to react overnight at room temperature. The reaction was thencooled to 0° C., quenched with a saturated ammonium chloride solutionand diluted with 550 mL of methylene chloride. The resulting layers wereseparated and the organic layer was washed sequentially with 1Nhydrochloric acid, 2N sodium hydroxide and brine, dried over sodiumsulfate, filtered and then concentrated under reduced pressure toprovide a colorless foam. This foam was purified using flashchromatography (gradient eluent of 10-25% hexane in ethyl acetate) toprovide 2.78 g of the desired subtitled intermediate.

Yield: 78%. ¹ H NMR (CDCl₃): δ 7.84 (s, 1H), 7.73 (m, 3H), 7.41 (m, 3H),7.29 (t, 2H), 7.16 (t, 2H), 6.53 (s, 1H), 5.32 (d, 1H), 3.86 (m, 2H),3.33 (m, 2H), 2.83 (m, 2H), 1.40 (s, 9H) MS (FD): m/e 523 (M⁺), 522(100). Analysis for C₃₀ H₃₈ N₂ O₄ S: Calcd: C, 68.94; H, 7.33; N, 5.36;Found: C, 68.65; H, 7.34; N, 5.15.

E. (2R-(2R*,3R*)!-N(t-Butyl)-2-2'-hydroxy-3'-amino-4'-naphth-2-ylthio!butyl-benzamide

To a cold (0° C.) solution of 2.89 g (5.53 mmol) of the subtitledintermediate of Preparation 25D in 100 mL of methylene chloride, wasadded 18 mL of trifluoroacetic acid. The resulting reaction mixture wasallowed to react for approximately one hour. The reaction mixture wasthen concentrated under reduced pressure to provide a foam. This foamwas slurried in toluene and then concentrated under reduced pressure toprovide a foam which was purified using flash chromatography (eluent of5% methanol in methylene chloride) to provide 1.71 g of a white foam.

Yield: 74%. ¹ H NMR (CDCl₃) δ 7.75-7.85 (m, 4H), 7.24-7.51 (m, 7H), 6.06(s, 1H), 3.75 (m, 1H), 3.61 (m, 1H), 3.07 (m, 2H), 2.95 (m, 2H), 1.47(s, 9H). MS(FD): m/e 423(M⁺), 422(100).

Preparation 26

A. N-t-Butyl-2-methyl-1-naphthylamide

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 24A. The crude material waspurified by recrystallization from a hexane/ethyl acetate mixture toprovide 20.99 g of colorless needles (mp 124°-126° C.).

Yield: 68%. ¹ H NMR (CDCl₃) δ 1.54 (s, 9H), 2.50 (s, 3H), 5.50-5.65(br.s, 1H), 7.23-7.54 (m, 3H), 7.74 (d, J=10 Hz, 1H), 7.78 (d, J=10 Hz,1H), 7.87 (d, J=10 Hz, 1H). IR (CHCl₃): 3424, 3010, 2969, 1660, 1512,1503, 1454, 1366, 1291, 1263, 1221 cm⁻¹. MS(FD): m/e 241(M⁺), 241(100).Analysis for C₁₆ H₁₉ NO: Calcd: C, 79.63; H, 7.94; N, 5.80; Found: C,79.90; H, 8.11; N, 5.76.

B.S-N-t-Butyl-2-(3-(N-benzyloxycarbonyl)amino-4-phenyl-2-oxobutyl)-1-naphthylamide

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 24A. The resultant residuewas purified using flash chromatography (gradient eluent of 10-30% ethylacetate in hexane) to provide 7.43 g of a colorless foam.

Yield: 86%. α!_(D) -6.86° (c 0.10, MeOH). ¹ H NMR (CDCl₃) δ 1.45 (s,9H), 3.03 (dd, J=15, 8 Hz, 1H), 3.18 (dd, J=15, 5 Hz, 1H), 3.91 (d, J=16Hz, 1H), 4.04 (d, J=16 Hz, 1H), 4.70-4.80 (m, 1H), 4.94-5.06 (m, 2H),5.41 (d, J=8 Hz, 1H), 6.12-6.20 (br.s, 1H), 7.10-7.38 (m, 11H),7.42-7.58 (m, 2H), 7.76-7.85 (m, 2H), 7.93 (d, J=9 Hz, 1H). IR (CHCl₃):3420, 3029, 3012, 2970, 1713, 1658, 1505, 1455, 1367, 1232, 1045 cm⁻¹.MS(FD): m(e 522(M⁺), 522(100). Analysis for C₃₃ H₃₄ N₂ O₄ : Calcd: C,75.84; H, 6.56; N, 5.36; Found: C, 75.56; H, 6.74; N, 5.17.

C.2R-(2R*,3S*)!-N-t-Butyl-2-(3-(N-benzyloxycarbonyl)amino-3-phenylmethyl-2-hydroxypropyl)-1-naphthylamide

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 24C. The resultant materialwas purified using flash chromatography (gradient eluent of 2-10% ethylacetate in methylene chloride) to provide 5.50 g of a colorless foam.

Yield: 74%. α!_(D) +11.85° (c 0.20, MeOH). ¹ H NMR (CDCl₃) δ 1.54 (s,9H), 2.85-3.15 (m, 4H), 3.85-3.95 (m, 1H), 4.00-4.13 (m, 2H), 4.90-5.34(m, 3H), 5.85-5.95 (m, 1H), 7.05-7.60 (m, 15H), 7.81 (d, J=9 Hz, 2H),7.91 (d, 9 Hz, 2H). IR (CHCl₃): 3420, 3012, 2970, 1713, 1643, 1515,1454, 1367, 1219, 1209, 1028 cm⁻¹. MS(FD): m/e 524 (M⁺), 524 (100)Analysis for C₃₃ H₃₆ N₂ O₄ : Calcd: C, 75.55; H, 6.92; N, 5.34; Found:C, 75.41; H, 7.16; N, 5.14.

D. 2R-(2R*,3S*)!-N-t-Butyl-2-(3-amino-2-hydroxypropyl)-1-naphthylamide

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 24D. The crude filtrate wasconcentrated to provide 1.30 g of a colorless foam which was usedwithout any further purification.

Yield: 92%.

Preparation 27

A. 2-Iodo-4-hydroxymethyl toluene

To a solution of 5.0 g (19.1 mmol) of 2-iodo-3-methyl benzoic acid in 50mL of anhydrous tetrahydrofuran, was slowly added 22 mL of a 1M boranesolution in tetrahydrofuran. The resultant reaction mixture was reactedfor approximately ninety minutes and then was quenched with ethanolresulting in the evolution of hydrogen gas. The mixture was diluted withethyl acetate. The resulting layers were separated and the organic layerwas washed sequentially with sodium bicarbonate and brine, dried oversodium sulfate, filtered and crystallized from a hexane/ethyl acetatemixture to provide 120 mg of the desired subtitled compound.

B. 2-Methyl-5-hydroxymethyl benzoic acid

A mixture of 142 mg (5.92 mmol) of lithium hydroxide and 249 mg (1.48mmol) of the subtitled compound of Preparation 27A in a 3:1tetrahydrofuran/water mixture were reacted for approximately twenty fourhours. When the reaction was complete, as indicated by TLC, the reactionmixture was concentrated under reduced pressure and acidifed by theaddition of 1N hydrochloric acid. The mixture was diluted with ethylacetate and the resulting layers were separated. The organic layer waswashed with brine, dried over sodium sulfate, filtered and reduced todryness to provide 70 mg of the desired subtitled compound.

Preparation 28

2-Methyl-3-methylamino benzoic acid

To a solution of 500 mg (2.5 mmol) of 2-methyl-3-amino benzoate methylester in 5 mL of dimethylformamide, was added 387 mg (2.7 mmol) ofmethyl iodide and 700 mg (5.4 mmol) of diisopropylethylamine. Theresultant reaction mixture was heated to 70° C. for approximately twohours and then poured into 10 mL of 1N potassium hydroxide. After aboutsixteen hours, the mixture was acidified to pH 6 by the addition of 2Nhydrochloric acid. The desired titled compound was extracted into ethylacetate, dried and reduced to dryness under reduced pressure to provide343 mg of a white solid (m.p. 165°-167° C.).

Yield: 84%. ¹ H NMR (CDCl₃): δ 12.52 (br.s, 1H), 7.38 (d, J=7.8 Hz, 1H),7.25 (t, J=7.9 Hz, 1H), 6.93 (d, J=7.8 Hz, 1H), 2.92 (s, 3H), 2.21 (s,3H). Analysis for C₉ H₁₁ NO₂ : Calcd: C, 65.44; H, 6.71; N, 8.48; Found:C, 65.62; H, 6.84; N, 8.26.

Preparation 29

A. 2-Methyl-5-amino benzoic acid

The desired titled compound was prepared by reducing2-methyl-5-nitrobenzoic acid using a tin/hydrochloric acid mixture (m.p.142°-144° C.)

Yield: 75% ¹ H NMR (DMSO-d₆): δ 12.67 (br.s, 1H), 7.23 (s, 1H), 7.04 (d,J=8.2 Hz, 1H), 6.82 (d, J=7.9 Hz, 1H), 3.25 (s, 2H), 2.40 (s, 3H).Analysis for C₈ H₉ NO₂ : Calcd: C, 63.57; H, 6.00; N, 9.27; Found: C,63.81; H, 6.24; N, 9.06.

B. 2-Methyl-5-hydroxybenzoic acid

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Alternate Preparation 23C, using thesubtitled compound of Preparation 29A.

Yield: 65% (m.p. 136°-139° C.). ¹ H NMR (DMSO): δ 12.77 (br.s, 1H), 9.46(br. s, 1H), 7.26 (s, 1H), 7.12 (d, J=8.3 Hz, 1H), 6.85 (d, J=8.1 Hz,1H), 2.41 (s, 3H). Analysis for C₈ H₈ O₃ : Calcd: C, 63.15; H, 5.29;Found: C, 63.27; H, 5.22.

Preparation 30

A. 5-Cyanoisoquinoline

To a cold (0° C.) solution of 10.0 g (61.4 mmol) of 5-aminoisoquinolinein 288 mL of 1.5N hydrochloric acid, was added 15 mL of 5.2M sodiumnitrite in water. After approximate y 5 minutes, a cool saturatedsolution of sodium bicarbonate was added to the reaction mixture untilthe reaction solution tested negative using the iodide and starch papertest. The resultant solution was poured into a cold (0°-5° C.) biphasicmixture containing 300 ml of toluene and 150 mL of an aqueous solutioncontaining 8.4 g (177 mmol) of sodium cyanide and 7.6 g (85 mmol) ofcopper cyanide. The resultant reaction mixture was warmed to roomtemperature, reacted for approximately 1 hour, and then diluted with amixture of ethyl acetate and water. The resulting layers were separated,and the organic phase was dried over sodium sulfate, filtered, and thenreduced to dryness under reduced pressure to provide 5.9 g of a yellowsolid.

Yield: 56%. ¹ H NMR (CDCl₃) δ 9.38 (s, 1H), 8.76 (d, J=5.89 Hz, 1H),8.25 (d, J=8.29 Hz, 1H), 8.13 (d, J=8.30 Hz, 1H), 8.03 (d, J=8.59 Hz,1H), 7.71 (t, J=7.78 Hz, 1H); IR (KBr): 3433, 3090, 3026, 2924, 2226,1618, 1574, 1495, 1433, 1373, 1277, 1225, 1034, 829, 766, 714.

B. 5-Carboxyisoquinoline

A solution of 6.5 g (42 mmol) of the subtitled compound of Preparation30A in 55 mL of concentrated hydrochloric acid was heated to 155° C. ina sealed tube for 5.5 hours and then was cooled to room temperature, andthen reduced to dryness to provide a solid. This solid was redissolvedin 300 mL of water, and resultant solution was adjusted to pH 6 using adilute ammonium hydroxide solution, resulting in the precipitation of abrown solid. This solid was isolated using filtration, azeotroped withbenzene, and then dried at 130° C. under reduced pressure forapproximately 3 hours to provide 5.7 g of a fine dark tan powder (m.p.270°-272° C.).

Yield: 78%. ¹ H NMR (DMSO): δ 13.4 (br.s, 1H), 8.69 (d, 1H, J=6.00 Hz),8.58 (d, 1H, J=4.6 Hz), 8.40 (d, 1H, J=7.37 Hz), 8.36 (d, 1H, J=8.12Hz), 7.74 (t, 1H, J=7.76); IR (KBr): 3460, 3014, 2930, 2851, 2777, 2405,1912, 1711, 1622, 1574, 1493, 1427, 1375, 1264, 1211, 1152, 1044.

C. 5-Carboxyisoquinoline pentafluorophenylester

To a cold (0° C.) solution of 1.53 g (7.39 mmol) of1,3-dicyclohexylcarbodiimide (DCC) in 60 mL of ethyl acetate, was added1.28 g (7.39 mmol) of the subtitled compound of Preparation 30B, and4.08 g (22.17 mmol) of pentafluorophenol in 30 mL of ethyl acetate. Theresultant reaction mixture was reacted for approximately 6 hours at 0°C. and then filtered through celite. The resultant filtrate was washedsequentially with 1N sodium hydroxide, water, and brine, and thenconcentrated under reduced pressure to provide a white solid. This solidwas purified using column chromatography (silica; eluent of 33% ethylacetate in hexanes) to provide 1.80 g of the desired subtitled compound.(m.p. 142°-144° C.)

Yield 72%. ¹ H NMR (CDCl₃): δ 9.38 (s, 1H), 8.74 (m, 3H), 8.34 (d, J=8.1Hz, 1H), 7.78 (t, J=7.7 Hz, 1H); IR (KBr): 3422, 3021, 2089, 1752, 1622,1522, 1215, 758. Analysis for C₁₆ H₆ NO₂ F₅.0.3CH₂ Cl₂ : Calcd: C,57.30; H, 2.17; N, 4.03. Found: C, 57.40; H, 2.10; N, 4.33.

Preparation 31

5-Carboxyquinoline pentafluorophenylester

The desired subtitled compound was prepared substantially in accordancewith the procedure detailed in Preparation 30C, using 0.236 g (1.36mmol) of 5-carboxyquinoline, 0.746 g (4.05 mmol) of pentafluorophenol,and 0.571 g (2.76 mmol) of DCC in 25 mL of ethyl acetate, with theexception that the reaction mixture was allowed to react for 48 hours.The resultant crude material was purified using column chromatography toprovide 0.40 g of a white solid.

Yield 87%. ¹ H NMR (CDCl₃): δ 9.33 (d, j=8.54 Hz, 1H), 9.03 (dd, J=4.16,1.28 Hz, 1H), 8.63 (d, J=7.25 Hz, 1H), 8.47 (d, J=8.53 Hz, 1H); 7.87 (t,J=7.96 Hz, 1H), 7.61 (dd, J=8.76, 4.18 Hz, 1H); IR (KBr): 3472, 2667,2461, 1749, 1520, 1319, 1259, 1182, 1145, 1105, 1005, 947, 812.

Preparation 32

1H-indoline-4-carboxylic acid

To a cold (10° C.) solution containing 100 mg (0.62 mmol) ofindole-4-carboxylic acid in 5 mL of acetic acid, was added 390 mg (6.2mmol) of solid sodium cyanoborohydride. The resultant mixture wasreacted at room temperature for approximately 16 hours and then dilutedwith water. The desired compound was extracted from this solution usingmethylene chloride and the organic extracts were then dried over sodiumsulfate and filtered. The crude material was purified using columnchromatography (silica; eluent of 1% methanol in methylene chloride) toprovide 12 mg of the titled compound. (m.p. 97°-98° C.).

Yield: 12%. ¹ H NMR (CDCl₃): δ 7.48 (d, J=8.8 Hz, 1H), 7.34 (t, J=8.6Hz, 1H), 6.88 (d, J=8.8 Hz, 1H), 3.59 (m, 4H). Analysis for C₉ H₉ NO₂ :Calcd: C, 66.25; H, 5.56; N, 8.58. Found: C, 66.36; H, 5.82; N, 8.42.

Preparation 33

A. 2,3-Dimethoxy-6-chlorotoluene

To a mixture of 25 g (0.16 mmol) of 1-methyl-2,3-dimethoxybenzene in 25mL of acetic acid, was slowly added 26.4 g (0.33 mmol) of1-chloromethylmethylether. The resultant reaction mixture was reactedovernight at 30° C. and then diluted with cold water, resulting in theformation of a precipitate. This precipitate was purified byrecrystallization from hot hexanes and then reduced to dryness underreduced pressure to provide 20.3 g of a white solid (m.p. 69°-70° C.).

Yield: 62%. ¹ H NMR (CDCl₃): δ 7.01 (d, J=6.1 Hz, 1H), 6.75 (d, 4.62 (s,2H), 3.85 (s, 3H), 3.76 (s, 3H), 2.37 (s, 3H). Analysis for C₁₀ H₁₃ O₂Cl: Calcd: C, 59.93; H, 6.54; Found: C, 59.87; H, 6.43.

B. 2-Methyl-3,4-dimethoxybenzoic acid

To a mixture of 3.0 g (15 mmol) of the subtitled compound of Preparation33A in 150 mL of water, was added 3.2 g (20 mmol) of solid potassiumpermangenate and 3.0 g (36 mmol) of sodium carbonate. The resultantreaction mixture was then heated to 80° C. and allowed to react forapproximately 24 hours. After cooling, the reaction mixture was filteredand diluted with ethyl acetate. The resultant layers were then separatedand the aqueous layer was acidifed using 2N hydrochloric acid whichresulted in the formation of a precipitate. This precipitate wasisolated using filtration and washed with cold hexane to provide 1.7 gof a solid (m.p. 179°-180° C.).

Yield: 58%. ¹ H NMR (DMSO-d₆): δ 12.49 (br.s, 1H), 7.71 (br.s, 1H), 6.99(br.s, 1H), 3.89 (s, 3H), 3.77 (s, 3H), 2.45 (s, 3H). Analysis for C₁₀H₁₂ O₄ : Calcd: C, 61.28; H, 6.17; Found: C, 61.36; H. 6.24.

C. 2-Methyl-3,4-dihydroxybenzoic acid

To a cold (0° C.) mixture of 250 mL (1.3 mmol) of the subtitled compoundof Preparation 33B in 5 mL of methylene chloride, was added 6.4 mL of a6.4 mmol/1.0 m solution of boron tribromide in methylene chloride. Theresultant reaction mixture was reacted for approximately 90 minutes andthen diluted with 25 mL of 2N hydrochloric acid. The desired compoundwas extracted using ethyl acetate, and the organic extracts were driedover sodium sulfate, filtered, and concentrated to provide 197 mg of atan solid (m.p. 200°-201° C.).

Yield: 92%. ¹ H NMR (DMSO): δ 12.14 (br.s, 1H), 9.96 (br.s, 1H,), 8.34(br.s, 1H), 7.27 (d, J=7.0 Hz, 1H), 6.67 (d, J=6.7 Hz, 1H), 2.37 (s, 3H)Analysis for C₈ H₈ O₄ : Calcd: C, 57.14; H, 4.80; Found: C, 57.34; H.4.76.

EXAMPLE 1

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-fluoro-3''-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

To a cold (-10° C.) solution containing 80 mg (0.20 mmol) of thesubtitled compound of Preparation 1B, 31 mg (0.20 mmol) of Preparation11B and 27 mg (0.20 mmol) of 1-hydroxybenzotriazole hydrate (HOBT.H₂ O)in 3 mL of anhydrous tetrahydrofuran, was added 41 mg (0.20 mmol) of1,3-dicyclohexylcarbodiimide (DCC). The reaction mixture was stirred for36 hours at room temperature and then concentrated under reducedpressure. The resultant residue was redissolved in ethyl acetate,filtered through celite, washed sequentially with saturated sodiumbicarbonate and brine, dried over sodium sulfate, filtered andconcentrated. The crude product was purifed using radial chromatography(1 mm plate; gradient eluent of 2-5% methanol in methylene chloride) toprovide 79 mg of a white foam.

Yield: 73%. α!_(D) -90.80° (c=0.333, MeOH). ¹ H NMR (CDCl₃): δ 1.24 (s,9H), 1.16-2.05 (m, 14H), 2.20-2.40 (m, 2H), 2.55-2.70 (m, 2H), 2.90-3.04(m, 2H), 3.10-3.25 (m, 1H), 4.03 (br.s, 1H), 4.51 (br.s, 1H), 6.01 (s,1H), 6.90-7.35 (m, 9H). IR (CHCl₃): 3580, 3550-3100 (br.), 2929, 2865,1662, 1596, 1521, 1472, 1455, 1394, 1368, 1293, 1157, 1047, 879, 839cm⁻¹. MS(FD): m/e 540 (M⁺, 100). HR MS(FAB): m/e for C₃₁ H₄₃ N₃ O₄ F:Calcd: 540.3238; Found: 540.3228.

EXAMPLE 2

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-chloro-pyrid-3''-yl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 80 mg (0.20 mmol) of thesubtitled compound of Preparation 1B, 31 mg (0.20 mmol) of2-chloronicotinic acid, 41 mg (0.20 mmol) of DCC and 27 mg (0.20 mmol)of HOBT.H₂ O in 3 mL of anhydrous tetrahydrofuran. The crude product waspurified using radial chromatography (1 mm plate; gradient eluent of0-5% methanol in methylene chloride) to provide 58 mg of an off-whitefoam.

Yield: 54%. a!_(D) -70.64° (c =0.224, MeOH). ¹ H NMR (CDCl₃): δ 1.16 (s,9H), 1.17-2.10 (m, 12H) 2.25-2.37 (m, 2H), 2.52-2.70 (m, 2H), 2.97-3.06(m, 2H), 3.44-3.53 (m, 2H), 4.05 (br.s, 1H), 4.60-4.70 (m, 1H), 5.64 (s,1H), 7.18-7.38 (m, 7H), 7.60-7.63 (m, 1H), 8.38-8.40 (m, 1H). IR(CHCl₃): 3618, 3428, 3650-3100 (br.), 2929, 1667, 1583, 1515, 1455,1401, 1368, 1247, 1071, 1046, 877 cm⁻¹. MS(FD): m/e 541 (M⁺), 440 (100).Analysis for C₃₀ H₄₁ N₄ O₃ Cl: Calcd: C, 66.59; H, 7.64; N, 10.35; Cl,6.55; Found: C, 66.60; H, 7.58; N, 10.17; Cl, 6.84.

EXAMPLE 3

3S-(3R*,4aR*,8aR*,2'S*,3 'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-ethyl-3''-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 80 mg (0.20 mmol) of thesubtitled compound of Preparation 1B, 35 mg (0.21 mmol) of the subtitledcompound of Preparation 10B, 41 mg (0.20 mmol) of DCC and 27 mg (0.20mmol) of HOBT.H₂ O in 3 mL of anhydrous tetrahydrofuran. The crudeproduct was purified using radial chromatography (1 mm plate; gradienteluent of 3-5% methanol in methylene chloride) to provide 71 mg of anoff-white foam.

Yield: 65%. α!_(D) : -76.29° (c=0.291, MeOH). ¹ H NMR (CDCl₃): δ 1.03(t, J=7.42 Hz, 3H), 1.21 (s, 9H), 1.22-2.10 (m, 11H), 2.24-2.35 (m, 2H),2.44-2.70 (m, 4H), 2.96-3.05 (m, 2H), 3.26-3.40 (m, 1H), 3.96-4.23 (m,2H), 4.53 (br.s, 1H), 5.80 (s, 1H), 6.30-6.56 (m, 3H), 6.77 (d, J=7.77Hz, 1H), 6.88 (t, J=7.75 Hz, 1H), 7.19-7.39 (m, 5H). IR (CHCl₃):3700-3100 (br.), 3429, 3327, 3011, 2971, 2930, 2867, 1662, 1604, 1585,1514, 1455, 1394, 1368, 1278, 1155, 1087, 1046, 910 cm⁻¹. MS(FD): m/e550 (M⁺, 100). HR MS(FAB): m/e for C₃₃ H₄₈ N₃ O₄ : Calcd: 550.3645;Found: 550.3664.

EXAMPLE 4

2S-(2R*,2'S*,3'R*)!-1-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl!pyrrolidine-2-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 55 mg (0.16 mmol) of thesubtitled compound of Preparation 3E, 25 mg (0.16 mmol) of the subtitledcompound of Preparation 9B, 33 mg (0.16 mmol) of DCC and 22 mg (0.16mmol) of HOBT.H₂ O in 2 mL of anhydrous tetrahydrofuran. The crudeproduct was purified using radial chromatography (1 mm plate; gradienteluent of 4-8% methanol in methylene chloride) to provide 52 mg of awhite solid.

Yield: 69%. α!_(D) : -72.15° (c=0.211, MeOH). ¹ H NMR (CD₃ OD): δ 1.33(s, 9H), 1.70-1.90 (m, 4H), 2.06-2.20 (m, 1H), 2.45-3.30 (m, 8H),3.60-3.70 (m, 1H), 4.25-4.38 (m, 1H), 6.48 (d, J=8.8 Hz, 1H), 6.74 (d,J=7.7 Hz, 1H), 6.93 (t, J=7.7 Hz, 1H), 7.15-7.32 (m, 5H). IR (CHCl₃):3600-2700 (br.), 3450, 3255, 2968, 2928, 1653, 1632, 1588, 1513, 1454,1364, 1291, 1233, 1064, 884, 836 cm⁻¹. MS(FD): m/e 468 (M⁺, 100).Analysis for C₂₇ H₃₇ N₃ O₄ : Calcd: C, 69.35; H, 7.98; N, 8.99. Found:C, 69.54; H, 8.10; N, 9.19.

EXAMPLE 5

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(pyrid-3''-yl-N-oxidyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 80 mg (0.20 mmol) of thesubtitled compound of Preparation 1B, 28 mg (0.20 mmol) of nicotinicacid N-oxide, 41 mg (0.20 mmol) of DCC and 27 mg (0.20 mmol) of HOBT.H₂O in 3 mL of anhydrous tetrahydrofuran. The crude product was purifiedusing radial chromatography (1 mm plate; gradient eluent of 5-10%methanol in methylene chloride) to provide 81 mg of a white foam.

Yield: 76%. α!_(D) : -104.39° (c=0.213, MeOH). ¹ H NMR (DMSO-d₆): δ 1.19(s, 9H), 1.19-2.10 (m, 14H), 2.50-2.60 (m, 1H), 2.65-2.79 (m, 1H),2.95-3.10 (m, 2H), 3.83 (br.s, 1H), 4.22-4.32 (m, 1H), 4.87 (d, J=5.5Hz, 1H), 7.06-7.11 (m, 1H), 7.17-7.22 (m, 2H), 7.33-7.44 (m, 3H), 7.57(d, J=8.0 Hz, 1H), 8.26 (d, J=6.4 Hz, 1H), 8.44-8.48 (m, 2H). IR(CHCl₃): 3600-3100 (br.), 3428, 2930, 2864, 1669, 1603, 1515, 1479,1455, 1432, 1394, 1368, 1300, 1279, 1245, 1135, 1083, 1046, 1017 cm⁻¹.MS(FD): m/e 522 (M⁺, 100).

EXAMPLE 6

2S-(2R*,2'S*,3'R*)!-1-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!piperidine-2-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 100 mg (0.29 mmol) of thesubtitled compound of Preparation 4F, 44 mg (0.29 mmol) of the subtitledcompound of Preparation 9B, 59 mg (0.29 mmol) of DCC and 39 mg (0.29mmol) of HOBT.H₂ O in 5 mL of anhydrous tetrahydrofuran. The crudeproduct was purified using radial chromatography (1 mm plate; gradienteluent of 1.5-7% methanol in methylene chloride) to provide 57 mg of anoff-white foam.

Yield: 41%. α!_(D) : -58.90° (c=0.163, MeOH). ¹ H NMR (CD₃ OD): δ 1.29(s, 9H), 1.50-2.20 (m, 10H), 2.60-2.75 (m, 4H), 3.10-3.35 (m, 4H),3.85-4.02 (m, 2H), 4.10-4.35 (m, 2H), 4.85 (s, 1H), 3.85-4.02 (m, 2H),4.10-4.35 (m, 2H), 4.85 (s, 1H), 6.55 (d, J=7.29 Hz, 1H), 6.75 (d,j=7.83 Hz, 1H), 6.90-6.96 (m, 1H), 7.15-7.35 (m, 5H). IR (CDCl₃): 3601,3600-3100 (br), 3428, 3340, 3008, 2941, 2861, 1661, 1601, 1587, 1514,1455, 1394, 1367, 1284, 1156, 1086, 1047, 832 cm⁻¹. MS(FD): m/e 482 (M⁺,100). Analysis for C₂₈ H₃₉ N₃ O₄ : Calcd: C, 69.83; H, 8.16; N, 8.72.Found: C, 69.84; H, 8.46; N, 8.50.

EXAMPLE 7

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-fluorophenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 80 mg (0.20 mmol) of thesubtitled compound of Preparation 1B, 31 mg (0.20 mmol) of3-fluoro-2-methylbenzoic acid, 41 mg (0.20 mmol) of DCC and 27 mg (0.20mmol) of HOBT.H₂ O in 3 mL of anhydrous tetrahydrofuran. The crudeprouct was opurified using radial chromatography (1 mm plate; gradienteluent of 1.5-3% methanol in methylene chloride) to provide 40 mg of awhite foam.

Yield: 37%. α!_(D) : -80.10° (c=0.132, MeOH). ¹ H NMR (CDCl³): δ 1.13(s, 9H), 1.13-2.10 (m, 16H), 2.20-2.35 (m, 2H), 2.50-2.70 (m, 2H),2.95-3.05 (m, 2H), 3.53-3.58 (m, 1H), 3.98 (s, 1H), 4.03-4.10 (m, 1H),5.68 (s, 1H), 6.83-7.07 (m, 3H), 7.10-7.40 (m, 5H). IR (CHCl₃):3650-3150 (br), 3429, 3030, 3008, 2930, 2863, 1672, 1608, 1514, 1455,1394, 1368, 1277, 1046, 910, 830 cm⁻¹. MS(FD): m/e 538 (M⁺, 100). HRMS(FAB): m/e for C₃₂ H₄₅ N₃ O₃ F: Calcd: 538.3445; Found: 538.3469.

EXAMPLE 8

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-chloro-3",5"-dihydroxyphenyl)pentyl!decahydroisoquinoline-3-N- t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 100 mg (0.25 mmol) of thesubtitled compound of Preparation 1B, 47 mg (0.25 mmol) of2-chloro-3,5-dihydroxy benzoic acid, 51 mg (0.25 mmol) of DCC and 34 mg(0.25 mmol) of HOBT.H₂ O in 2 mL of anhydrous tetrahydrofuran. The crudeproduct was purified using radial chromatography (2 mm plate; gradienteluent of 2-10% methanol in methylene chloride) to provide 47 mg of awhite solid.

Yield: 33%. α!_(D) : -53.79° (c=0.097, MeOH). ¹ H NMR (CDCl₃): δ0.5-3.10 (m, 32H), 3.70-4.60 (m, 2H), 6.00-7.50 (m, 8H). IR (CHCl₃):3700-3100 (br.), 2930, 2865, 1658, 1604, 1521, 1455, 1368, 1246, 1156,1047, 1014, 856 cm⁻¹. MS(FD): 572 (M⁺, 100). Analysis for C₃₁ H₄₂ N₃ O₅Cl: Calcd: C, 65.08; H, 7.40; N, 7.34. Found: C, 65.30; H, 7.35; N,7.43.

EXAMPLE 9

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3",5"-diaminophenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 100 mg (0.25 mmol) of thesubtitled compound of Preparation 1B, 41 mg (0.25 mmol) of3,5-diamino-2-methyl benzoic acid, 51 mg (0.25 mmol) of DCC and 34 mg(0.25 mmol) of HOBT.H₂ O in 2 mL of anhydrous tetrahydrofuran and 0.5 mLof dimethylformamide. The crude product was purified using radialchromatography (1 mm plate; gradient eluent of 1-10% methanol inmethylene chloride) to provide 30 mg of a light orange foam.

Yield: 22% α!_(D) -89.27° (c=0.137, MeOH). ¹ H NMR (CDCl₃): δ 1.21 (s,9H), 1.30-2.02 (m, 16H), 2.19-2.35 (m, 2H), 2.48-2.70 (m, 2H), 2.90-3.07(m, 2H), 3.10-3.23 (m, 1H), 3.50 (br.s, 4H), 3.94 (br.s, 1H), 4.40-4.50(m, 1H), 5.70 (s, 1H), 5.89-5.95 (m, 2H), 6.30 (d, J=8.4 Hz, 1H),7.15-7.33 (m, 5H). IR (CHCl₃): 3600-3100 (br), 3029, 3005, 2928, 2865,1664, 1621, 1513, 1455, 1392, 1367, 1276, 1244, 1171, 1047, 841 cm₋₁.MS(FD): m/e 550 (M⁺, 100). HR MS(FAB): m/e for C₃₂ H₄₈ N₅ O₃ : Calcd:550.3757; Found: 550.3762.

EXAMPLE 10

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3",5"-dinitrophenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 100 mg (0.25 mmol) of thesubtitled compound of Preparation 1B, 56 mg (0.25 mmol) of3,5-dinitro-2-methyl benzoic acid, 51 mg (0.25 mmol) of DCC and 34 mg(0.25 mmol) of HOBT.H₂ O in 3 mL of anhydrous tetrahydrofuran. The crudeproduct was purified using radial chromatography (1 mm plate; gradienteluent of 0-3% methanol in methylene chloride) to provide 61 mg of anoff-white foam.

Yield: 41%. α!_(D) -105.96° (c=0.302, MeOH). ¹ H NMR (CDCl₃): δ 1.02 (s,9H), 1.02-2.60 (m, 20H), 2.90-3.06 (m, 2H), 3.21 (br.s, 1H), 3.60-3.75(m, 1H), 4.05-4.20 (m, 1H), 4.65-4.80 (m, 1H), 5.47 (s, 1H), 7.20-7.50(m, 5H), 8.00-8.20 (m, 2H), 8.56 (s, 1H). IR (CHCl₃): 3621, 3500-3100(br), 3428, 3024, 2977, 2931, 1665, 1615, 1539, 1455, 1347, 1278, 1245,1047, 878 cm⁻¹. MS(FD): m/e 610 (M⁺, 100). HR MS(FAB): m/e for C₃₂ H₄₄N₅ O₇ : Calcd: 610.3241; Found: 610.3240.

EXAMPLE 11

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-chloro-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 116 mg (0.29 mmol) of thesubtitled compound of Preparation 1B, 50 mg (0.29 mmol) of the titledcompound of Preparation 14, 60 mg (0.29 mmol) of DCC and 39 mg (0.29mmol) of HOBT.H₂ O in 4 mL of anhydrous tetrahydrofuran. The crudeproduct was purified using radial chromatography (1 mm plate; gradienteluent of 2.5-5% methanol in methylene chloride) to provide 83 mg of awhite solid.

Yield: 51%. α!^(D) -74.29° (c=0.140, MeOH). ¹ H NMR (CDCl₃): δ 1.19 (s,9H), 1.19-2.80 (m, 16H), 2.90-3.15 (m, 2H), 3.35 (br.s, 1H), 4.06 (br.s,1H), 4.56 (br.s, 1H), 5.85 (br.s, 1H), 6.60-6.70 (m, 1H), 6.90-7.35 (m,8H). IR (CHCl₃): 3621, 3600-3100 (br), 3429, 2977, 2929, 1671, 1584,1515, 1445, 1394, 1368, 1292, 1182, 1046, 878, 823 cm⁻¹. MS(FD): m/e 556(M⁺, 100). Analysis for C₃₁ H₄₂ N₃ O₄ Cl: Calcd: C, 66.95; H, 7.61; N,7.56. Found: C, 66.76; H, 7.72; N, 7.69.

EXAMPLE 12

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 261 mg (0.65 mmol) of thesubtitled compound of Preparation 1B, 100 mg (0.65 mmol) of thesubtitled compound of Preparation 9B, 134 mg (0.65 mmol) of DCC and 88mg (0.65 mmol) of HOBT.H₂ O in 6 mL of anhydrous tetrahydrofuran and 0.2mL of anhydrous dimethylformamide. The crude product was purified usingradial chromatography (2 mm plate; gradient eluent of 1-5% methanol inmethylene chloride) to provide 304 mg of a white solid.

Yield: 87%. α!_(D) -75.00° (c=0.200, MeOH). ¹ H NMR (CDCl₃): δ 1.18 (s,9H), 1.19-2.05 (m, 18H), 2.20-2.35 (m, 2H), 2.50-2.70 (m, 2H), 2.90-3.05(m, 2H), 3.22-3.35 (m, 1H), 3.96-4.05 (m, 1H), 4.45-4.55 (m, 1H), 5.77(s, 1H), 6.53 (d, J=7.4 Hz, 2H), 6.75 (d, J=7.8 Hz, 1H), 6.85-6.90 (m,1H), 7.15-7.35 (m, 6H). IR (CHCl₃): 3606, 3600-3100 (br.), 3429, 3011,2929, 2865, 1663, 1604, 1587, 1514, 1455, 1367, 1277, 1200, 1156, 1046,910 cm⁻¹. MS(FD): m/e 537 (M⁺, 100). HR MS(FAB): m/e for C₃₂ H₄₆ N₃ O₄ :Calcd: 536.3488; Found: 536.3488.

EXAMPLE 13

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-methoxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 80 mg (0.20 mmol) of thesubtitled compound of Preparation 1B, 33 mg (0.20 mmol) of the subtitledcompound of Preparation 15B, 41 mg (0.20 mmol) of DCC and 27 mg (0.20mmol) of HOBT.H₂ O in 2 mL of anhydrous tetrahydrofuran. The crudeproduct was purified using radial chromatography (2 mm plate; eluent of2.5% methanol in methylene chloride) to provide 93 mg of a white foam.

Yield: 84%. ¹ H NMR (CDCl₃): δ 1.17 (s, 9H), 1.17-2.05 (m, 12H), 2.05(s, 3H), 2.25-2.38 (m, 2H), 2.50-2.75 (m, 2H), 2.95-3.10 (m, 2H),3.35-3.50 (m, 1H), 3.79 (s, 3H), 3.98-4.15 (m, 2H), 4.59-4.65 (m, 1H),5.72 (s, 1H), 6.47 (br.d, J=8.21 Hz, 1H), 6.63 (d, J=7.7 Hz, 1H), 6.82(d, J=8.12 Hz, 1H), 7.08 (t, J=7.0 Hz, 1H), 7.15-7.45 (m, 5H). Analysisfor C₃₃ H₄₇ N₃ O₄ : Calcd: C, 72.10; H, 8.62; N, 7.64. Found: C, 71.84;H, 8.49; N, 7.67.

EXAMPLE 14

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2",3"-dichloro-phenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 80 mg (0.20 mmol) of thesubtitled compound of Preparation 1B, 38 mg (0.20 mmol) of 2,3-dichlorobenzoic acid, 41 mg (0.20 mmol) of DCC and 27 mg (0.20 mmol) of HOBT.H₂O in 3 mL of anhydrous tetrahydrofuran. The crude product was purifiedusing radial chromatography (2 mm plate; gradient eluent of 2.5-5%methanol in methylene chloride) to provide 95 mg of a white foam.

Yield: 84%. ¹ H NMR (CDCl₃): δ 1.16 (s, 9H), 1.17-2.05 (m, 12H),2.20-2.38 (m, 2H), 2.50-2.75 (m, 2H), 2.95-3.10 (m, 2H), 3.40-3.55 (m,1H), 3.69 (s, 1H), 4.00-4.10 (m, 1H), 4.58-4.72 (m, 1H), 5.77 (s, 1H),6.98-7.47 (m, 9H). MS(FD): m/e 574(M⁺), 473(100).

EXAMPLE 15

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-trifluoromethylphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 80 mg (0.20 mmol) of thesubtitled compound of Preparation 1B, 38 mg (0.20 mmol) of2-trifluoromethyl benzoic acid, 41 mg (0.20 mmol) of DCC and 27 mg (0.20mmol) of HOBT.H₂ O in 3 mL of anhydrous tetrahydrofuran. The crudeproduct was purified using radial chromatography (2 mm plate; gradienteluent of 2.5-5% methanol in methylene chloride) to provide 72 mg of awhite foam.

Yield: 63%. ¹ H NMR (CDCl₃): δ 1.10 (s, 9H), 1.16-2.05 (m, 14H),2.15-2.35 (m, 2H), 2.45-2.70 (m, 2H), 2.92-3.05 (m, 2H), 3.38-3.55 (m,1H), 3.70 (br.s, 1H), 3.98-4.10 (m, 1H), 4.58-4.70 (m, 1H), 5.90 (s,1H), 7.00-7.65 (m, 10H). MS(FD): m/e 573 (M⁺, 100). Analysis for C₃₂ H₄₂N₃ O₃ F₃ : Calcd: C, 67.00; H, 7.38; N, 7.32. Found: C, 67.11; H, 7.09;N, 7.10.

EXAMPLE 16

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-oxo-3"-methyl-pyrid-4"-yl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 14.7 mg (0.037 mmol) of thesubtitled compound of Preparation 1B, 5.6 mg (0.037 mmol) of thesubtitled compound of Preparation 12F, 7.6 mg (0.037 mmol) of DCC and4.9 mg (0.037 mmol) of HOBT.H₂ O in 1.3 mL of anhydrousdimethylformamide. The crude product was purified using radialchromatography (1 mm plate; eluent of 10% methanol in methylenechloride) to provide 6.5 mg of a white solid.

Yield: 34%. ¹ H NMR (CDCl₃): δ 1.00-3.40 (m, 32H), 4.00-4.70 (m, 3H),5.90-6.10 (m, 1H), 6.90-7.40 (m, 8H). MS(FD): m/e 537 (M⁺, 100).

EXAMPLE 17

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2",6"-dichloro-3',-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 48 mg (0. 12 mmol) of thesubtitled compound of Preparation 1B, 25 mg (0.12 mmol) of the subtitledcompound of Preparation 13, 2.5 mg (0.12 mmol) of DCC and 16 mg (0.12mmol) of HOBT.H₂ O in 2 mL of anhydrous tetrahydrofuran. The crudeproduct was purified using radial chromatography (1 mm plate; gradienteluent of 2-5% methanol in methylene chloride) to provide 14 mg of thedesired titled compound. ¹ H NMR (CDCl₃): δ 0.9-2.15 (m, 23H), 2.22-2.85(m, 4H), 2.95-3.10 (m, 2H), 3.30-3.58 (m, 1H), 3.98-4.12 (m, 1H),4.56-4.75 (m, 1H), 5.60-5.82 (m, 1H), 6.60-6.79 (m, 1H), 6.90-7.40 (m,6H). IR (CHCl₃): 3010, 2937, 1644, 1606, 1605, 1497, 1474, 1454, 1433,1417, 1341, 1313, 1274, 1252, 1161, 1093, 1074, 1027, 991 cm¹. MS(FD):m/e 590 (M⁺, 100).

EXAMPLE 18

3S-(3R*,4aR*,8aR*,2'S*,3 'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-aminophenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 100 mg (0.25 mmol) of thesubtitled compound of Preparation 1B, 38 mg (0.25 mmol) of3-amino-2-methyl benzoic acid, 34 mg (0.25 mmol) of HOBT.H₂ O, 52 mg(0.25 mmol) of DCC in 3 mL of anhydrous tetrahydrofuran, with theexception that the reaction was conducted in the presence of 76 mg (0.75mmol) of triethylamine. The resultant material was purified using radialchromatography (2 mm plate; gradient eluent of 2-5% methanol inmethylene chloride) to provide 78 mg of an off-white foam.

Yield: 58%. ¹ H NMR (CDCl₃): δ 1.19 (s, 9H), 1.20-2.08 (m, 15H),2.20-2.35 (m, 2H), 2.50-2.70 (m, 2H), 2.92-3.05 (m, 2H), 3.28-3.38 (m,1H), 3.61 (br.s, 1H), 3.93-4.20 (m, 2H), 4.45-4.58 (m, 1H), 5.80 (s,1H), 6.44 (d, J=7.5 Hz, 2H), 6.63 (d, J=7.9 Hz, 1H), 6.90 (t, J=7.7 Hz,1H), 7.17-7.36 (m, 6H). MS(FD): m/e 535 (M⁺, 100).

EXAMPLE 19

2S-(2R*,2'S*,3'S*)!-1-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(3"-hydroxy-2"-methylphenyl)pentyl!-4-pyrid-3"-ylmethylpiperazine-2-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 50 mg (0.11 mmol) of thesubtitled compound of Preparation 6B, 16 mg (0.11 mmol) of the subtitledcompound of Preparation 9C, 14 mg (0.11 mmol) of HOBT.H₂ O and 22 mg(0.11 mmol) of DCC in 2 mL of anhydrous tetrahydrofuran. The resultantmaterial was purified using radian chromatography (1 mm plate; gradienteluent of 5-10% methanol in methylene chloride) to provide 35 mg of anoff-white foam.

Yield: 55%. ¹ H NMR (CDCl₃): δ 1.29 (s, 9H), 2.18 (s, 3H), 2.23-2.33 (m,1H), 2.45-2.85 (m, 7H), 3.20-3.35 (m, 3H), 3.45 (s, 1H), 4.00-4.10 (m,1H), 4.25-4.35 (m, 1H), 5.00-5.40 (br.s, 1H), 6.61 (d, J=7.6 Hz, 1H),6.76-6.80 (m, 2H), 6.92 (t, J=7.7 Hz, 1H), 7.12-7.43 (m, 7H), 7.57-7.62(m, 1H), 7.78 (br.s, 1H), 8.48-8.58 (m, 2H). MS (FD): m/e 606 (M⁺, 100).

EXAMPLE 20

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-isopropyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 55 mg (0.137 mmol) of thesubtitled compound of Preparation 1B, 24.7 mg (0.137 mmol) of thesubtitled compound of Preparation 18B, 28.25 mg (0.137 mmol) of DCC, and18.5 mg (0.137 mmol) of HOBT.H₂ O in 8 mL of tetrahydrofuran. Theresultant crude material was purified using radial chromatography (1 mmplate; eluent of 3% methanol in methylene chloride) to provide 46 mg ofa white foam.

Yield: 60%. α!_(D) -84.61 (c=2.60, MeOH). ¹ H NMR (CDCl₃): δ 1.19 (d,J=3.7 Hz, 3H), 1.21 (d, J=3.75 Hz, 3H), 1.23 (s, 9H), 1.27-1.51 (m, 7H),1.61-2.00 (m, 6H), 2.26-2.35 (m, 2H), 2.56-2.65 (m, 2H), 2.91-3.03 (m,3H), 3.19-3.27 (m, 1H), 3.96 (m, 1H), 4.51 (m, 1H), 5.82 (br.s, 1H),5.93 (br.s, 1H), 6.23 (d, J=8.53 Hz, 1H), 6.46 (d, J=7.15 Hz, 1H), 6.66(d, J=7.17 Hz, 1H), 6.86 (t, J=7.74 Hz, 1H), 7.21-7.31 (m, 5H). IR(CDCl₃): 3427, 3322, 3028, 3008, 2930, 2868, 1660, 1603, 1582, 1513,1455, 1393, 1366, 1304, 1278, 1245, 1088, 1059 cm⁻¹. MS(FD): m/e 564(M⁺, 100). Analysis for C₃₄ H₄₉ N₃ O₄ : Calcd: C, 72.43; H, 8.76; N,7.45; Found: C, 72.13; H, 8.85; N, 7.30.

EXAMPLE 21

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-butyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 91 mg (0.227 mmol) of thesubtitled compound of Preparation 1B, 44 mg (0.227 mmol) of thesubtitled compound of Preparation 16B, 46.7 mg (0.227 mmol) DCC, and30.6 mg (0.227 mmol) of HOBT.H₂ O in 10 mL of tetrahydrofuran. Theresultant crude material was purified using radial chromatography (1 mmplate; gradient eluent of 4-7% methanol in methylene chloride) toprovide 72 mg of a white foam.

Yield: 55%. α!_(D) -77.36 (c=0.36, MeOH). ¹ H NMR (CDCl₃): δ 0.84 (t,J=7.2 Hz, 3H), 1.20 (s, 9H), 1.29-2.00 (m, 18H), 2.27 (m, 2H), 2.48-2.69(m, 4H), 2.99 (m, 2H), 3.29 (m, 1H), 3.99 (m, 1H), 4.49 (m, 1H), 5.85(s, 1H), 6.45 (m, 2H), 6.75 (d, J=7.19 Hz, 1H), 6.86 (t, J=7.67 Hz, 1H),7.21-7.31 (m, 5H). IR (KBr): 3303 (br.), 3087, 3029, 2927, 2862, 1647,1583, 1520, 1455, 1366, 1281, 1209, 1108, 735, 698 cm¹. MS(FD): m/e 578(M⁺, 100). HR MS(FAB): m/e for C₃₅ H₅₁ N₃ O₄ : Calcd: 578.3958; Found:578.3962.

EXAMPLE 22

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-propyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 67 mg (0.167 mmol) of thesubtitled compound of Preparation 1B, 30 mg (0.167 mmol) of thesubtitled compound of Preparation 17B, 34 mg (0.167 mmol) of DCC, and 23mg (0.167 mmol) of HOBT.H₂ O in 4 mL of tetrahydrofuran. The resultantcrude material was purified using radial chromatography (1 mm plate;eluent of 3% methanol in methylene chloride) to provide 75 mg of a whitefoam.

Yield: 80%. α!_(D) -43.75 (c=0.160, MeOH). ¹ H NMR (CDCl₃): δ 0.87 (t,3H), 1.18 (s, 9H), 1.21-2.04 (m, 15H), 2.24-2.33 (m, 2H), 2.49-2.58 (m,3H), 2.66 (m, 1H), 2.98 (m, 2H), 3.37 (m, 1H) 3.99 (m, 1H), 4.52 (m,1H), 5.07 (m, 1H), 5.70 (s, 1H), 6.43 (d, J=8.32 Hz, 1H), 6.56 (d,J=7.32 Hz, 1H), 6.76 (d, J=7.12 Hz, 1H), 6.95 (t, J=7.78 Hz, 1H),7.20-7.33 (m, 5H). IR (KBr): 3287 (br.), 3086, 2932, 2868, 1681, 1558,1456, 1368, 1334, 1291, 1261, 1218, 1169, 1101, 1042, 776, 734, 552cm⁻¹. MS(FD): m/e 564 (M⁺, 100). HR MS(FAB): m/e for C₃₄ H₅₀ N₃ O₄ :Calcd: 564.3801; Found: 564.3789.

EXAMPLE 23

3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 70 mg (0.16 mmol) of the subtitlecompound of Preparation 8G, 24.6 mg (0.16 mmol) of the subtitledcompound of Preparation 9C, 33 mg (0.16 mmol) of DCC, and 22 mg (0.16mmol) of HOBT.H₂ O in 4 mL of tetrahydrofuran. The resultant crudematerial was purified using radial chromatography (1 mm plate; eluent of3% methanol in methylene chloride) to provide 54 mg of a white foam.

Yield: 60%. α!_(D) -119.23 (c=0.26, MeOH). ¹ H NMR (CDCl₃): δ 1.09 (s,9H), 1.12-1.79 (m, 12H), 1.93-2.02 (m, 2H), 2.17-2.30 (m, 2H), 2.31 (s,3H), 2.43-2.61 (m, 2H), 2.91 (m, 1H), 3.42 (m, 1H), 3.78 (m, 1H), 4.07(m, 1H), 4.47 (m, 1H), 5.37 (m, 1H), 5.51 (br.s, 1H), 6.84 (m, 1H), 7.06(m, 2H), 7.17-7.32 (m, 4H), 7.45 (m, 2H). IR (KBr): 3297, 2925, 2862,1627, 1586, 1530, 1482, 1466, 1439, 1366, 1287, 1221, 1156, 1119, 1026,801, 735, 689 cm⁻¹. MS(FD): m/e 568 (M⁺, 100). HR MS(FAB) for C₃₂ H₄₆ N₃O₄ S: Calcd: 568.3209; Found: 568.3182.

EXAMPLE 24

3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-Hydroxy-3'-(napht-2-ylthiomethyl)-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 70 mg (0.145 mmol) of thesubtitled compound of Preparation 7B, 22 mg (0.145 mmol) of thesubtitled compound of Preparation 9C, 29 mg (0.145 mmol) of DCC, and 19mg (0.145 mmol) of HOBT.H₂ O in 4 mL of tetrahydrofuran. The resultantcrude material was purified using flash chromatography (gradient eluentof 5-15% acetone in methylene chloride) to provide 65 mg of a whitesolid.

Yield: 73%. α!_(D) -112.00 (c=0.25, MeOH). ¹ H NMR (CDCl₃): δ 1.10 (s,9H), 1.15-1.80 (m, 12H), 1.93-2.06 (m, 1H), 2.17-2.28 (m, 2H), 2.29 (s,3H), 2.42-2.61 (m, 2H), 2.94 (d, 1H), 3.51 (m, 1H), 3.83-3.92 (m, 1H),4.10 (m, 1H), 5.36 (br.s, 1H), 5.53 (br.s, 1H), 6.79 (m, 1H), 6.93 (m,2H), 7.21 (d, j=8.83 Hz, 1H), 7.40-7.53 (m, 3H), 7.73 (m, 3H), 7.90 (s,1H). IR (KBr): 3427, 3311 (br), 2929, 2864, 1703, 1661, 1587, 1514,1456, 1393, 1366, 1276, 1200, 1177, 1146, 1119, 1070, 1042 cm⁻¹. MS(FD):m/e 618 (M⁺, 100). Analysis for C₃₄ H₄₉ N₃ O₄ : Calcd: C, 69.98; H,7.67; N, 6.80. Found: C, 69.92; H, 7.72; N, 6.75.

EXAMPLE 25

2S-(2R*,2'S*,3'S*)!-1-2'-Hydroxy-3'-(naphth-2-ylthiomethyl)-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyhenyl)pentyl!piperidine-2-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 28 mg (0.065 mmol) of thesubtitled compound of Preparation 2G, 10 mg (0.065 mmol) of thesubtitled compound of Preparation 9C, 13.5 mg (0.065 mmol) of DCC, and 9mg (0.065 mmol) HOBT.H₂ O in 2 mL of tetrahydrofuran. The resultantcrude material was purified using radial chromatography (1 mm plate;eluent of 2% methanol in methylene chloride) to provide 23 mg of a whitefoam.

Yield: 63%. α!_(D) -233.33 (c=0.09, MeOH). ¹ H NMR (CDCl₃): δ 1.17 (s,9H), 1.26 (m, 1H), 1.56-1.73 (m, 6H), 2.19-2.23 (m, 2H), 2.25 (s, 3H),2.42 (m, 1H), 2.62-2.73 (m, 2H), 3.11-3.19 (m, 1H), 3.50-3.72 (m, 2H),4.10 (m, 1H), 4.45 (m, 1H), 5.89 (s, 1H), 6.77-6.87 (m, 3H), 7.00 (d,J=8.65 Hz, 1H), 7.43-7.51 (m, 3H), 7.72-7.80 (m, 3H), 7.88 (s, 1H). IR(KBr): 3329, 2934, 2857, 1646, 1586, 1522, 1457, 1364, 1284, 1223, 1133,1072, 944, 835, 811, 744, 474 cm⁻¹. MS(FD): m/e 564 (M⁺, 100). HRMS(FAB): for C₃₂ H₄₂ N₃ O₄ S: Calcd: 564.2896; Found: 564.2916.

EXAMPLE 26

2S-(2R*,2'S*,3'R*)!-1-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-4-(pyrid-3'"-ylmethyl)piperazine-2-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theProcedure detailed in Example 1, using 65 mg (0.148 mmol) of thesubtitled compound of Preparation 5E, 22.5 mg (0.148 mmol) of thesubtitled compound of Preparation 9C, 30.5 mg (0.148 mmol) of DCC, and20 mg (0.148 mmol) of HOBT.H₂ O in 5 mL of tetrahydrofuran. Theresultant crude material was purified using radial chromatography (1 mmplate; eluent of 3% methanol in methylene chloride) to provide 64 mg ofa white foam.

Yield: 75%. ¹ H NMR (CDCl₃): δ 1.33 (s, 9H), 1.86 (s, 3H), 2.30 (m, 1H),2.49-2.98 (m, 11H), 3.33 (m, 1H), 3.46 (m, 1H), 4.02 (m, 1H), 4.46 (m,1H), 6.29 (d, J=9.16 Hz, 1H), 6.46 (d, J=7.23 Hz, 1H), 6.73 (d, J=7.79Hz, 1H), 6.83 (t, J=7.84 Hz, 1H), 7.17-7.31 (m, 7H), 7.60 (m, 1H), 7.95(br.s, 1H), 8.50-8.55 (m, 2H). MS(FD): m/e 574 (M⁺, 100). HR MS(FAB):m/e for C₃₃ H₄₄ N₅ O₄ : Calcd: 574.3393; Found: 574.3373.

EXAMPLE 27

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-ethyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide monomesylate salt

To a cold (0° C.) solution of 35.1 mg (0.064 mmol) of the titledcompound of Example 3 in 2 mL of anhydrous methylene chloride, was addeddropwise 134 μL (0.067 mmol) of a 0.5M solution of methanesulfonic acidin methylene chloride. The resulting reaction was reduced to drynessunder reduced pressure (0.2-0.1 Torr) to provide 38 mg (crude) of alight yellow foam.

Yield: 90%. ¹ H NMR (CD₃ OD): δ 0.91 (t, J=7.39, 3H), 1.29 (s, 9H),1.30-3.20 (m, 21H), 4.00-4.40 (m, 2H), 6.47 (d, J=7.30 Hz, 1H), 6.73 (d,J=7.78 Hz, 1H), 6.91 (t, J=7.78 Hz, 1H), 7.15-7.32 (m, 5H).

EXAMPLE 28

3S-(3R*,4aR*,8aR*,2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide monomesylate salt

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 27, using 125 mg (0.23 mmol) of the titledcompound of Example 13 in 5 mL of anhydrous methylene chloride, and 240μL (0.24 mmol) of a 1.0M solution of methanesulfonic acid in methylenechloride to provede 136 mg (crude) of an off-white foam.

Yield: 95%. ¹ H NMR (CD₃ OD): δ 1.12 (s, 9H), 1.10-2.20 (m, 16H),2.60-2.75 (m, 4H), 3.10-3.50 (m, 6H), 3.60-3.70 (m, 1H), 3.90-4.30 (m,3H), 6.53 (d, j=7.35 Hz, 1H), 6.65 (t, J=7.87 Hz, 1H), 6.89 (t, J=7.82Hz, 1H).

EXAMPLE 29

3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-phenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 15 mg (0.034 mmol) of thesubtitled compound of Preparation 8G, 4.7 mg (0.034 mmol) of o-toluicacid, 7.13 mg (0.034 mmol) of DCC, and 4.7 mg (0.034 mmol) of HOBT.H₂ Oin 2.5 mL of tetrahydrofuran. The resultant material was purified usingradial chromatography (1 mm plate; eluent 10% acetone in methylenechloride) to provide 16 mg of a white foam.

Yield: 84%. α!_(D) -80.00 (c=0.15). ¹ H NMR (CDCl₃): δ 1.04 (s, 9H),1.08-1.80 (m, 11H), 1.93 (m, 3H), 2.22 (m, 4H), 2.44 (m, 1H), 2.49 (s,3H), 2.58 (m, 1H), 2.94 (m, 1H), 3.47 (m, 1H), 3.84 (m, 1H), 4.03 (m,1H), 4.50 (m, 1H), 5.45 (br.s, 1H), 7.12-7.32 (m, 7H), 7.45 (m, 2H),7.51 (d, J=7.51 Hz, 1H). IR (KBr): 3327, 2928, 2852, 1627, 1574, 1535,1481, 1364, 1311, 1275, 1225, 1088, 737 cm⁻¹. HR MS(FAB) for C₃₂ H₄₆ N₃O₃ S: Calcd: 552.3260; Found: 552.3272.

EXAMPLE 30

3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-3"-methyl-pyrid-4"-yl)!pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 15 mg (0.034 mmol) of thesubtitled compound of Preparation 8G, 6.69 mg (0.048 mmol) of the titledcompound of Preparation 19, 7.13 mg (0.034 mmol) of DCC, and 4.7 mg(0.034 mmol) of HOBT.H₂ O in 1.5 mL of tetrahydrofuran and 1 mL ofdimethylformamide. The resultant material was purified using radialchromatography (1 mm plate; gradient eluent of 3-5% methanol inmethylene chloride) to provide 10 mg of a white foam.

Yield: 52%. α!_(D) -95.65 (c=0.115). ¹ H NMR (CDCl₃): δ 1.00 (s, 9H),1.20-1.77 (m, 12H), 1.99 (m, 1H), 2.17 (m, 2H), 2.44 (m, 5H), 2.92 (m,1H), 3.41 (m, 1H), 3.84 (m, 1H), 4.13 (m, 1H), 4.56 (m, 1H), 5,39 (s,1H), 7.20-7.46 (m, 6H), 7.75 (d, J=8.94 Hz, 1H), 8.46 (m, 2H). IR (KBr):3307, 2925, 2860, 1653, 1542, 1481, 1439, 1391, 1365, 1281, 1224, 1058,1041, 738, 691, 669 cm⁻¹. HR MS(FAB) for C₃₁ H₄₅ N₄ O₃ S: Calcd:553.3212; Found: 553.3222.

EXAMPLE 31

3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(quinolin-5"-yl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 15 mg (0.034 mmol) of thesubtitled compound of Preparation 8G, 6.0 mg (0.034 mmol) of the titledcompound of Preparation 20, 7.13 mg (0.034 mmol) of DCC, and 4.7 mg(0.034 mmol) HOBT.H₂ O in 2 mL of tetrahydrofuran. The resultantmaterial was purified using radial chromatography (1 mm plate; gradienteluent of 3-5% methanol in methylene chloride) to provide 15 mg of awhite foam.

Yield: 74%. α!_(D) -99.50 (c=0.201). ¹ H NMR (CDCl₃): δ 0.74 (s, 9H),1.15-1.79 (m, 12H), 1.97 (m, 1H), 2.17 (m, 2H), 2.36 (m, 1H), 2.54 (m,1H), 2.90 (m, 1H), 3.45 (m, 1H), 3.39 (m, 1H), 4.16 (m, 1H), 4.62 (m,1H), 5.29 (s, 1H), 7.18-7.32 (m, 3H), 7.40-7.50 (m, 3H), 7.70 (m, 1H),7.89 (m, 2H), 8.17 (m, 1H), 8.91 (m, 2H). IR (KBr): 3299, 2923, 2862,1644, 1546, 1481, 1439, 1390, 1327, 1279, 1222, 1207, 1037, 810, 735,689 cm⁻¹. HR MS(FAB) for C₃₄ H₄₅ N₄ O₃ S: Calcd: 569.3212; Found:589.3237.

EXAMPLE 32

3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(1",2",3",4"-tetrahydroquinolin-5"-yl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 18 mg (0.04 mmol) of thesubtitled compound of Preparation 8G, 7.38 mg (0.04 mmol) of the titledcompound of Preparation 21, 8.56 mg (0.04 mmol) of DCC, and 5.61 mg(0.04 mmol) of HOBT.H₂ O in 2 mL of tetrahydrofuran. The resultantmaterial was purified using radial chromatography (1 mm plate; gradienteluent of 3-5% methanol in methylene chloride) to provide 12 mg of awhite foam.

Yield: 50%. α!_(D) -98.59 (c=0.142). ¹ H NMR (CDCl₃): δ 1.13 (s, 9H),1.14-2.04 (m, 15H), 2.19 (m, 2H), 2.45 (m, 1H), 2.57 (m, 1H), 2.75 (m,1H), 2.90-3.09 (m, 2H), 3.26 (m, 2H), 3.44 (m, 2H), 3.75 (m, 1H),4.01-4.14 (m, 2H), 4.42 (m, 1H), 5.56 (s, 1H), 6.49 (d, J=7.96 Hz, 1H),6.80 (d, J=7.40 Hz, 1H), 6.93 (t, J=7.72 Hz, 1H), 7.08 (d, J=8.39 Hz,1H), 7.18 (m, 1H), 7.27 (m, 2H), 7.42 (d, 2H). IR (KBr): 3327, 2928,2852, 1629, 1590, 1519, 1481, 1449, 1364, 1310, 1275, 1229, 1087, 738,690 cm⁻¹. HR MS (FAB) for C₃₄ H₄₉ N₄ O₃ S; Calcd: 593.3525; Found:593.3552.

EXAMPLE 33

2S-(2R*,2'S*,3'S*,)!-1-2'-Hydorxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(1",2",3",4"-tetrahydroquinolin-5"-yl)pentyl!-4-(pyrid-3'"-ylmethyl)piperazine-2-N-t-butylcarboxamide

To a cooled (-10° C.) solution containing 45 mg (0.10 mmol) of thesubtitled compound of Preparation 6B, 18 mg (0.10 mmol) of1,2,3,4-tetrahydroquinoline-5-carboxylic acid, 30 mg (0.30 mmol) oftriethylamine, and 14 mg (0.10 mmol) of HOBT.H₂ O in 2 mL of anhydroustetrahydrofuran, was added 22 mg (0.11 mmol) of DCC. The resultantreaction mixture was stirred for approximately 24 hours at roomtemperature and then concentrated under reduced pressure to provide aresidue. This residue was redissolved in ethyl acetate, and filteredthrough celite. The filtrate was then extracted sequentially withsaturated sodium bicarbonate (twice), brine, dried over sodium sulfate,filtered and concentrated under reduced pressure. The crude material waspurified using radial cnromatography (1 mm plate; gradient eluent of2.5-5% methanol in methylene chloride) to provide 33 mg of an off-whitefoam.

Yield: 62%. ¹ H NMR (CDCl₃): δ 1.29 (s, 9H), 1.79-1.97 (m, 2H),2.26-3.00 (m, 11H), 3.20-3.50 (m, 9H), 3.95-4.05 (m, 1H), 4.23-4.35 (m,1H), 6.43-6.62 (m, 2H), 6.89 (t, J=7.8 Hz, 1H), 7.12-7.35 (m, 6H), 7.41(d, J=7.7 Hz, 2H), 7.57-7.70 (m, 2H), 8.50-8.58 (m, 2H). MS(FD): m/e 631(M⁺, 100).

EXAMPLE 34

2S-(2R*,2'S*,3'S*)!-1-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(quinolin-5"-yl)pentyl!-4-(pyrid-3'"-ylmethyl)piperazine-2-N-t-butylcarboxamide

The titled compound was isolated from Example 33 Yield: 13 mg of anoff-white foam. ¹ H NMR (CDCl₃): δ 1.18 (s, 9H), 2.27-2.90 (m, 9H),3.17-3.60 (m, 5H), 4.07-4.19 (m, 1H), 4.40-4.55 (m, 1H), 4.75-4.95 (m,1H), 6.90-7.68 (m, 11H), 8.16 (d, J=8.1 Hz, 1H), 8.48-8.60 (m, 2H), 8.80(d, J=8.4 Hz, 1H), 8.89-8.97 (m, 1H). MS(FD): m/e 527 (M⁺, 100).

EXAMPLE 35

2S-(2R*,2'S*,3'S*)!-1- 2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-3"-methyl-pyrid-4-yl)!pentyl!-4-(pyrid-3'"-ylmethyl)piperazine-2-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 20.3 mg (0.148 mmol) of thetitled compound of Preparation 19, 70 mg (0.148 mmol) of the subtitledcompound of Preparation 19, 31 mg (0.148 mmol) of DCC, and 20 mg (0.148mmol) of HOBT.H₂ O in tetrahydrofuran containing 62 mL of triethylamine.The resultant material was purified using radial chromatography (2 mmplate; gradient eluent of 2.5-15% methanol in methylene chloride) toprovide 48 mg of a white foam.

Yield: 55%. ¹ H NMR (CDCl₃): δ 1.23 (s, 9H), 2.30-2.90 (m, 12H),3.16-3.50 (m, 5H), 4.02-4.10 (m, 1H), 4.30-4.42.41 (m, 1H), 4.85 (br.s,1H), 6.90-7.60 (m, 10H), 8.38-8.57 (m, 3H). MS(FAB): m/e 591.4 (M⁺,100).

EXAMPLE 36

3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-2"-methyl-3"-N-(methylsulfonyl)amino-phenyl)!pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 70 mg (0.17 mmol) of thesubtitled compound of Preparation 1B, 40 mg (0.17 mmol) of the titledcompound of Preparation 22, 35 mg (0.17 mmol) of DCC, and 23 mg (0.17mmol) of HOBT.H₂ O in 2 mL of anhydrous tetrahydrofuran. The resultantmaterial was purified using radial chromatography (2 mm plate; gradienteluent of 1-5% methanol in methylene chloride) to provide 72 mg of anoff-white solid.

Yield: 69%. ¹ H NMR (CDCl₃): δ 1.14 (s, 9H), 1.19-2.38 (m, 19H),2.50-2.70 (m, 2H), 2.92-3.06 (m, 4H), 3.43-3.55 (m, 1H), 4.01-4.10 (m,1H), 4.58-4.70 (m, 1H), 5.66 (s, 1H), 6.37 (br.s, 1H), 6.82-6.93 (m,2H), 7.10-7.39 (m, 6H), 7.48 (d, J=8.16 Hz, 1H). IR (KBr): 3691,3600-3300 (br.), 2929, 2866, 1672, 1603, 1513, 1455, 1393, 1368, 1327,1277, 1154, 1047, 972, 909, 877 cm⁻¹. MS(FD): m/e (M⁺, 100).

EXAMPLE 37

3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-Hydroxy-3'-phenylmethyl-4-aza-5'-oxo-5'- 1",2",3",4"-tetrahydroquinolin-5"-yl)!pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 18.5 mg (0.046 mmol) of thesubtitled compound of Preparation 1B, 8.14 mg (0.046 mmol) of the titledcompound of Preparation 20, 9.48 mg (0.046 mmol) of DCC, and 6.21 mg(0.046 mmol) of HOBT.H₂ O in 2 mL of anhydrous tetrahydrofuran. Theresultant material was purified using radial chromatography (1 mm plate;gradient eluent of 2-5% methanol in methylene chloride) to provide 11 mgof a foam.

Yield: 43%. ¹ H NMR (CDCl₃): δ 1.20 (s, 9H), 1.25-2.02 (m, 15H), 2.28(m, 2H), 2.46-2.70 (m, 4H), 2.99 (m, 2H), 3.21 (m, 1H), 3.35 (m, 1H),3.98 (m, 1H), 4.49 (m, 1H), 5.75 (br.s, 1H), 6.38 (m, 3H), 6.83 (t, 1H),7.21-7.33 (m, 5H).

EXAMPLE 38

3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-6"-methyl-(1",2",3",4"-tetrahydroquinolin-5"-yl)!pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 15 mg (0.035 mmol) of thesubtitled compound of Preparation 8G, 6.5 mg (0.035 mmol) of6-methyl-1,2,3,4-tetrahydro-5-quinoline carboxylic acid, 7.15 mg (0.035mmol) of DCC, and 4.7 mg (0.035 mmol) of HOBT.H₂ O in 2 mL oftetrahydrofuran and 1 mL of dimethylformamide. The resultant materialwas purified using radial chromatography (1 mm plate; gradient eluent of3-5% methanol in methylene chloride) to provide 12.5 mg of a whitesolid.

Yield: 60%. HR MS(FAB) for C₃₅ H₄₇ N₄ O₃ S: Calcd: 603.3369; Found:603.3384.

EXAMPLE 39

3S-(3R*,4aR*,8aR*,2'S*,3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-2",6"-dimethyl-3"-hydroxyphenyl!pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 1, using 20 mg (0.046 mmol) of thesubtitled compound of Preparation 8G, 11.53 mg (0.0694 mmol) of2,6-dimethyl-3-hydroxy benzoic acid, 9.54 mg (0.046 mmol) of DCC, and6.25 mg (0.046 mmol) of HOBT.H₂ O in 3 mL of tetrahydrofuran. Theresultant material was purified using radial chromatography (1 mm plate;eluent of 4% methanol in methylene chloride) to provide 14 mg of a whitesolid.

Yield: 52%. HR MS(FA3) for C₃₃ H₄₈ N₃ O₄ S: Calcd: 582.3375; Found:582.3373.

EXAMPLE 40

2R'-(2R'*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 40, using 100 mg (0.29 mmol) of thesubtitled compound from Preparation 24D, 44 mg (0.29 mmol) of thesubtitled compound of Preparation 23C, 60 mg (0.29 mmol) of DCC and 39mg (0.29 mmol) of 1-hydroxybenzotriazole hydrate (HOBT.H₂ O) in 4 mL ofanhydrous tetrahydrofuran. The crude product was purifed using radialchromatography (2 mm plate; gradient eluent of 2-5% methanol inmethylene chloride) to provide 58 mg of a white powder.

Yield: 42%. α!_(D) 2.34° (c=3.4, MeOH). ¹ H NMR (CD₃ OD): δ 1.47 (s,9H), 1.88 (s, 3H), 2.70-2.80 (m, 1H), 2.95-3.10 (m, 3H), 3.25-3.30 (m,1H), 3.85-3.95 (m, 1H), 4.35-4.45 (m, 1H), 4.84 (s, 1H), 6.55-6.58 (m,1H), 6.74 (d, J=8.0 Hz, 1H), 6.94 (t, J=7.8 Hz, 1H), 7.15-7.45 (m, 11H).IR (CHCl₃): 3580, 3550-3100 (br), 2929, 2865, 1662, 1596, 1521, 1472,1455, 1394, 1368, 1293, 1157, 1047, 879, 839 cm⁻¹. MS(FD): 475 (M⁺,100). HR MS(FAB): m/e for C₂₉ H₃₅ N₂ O₄ : Calcd: 475.2597; Found:475.2610.

EXAMPLE 41

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-5"-hydroxymethylphenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 40, using 95 mg (0.28 mmol) of thesubtitled compound of Preparation 24D, 65 mg (0.28 mmol) of thesubtitled compound of Preparation 27B, 58 mg (0.28 mmol) of DCC and 38mg (0.28 mmol) of HOBT.H₂ O in 2 mL of tetrahydrofuran containing 0.2 mLof dimethylformamide. The crude product was purified using radialchromatography (2 mm plate; eluent to 4% methanol in methylene chloride)to provide 64.6 mg of the desired titled compound.

Yield: 47%. α!_(D) -0.003 (c=1.02, MeOH). ¹ H NMR (CDCl₃): δ 1.44 (s,9H), 1.98 (s, 3H), 2.70-2.85 (m, 1H), 3.00-3.12 (m, 2H), 3.25-3.35 (m,1H), 3.85-3.97 (m, 1H), 4.00-4.10 (m, 2H), 4.35-4.46 (m, 1H), 4.50 (s,2H), 6.98-7.43 (m, 11H), 8.06-8.18 (m, 1H) MS(FD): m/e (M⁺ +1, 490).Analysis for C₃₀ H₃₆ N₂ O₄ : Calcd: C, 73.74; H, 7.43; N, 5.52; Found:C, 74.00; H, 7.49; N, 5.68.

EXAMPLE 42

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-aminophenyl)pentyl!benzamide

To a cold (0° C.) solution of 50 mg (0.12 mmol) of the subtitledcompound of Preparation 25E in 2.0 mL of dimethylformamide, was added 22mg (0.14 mmol) of 2-methyl-3-aminobenzoic acid, 16 mg (0.12 mmol) ofHOBT, 22 mg (0.12 mmol) of EDC and 0.081 mL (0.58 mmol) oftriethylamine. The resulting reaction mixture was stirred at 0° C. forapproximately one hour and then sixteen hours at room temperature. Themixture was then quenched wich water and extracted with ethyl acetate.The resulting layers were separated and the organic layer was dried,filtered and concencentrated under reduced pressure to provide a cruderesidue. This residue was purified using flash chromatograofh (eluent of3% methanol in methylene chloride) to provide 52 mg of a white solid (mp105°-106° C.).

Yield: 80%. ¹ H NMR (CDCl₃): δ 7.89 (s, 1H), 7.75 (m, 3H), 7.40 (m, 7H),6.86 (t, J=9.0 Hz, 1H), 6.12 (s, 1H), 5.93 (s, 1H), 4.51 (m, 1H), 4.02(m, 1H), 3.68 (br.s, 2H), 3.51 (m, 3H), 3.12 (s, 2H), 3.04 (dd, J=13.4,10.1 Hz, 1H), 2.92 (dd, J=13.4, 3.3 Hz, 1H), 2.23 (s, 3H), 1.50 (s, 9H).IR (KBr): 3304, 3068, 1633, 1516, 1321, 1221, 1076, 746 cm⁻¹. Analysisfor C₃₃ H₃₇ N.sub. 3O₃ S: Calcd: C, 71.32; H, 6.71; N, 7.56; Found: C,71.54; H, 6.83; N, 7.32.

EXAMPLE 43

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-N(methyl)aminophenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 100 mg (0.23 mmol) of thesubtitled compound of Preparation 25E in 2.0 mL of dimethylformamide, 42mg (0.26 mmol) of the titled compound of Preparation 28, 32 mg (0.23mmol) of HOBT, 45 mg (0.23 mmol) of EDC and 0.15 mL (1.20 mmol) oftriethylamine. The crude residue was purified using flash chromatography(eluent of 2% methanol in methylene chloride) to provide 102 mg of awhite solid (mp 111°-133° C.).

Yield: 76%. ¹ H NMR (CDCl₃): δ 7.89 (s, 1H), 7.75 (m, 2H), 7.52-7.21 (m,9H), 7.00 (t, J=7.9 Hz, 1H), 6.62 (t, J=7.4 Hz, 1H), 6.41 (d, J=9.1 Hz,1H), 6.09 (d, J=5.8 Hz, 1H), 5.91 (s, 1H), 4.48 (m, 1H), 4.01 (m, 1H),3.69 (s, 1H), 3.50 (m, 2H), 3.01 (m, 2H), 2.85 (s, 3H), 2.15 (s, 3H),1.45 (s, 9H). Analysis for C₃₄ H₃₉ N₃ O₃ S: Calcd: C, 71.67; H, 6.89; N,7.37; Found: C, 71.92; H, 6.74; N, 7.42.

EXAMPLE 44

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-chloro-3"-aminophenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 100 mg (0.23 mmol) of thesubtitled compound of Preparation 25E in 2.0 mL of dimethylformamide, 48mg (0.28 mmol) of 2-chloro-3-aminobenzoic acid, 32 mg (0.23 mmol) ofHOBT, 45 mg (0.23 mmol) of EDC and 0.16 mL (1.20 mmol) of triethylamine.The crude residue was purified using flash chromatography (eluent of 2%methanol in methylene chloride) to provide 97 mg of a white solid (mp107°-108° C.).

Yield: 72%. ¹ H NMR (CDCl₃): δ 7.89 (s, 1H), 7.78 (m, 2H), 7.61-7.23 (m,9H), 6.95 (t, J=7.8 Hz, 1H), 6.78 (m, 1H), 6.52 (d, J=7.9 Hz, 1H), 6.05(d, J=6.0 Hz, 1H), 5.92 (s, 1H), 4.51 (m, 1H), 4.21 (s, 2H), 4.16 (m,1H), 3.51 (m, 2H), 3.01 (m, 3H), 1.49 (s, 9H). Analysis for C₃₂ H₃₄ ClN₃O₃ S: Calcd: C, 66.71; H, 5.95; N, 7.29; Found: C, 66.85; H, 6.06; N,7.42.

EXAMPLE 45

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hyd-oxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-bromo-3"-aminophenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 100 mg (0.23 mmol) of subtitledcompound of Preparation 25E in 2.0 mL of dimethylformamide, 61 mg (0.28mmol) of 2-bromo-3-aminobenzoic acid, 32 mg (0.23 mmol) of HOBT, 45 mg(0.23 mmol) of EDC and 0.16 mL (1.20 mmol) of triethylamine. The cruderesidue was purified using flash chromatography (eluent of 2% methanolin methylene chloride) to provide 102 mg of a white solid (mp 110°-112°C.).

Yield: 71%. ¹ H NMR (CDCl₃): δ 7.88 (s, 1H), 7.78 (m, 2H), 7.60-7.25 (m,9H), 6.95 (t, J=7.8 Hz, 1H), 6.78 (m, 1H), 6.52 (d, J=7.9 Hz, 1H), 6.1(d, J=6.1 Hz, 1H), 5.90 (m, 1H), 4.52 (m, 1H), 4.21 (s, 2H), 4.15 (m,1H), 3.50 (m, 2H), 3.00 (m, 3H), 1.49 (s, 9H). Analysis for C₃₂ H₃₄ BrN₃O₃ S: Calc: C, 61.93; H, 5.52; N, 6.77; Found: C, 61.82; H, 5.83; N,6.63.

EXAMPLE 46

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-yltliomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 75 mg (0.18 mmol) of subtitledcompound of Preparation 25E in 2.0 mL of dimethylformamide, 32 mg (0.21mmol) of the subtitled compound of Preparation 23C, 24 mg (0.18 mmol) ofHOBT, 34 mg (0.18 mmol) of EDC and 0.12 mL (0.88 mmol) of triethylamine.The crude residue was purified using flash chromatography (eluent of 1%methanol in methylene chloride) to provide 52 mg of a white solid (mp119°-120 ° C.).

Yield: 53%. IR (KBr): 3297, 1636, 1518, 1284, 1221, 1073, 746 cm⁻¹. ¹ HNMR (CDCl₃): δ 7.90 (s, 1H), 7.76 (m, 3H), 7.48 (m, 6H), 6.79 (m, 4H),6.52 (d, J=9.2 Hz, 1H), 6.23 (s, 1H), 5.92 (s, 1H), 4.50 (m, 1H), 4.02(m, 1H), 3.49 (m, 3H), 3.03 (dd, J=13.4, 10.2 Hz, 1H), 2.97 (dd, J=13.4,3.4 Hz, 1H), 2.25 (s, 3H), 1.49 (s, 9H). Analysis for C₃₃ H₃₆ N₂ O₄ S:Calcd: C, 71.19; H, 6.52; N, 5.03; Found: C, 70.95; H, 6.59; N, 4.87.

EXAMPLE 47

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-5"-aminophenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 100 mg (0.23 mmol) of subtitledcompound of Preparation 25E in 2.0 mL of dimethylformamide, 44 mg (0.28mmol) of the titled compound of Preparation 29, 32 mg (0.23 mmol) ofHOBT, 45 mg (0.23 mmol) of EDC and 0.16 mL (1.20 mmol) of triethylamine.The crude residue was purified using flash chromatography (eluent of 2%methanol in methylene chloride) to provide 101 mg of a white solid (mp106°-107° C.).

Yield: 79%. ¹ H NMR (CDCl₃): δ 7.89 (s, 1H), 7.76 (m, 3H), 7.40-7.25 (m,7H), 6.85 (t, J=9.0 Hz, 1H), 6.62 (d, J=7.7 Hz, 1H), 6.43 (d, J=9.0 Hz,1H), 6.08 (d, J=5.8 Hz, 1H), 5.89 (s, 1H), 4.51 (m, 1H), 4.02 (m, 1H),3.70 (br.s, 2H), 3.50 (m, 3H), 3.04 (dd, J=13.3, 10.1 Hz, 1H), 2.92 (dd,J=13.3, 3.2 Hz, 1H), 2.21 (s, 3H), 1.50 (s, 9H). Analysis for C₃₃ H₃₇ N₃O₃ S: Calcd: C, 71.32; H, 6.71; N, 7.56; Found: C, 71.64; H, 6.93; N,7.45.

EXAMPLE 48

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-1-naphthylamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 100 mg (0.21 mmol) of subtitledcompound of Preparation 26D in 2.0 mL of dimethylformamide, 35 mg (0.23mmol) of the subtitled compound of Preparation 23C, 29 mg (0.21 mmol) ofHOBT, 40 mg (0.21 mmol) of EDC and 0.15 mL (1.10 mmol) of triethylamine.The crude residue was purified using flash chromatography (eluent of1.5% methanol in methylene chloride) to provide 106 mg of a white solid(mp 115°-117° C.).

Yield: 82%. ¹ H NMR (CDCl₃): δ 7.90 (s, 1H), 7.76 (m, 2H), 7.53-7.24 (m,11H), 6.85 (t, J=7.6 Hz, 1H), 6.73 (m, 1H), 6.63 (d, J=5.7 Hz, 1H), 6.51(d, J=9.2 Hz, 1H), 6.10 (s, 1H), 5.90 (s, 1H), 4.50 (m, 1H), 4.09 (m,1H), 3.48 (m, 2H), 3.10 (dd, J=12.9, 9.7 Hz, 1H), 2.88 (dd, J=12.9, 3.2Hz, 1H), 2.13 (s, 3H), 1.46 (s, 9H). Analysis for C₃₇ H₃₈ N₂ O.sub.₄ S:Calcd: C, 73.24; H, 6.31; N, 4.62; Found: C, 73.46; H, 6.70; N, 4.35.

EXAMPLE 49

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-chloro-3"-aminophenyl)pentyl!-1-naphthylamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 100 mg (0.21 mmol) of subtitledcompound of Preparation 26D in 2.0 mL of dimethylformamide, 39 mg (0.23mmol) of 2-chloro-3-aminobenzoic acid, 29 mg (0.21 mmol) of HOBT, 40 mg(0.21 mmol) of EDC, and 0.15 mL (1.10 mmol) of triethylamine. The cruderesidue was purified using flash chromatography (eluent of 1.5% methanolin methylene chloride) to provide 97 mg of a white solid (mp 110°-112°C.).

Yield: 74%. ¹ H NMR (CDCl₃): δ 7.90 (s, 1H), 7.81 (m, 4H), 7.75-7.21 (m,9H), 6.95 (t, J=7.8 Hz, 1H), 6.75 (m, 1H), 6.51 (d, J=8.2 Hz, 1H), 6.12(d, J=5.9 Hz, 1H), 5.95 (s, 1H), 4.50 (m, 1H), 4.21 (s, 2H), 4.15 (m,1H), 3.51 (m, 2H), 3.00 (m, 3H), 1.49 (s, 9H), Analysis for C₃₆ H₃₆ ClN₃O₃ S: Calcd: C, 69.05; H, 5.79; N, 6.71; Found: C, 69.21; H, 5.85; N,6.54.

EXAMPLE 50

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(3"-aminophenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 100 mg (0.23 mmol) of subtitledcompound of Preparation 25E in 2.0 mL of dimethylformamide, 38 mg (0.28mmol) of 3-aminobenzoic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine. The cruderesidue was purified using flash chromatography (eluent of 2% methanolin methylene chloride) to provide 90 mg of a white solid (mp 101°-102°C.).

Yield: 72%. ¹ H NMR (CDCl₃): δ 7.87 (s, 1H), 7.78 (m, 2H), 7.61-7.22 (m,10H), 6.96 (t, J=7.7 Hz, 1H), 6.76 (m, 1H), 6.52 (d, J=7.8 Hz, 1H), 6.04(d, J=6.1 Hz, 1H), 5.91 (s, 1H), 4.5 (m, 1H), 4.20 (s, 2H), 4.15 (m,1H), 3.50 (m, 2H), 3.01 (m, 3H), 1.49 (s, 9H). Analysis for C₃₂ H₃₅ N₃O₃ S: Calcd: C, 70.95; H, 6.51; N, 7.76; Found: C, 71.21; HI 6.72; N,7.72.

EXAMPLE 51

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(3"-hydroxyphenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 50 mg (0.12 mmol) of subtitledcompound of Preparation 25E in 2.0 mL of dimethylformamide, 20 mg (0.14mmol) of 3-hydroxybenzoic acid, 16 mg (0.12 mmol) of HOBT, 22 mg (0.12mmol) of EDC, and 0.081 mL (0.58 mmol) of triethylamine. The cruderesidue was purified using flash chromatography (eluent of 50% ethylacetate in hexane) to provide 36 mg of a white solid (mp 125°-128° C.).

Yield: 57%. ¹ H NMR (CDCl₃): δ 7.87 (s, 1H), 7.73 (m, 3H), 7.20-7.50 (m,7H), 6.95-7.15 (m, 4H), 6.80 (m, 1H), 6.80 (m, 1H), 6.50 (s, 1H), 6.30(m, 1H), 5.95 (s, 1H), 4.53 (m, 1H), 4.10 (m, 1H), 3.45 (m, 2H), 3.03(dd, J=13.4, 10.5 Hz, 1H), 2.90 (dd, J=13.4, 3.5 Hz, 1H), 1.46 (s, 9H).HR MS for C₃₂ H₃₄ N₂ O₄ S: Calcd: m/e 675.1294; Found: m/e 675.1311.

EXAMPLE 52

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-methylyphenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 50 mg (0.12 mmol) of subtitledcompound of Preparation 25E in 2.0 mL of dimethylformamide, 19 mg (0.14mmol) of 2-methylbenzoic acid, 16 mg (0.12 mmol) of HOBT, 22 mg (0.12mmol) of EDC, and 0.081 mL (0.58 mmol) of triethylamine. The cruderesidue was purified using flash chromatography (eluent of 40% ethylacetate in hexane) to provide 33 mg of a white solid (m.p. 85°-87° C.).

Yield: 52%. ¹ H NMR (CDCl₃): δ 7.89 (d, J=1.0 Hz, 1H), 7.76 (m, 3H),7.15-7.52 (m, 11H), 7.02 (t, J=7.4 Hz, 1H), 6.48 (d, J=9.0 Hz, 1H), 6.08(d, J=6.1 Hz, 1H), 5.89 (s, 1H), 4.53 (m, 1H), 4.02 (m, 1H), 3.48 (d,J=6.8 Hz, 2H), 3.00 (dd, J=13.4, 10.2 Hz, 1H), 2.92 (dd, J=13.4, 3.6 Hz,1H), 2.46 (s, 3H), 1.45(s, 9H). HR MS for C₃₃ H₃₆ N₂ O₃ S: Calcd: m/e673.1501; Found: m/e 673.1504.

EXAMPLE 53

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3",5"-diaminophenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 50 mg (0.12 mmol) of subtitledcompound of Preparation 25E in 2.0 mL of dimethylformamide, 23 mg (0.14mmol) of 2-methyl-3,5-diaminobenzoic acid, 16 mg (0.12 mmol) of HOBT, 22mg (0.12 mmol) of EDC, and 0.081 mL (0.58 mmol) of triethylamine. Thecrude oil was purified by flash chromatography (eluent of 5% methanol inmethylene chloride) to provide 28 mg of an off-white powder (m.p.125°-128° C.).

Yield: 42%. ¹ H NMR (CDCl₃): δ 7.90 (d, J=1.2 Hz, 1H), 7.77 (m, 3H),7.20-7.53 (m, 10H), 6.35 (d, J=9.3 Hz, 1H), 6.15 (br.m, 1H), 6.01 (d,J=2.1 Hz, 1H), 5.92 (s, 1H), 5.83 (d, J=2.1 Hz, 1H), 4.50 (m, 1H), 3.96(m, 1H), 3.50 (m, 4H), 3.03 (dd, J=13.4, 10.2 Hz, 1H), 2.91 (dd, J=13.4,3.5 Hz, 1H), 2.10 (s, 3H), 1.47 (s, 9H). HR MS for C₃₃ H₃₈ N₄ O₃ S:Calcd: m/e 703.1719; Found: m/e 703.1733.

EXAMPLE 54

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2",2"-dichlorophenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 75 mg (0.18 mmol) of subtitledcompound of Preparation 25E in 1.0 mL of dimethylformamide, 40 mg (0.21mmol) of 2,3-dichlorobenzoic acid, 24 mg (0.18 mmol) of HOBT, 34 mg(0.18 mmol) of EDC, and 0.12 mL (0.88 mmol) of triethylamine. The crudeoil was purified using flash chromatography (gradient eluent of 25-50%ethyl acetate in hexane) to provide 75 mg of a white solid (m.p.116°-119° C.).

Yield: 74%. ¹ H NMR (CDCl₃): δ 7.90 (s, 1H), 7.75 (m, 3H), 7.20-7.52 (m,9H), 7.13 (dd, J=7.9, 1.2 Hz, 1H), 7.00 (t, J=7.8 Hz, 1H), 6.64 (d,J=9.9 Hz, 1H), 5.88 (br.s, 1H), 4.52 (m, 1H), 4.03 (m, 1H), 3.50 (d,J=6.0 Hz, 2H), 3.00 (m, 2H), 1.44 (s, 9H). Analysis for C₃₂ H₃₂ Cl₂ N₂O₃ S: Calcd: C, 64.53; H. 5.42; N, 4.70; Found: C, 64.54; H. 5.50; N,4.73.

EXAMPLE 55

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-chloro-5"-aminophenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 75 mg (0.18 mmol) of subtitledcompound of Preparation 25E in 1.0 mL of dimethylformamide, 36 mg (0.21mmol) of the titled compound of Preparation 29, 24 mg (0.18 mmol) ofHOBT, 34 mg (0.18 mmol) of EDC and 0.12 mL (0.88 mmol) of triethylamine.The crude oil was purified using flash chromatography (eluent of 50%ethyl acetate in hexane) to provide 90 mg of a white solid (m.p.109°-110° C.).

Yield: 90%. ¹ H NMR (CDCl₃): δ 7.89 (s, 1H), 7.75 (m, 3H), 7.21-7.52 (m,10H), 7.04 (d, J=8.3 Hz, 1H), 6.73 (m, 1H), 6.55 (m, 2H), 5.92 (br.s,1H), 4.50 (m, 1H), 3.99 (m, 1H), 3.52 (d, J=5.6 Hz, 2H), 3.02 (m, 2H),1.45 (s, 9H). Analysis for C₃₂ H₃₄ ClN₃ O₃ S: Calcd: C, 66.71; H, 5.95;N, 7.29; Found: C, 66.94; H, 6.34; N, 6.92.

EXAMPLE 56

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-chloro-3"-hydroxyphenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 42, using 75 mg (0.18 mmol) of subtitledcompound of Preparation 25E in 1.0 mL of dimethylformamide, 36 mg (0.21mmol) of the titled compound of Preparation 14, 24 mg (0.18 mmol) ofHOBT, 34 mg (0.18 mmol) of EDC, and 0.12 mL (0.88 mmol) oftriethylamine. The crude oil was purified using flash chromatography(gradient eluent of 25-50% ethyl acetate in hexane) to provide 71 mg ofa white solid (m.p. 104°-105° C.)

Yield: 71% ¹ H NMR (CDCl₃): δ 7.90 (d, J=1.0 Hz, 1H), 7.7 (m, 3H),7.19-7.52 (m, 8H), 7.00 (m, 2H), 6.87 (m, 1H), 6.64 (d, J=9.1 Hz, 1H),5.89 (s, 1H), 4.52 (m, 1H), 4.04 (m, 1H), 3.50 (d, J=6.1 Hz, 1H), 3.05(dd, J=13.4, 3.0.2 Hz, 2H), 2.94 (dd, J=13.4, 3.6 Hz, 1H), 1.45 (s, 9H).Analysis for C₃₂ H₃₃ ClN₂ O₄ S: Calcd: C, 66.59; H, 5.76; N, 4.85;Found: C, 66.64; H, 5.90; N, 4.93.

EXAMPLE 57

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(isoquinolin-5"-yl)pentyl!benzamide

To a solution of 0.40 g (0.95 mmol) of the subtitled compound ofPreparation 25E and 134 μL (1.22 mmol) of N-methyl morpholine in 15 mLof tetrahydrofuran, was added 0.45 g (1.33 mmol) of the subtitledcompound of Preparation 30C. The resultant reaction mixture was reactedfor approximately 8 hours and then diluted with ethyl acetate. Theresultant layers were separated and the organic layer was washedsequentially with water, and brine, and then concentrated to provide acrude material. This crude material was purified using flashchromatography (silica; eluent of 4% methanol in methylene chloride) toprovide 0.53 g of a white solid (m.p. 109°-112° C.).

Yield: 97%. ¹ H NMR (CDCl₃): δ 9.19 (s, 1H), 8.50 (d, J=4.6 Hz, 1H),8.23 (d, J=5.9 Hz, 1H), 7.92 (m, 2H), 7.76 (m, 3H), 7.56 (m, 3H), 7.43(m, 3H), 7.32 (m, 2H), 7.24 (m, 1H), 6.88 (d, J=9.0 Hz, 1H), 6.05 (br.s,1H), 5.93 (s, 1H), 4.64 (m, 1H), 4.12 (m, 1H), 3.51 (d, J=6.3 Hz, 2H),3.01 (m, 2H), 1.40 (s, 9H). IR (neat film): 3428, 3019, 2978, 1647,1514, 1215, 758 cm⁻¹. HR MS for C₃₅ H₃₆ N₃ O₃ S (MH⁺): Calcd: 578.2477;Found: 578.2468. Analysis for C₃₅ H₃₅ N₃ O₃ S.0.17 CH₂ Cl₂ : Calcd: C,71.33; H, 6.02; N, 7.10; S, 5.41; Found: C, 71.35; H, 6.00; N, 7.09; S,5.44.

EXAMPLE 58

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(1",2",3",4"-tetrahydroisoquinolin-5"-yl)pentyl!benzamide

To a solution of 0.15 g (0.26 mmol) of the titled compound of Example 57in 6 mL of acetic acid, was added 0.08 g (1.27 mmol) of sodiumcyanoborohydride. The resultant reaction mixture was reacted forapproximately 1 hour, and then was quenched by the addition of asaturated solution of sodium bicarbonate. The desired compound was thenextracted using ethyl acetate and the organic extracts were washedsequentially with water, and brine, and then concentrated under reducedpressure to provide a foam. This foam was purified using flashchromatography (silica; eluent of 4% methanol in methylene chloride) toprovided 0.10 of a white amorphous solid (m.p. 197°-199° C.).

Yield: 66%. ¹ H NMR (CDCl₃): δ 7.85 (s, 1H), 7.75 (m, 3H), 7.50-7.20 (m,7H), 7.06 (m, 1H), 6.95 (m, 2H), 6.59 (d, J=9.1 Hz, 1H), 6.02 (s, 1H),4.48 (br.s, 1H), 4.00 (br.s, 1H), 3.98 (s, 2H), 3.45 (m, 2H), 3.01 (s,1H), 2.98 (d, J=6.0 Hz, 3H), 2.89 (m, 3H), 1.44 (s, 9H), OH notobserved. IR (neat film): 3418, 3281, 3019, 1632, 1516, 1215, 756; HR MSfor C₃₅ H₄₀ N₃ O₃ S: Calcd: 582.2790; Found: 582.2792. Analysis for C₃₅H₃₅ N₃ O₃ S.0.17 CH₂ Cl₂ : Calcd: C, 70.85; H, 6.65; N, 7.05; S, 5.38;Found: C, 70.85; H, 6.74; N, 7.16; S, 5.42.

EXAMPLE 59

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2-N(methyl)-1",2",3",4"-tetrahydroisoquinolin-5"-yl)pentyl!benzamide

To a hot (60° C.) solution of 0.11 g (0.19 mmol) of the titled compoundof Example 57 in 3 mL of tetrahydrofuran, was added 53 mg (1.40 mmol) ofsodium borohydride and 75 μL of formic acid. After approximately 1 hour,the reaction mixture was quenched by the addition of a saturated sodiumbicarbonate solution. The desired compound was then extracted usingethyl acetate and the organic extracts were washed sequentially withwater, and brine, and then concentrated to provide a foam. This foam waspurified using flash chromatography (silica; eluent of 5% methanol inmethylene chloride) to provide 0.05 g of a white amorphous solid (m.p.110°-113° C.).

Yield: 44%. ¹ H NMR (CDCl₃): δ 7.86 (s, 1H), 7.75 (m, 3H), 7.50-7.20 (m,7H), 7.00 (m, 3H), 6.46 (d, J=9.0 Hz, 1H), 6.13 (d, J=5.0 Hz, 1H), 5.96(s, 1H), 4.45 (m, 1H), 3.97 (m, 1H), 3.54 (s, 2H), 3.46 (m, 2H),3.20-2.90 (m, 4H), 2.60 (t, J=5.9 Hz, 2H), 2.40 (s, 3H), 1.44 (s, 9H).IR (neat film): 3432, 3019, 2976, 1645, 1516, 1215, 756 cm⁻¹. HRMS forC₃₆ H₄₂ N₃ O₃ S (MH⁺): Calcd: 596.2947; Found: 596.2939. Analysis forC₃₆ H₄₁ N₃ O₃ S.0.32 CH₂ Cl₂ : Calcd: C, 70.02; H, 6.74; N, 6.75; S,5.15; Found: C, 70.03; H, 6.74; N, 6.81; S, 5.24.

EXAMPLE 60

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(1",2",3",4"-tetrahydroisoquinolin-5"-yl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 58.

¹ H NMR (CDCl₃): δ 7.42 (m, 10H), 7.00 (m, 3H), 6.28 (d, J=9.4 Hz, 1H),5.95 (s, 1H), 4.60 (m, 1H), 3.95 (bs, 3H), 2.80-3.20 (m, 7H), 2.62 (m,1H), 1.47 (s, 9H). Analysis for C₃₁ H₃₇ N₃ O₃.MeOH: Calcd: C, 72.29; H,7.77; N, 7.90; Found: C, 72.61; H, 7.58; N, 7.61.

EXAMPLE 61

2'R-(2'R*,2'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(naphth-1"-yl)pentyl!benzamide

To a cold (0° C.) solution of 100 mg (0.23 mmol) of the subtitledcompound of Preparation 25E in 2.0 mL of dimethylformamide, was added 45mg (0.26 mmol) of naphthalene-1-carboxylic acid, 32 mg (0.23 mmol) ofHOBT, 45 mg (0.23 mmol) of EDC and 0.16 mL (1.20 mmol) of triethylamine.The resultant reaction mixture was reacted for approximately 1 hour at0° C. and 16 hours at room temperature, then diluted with 10 mL of ethylacetate. The resultant mixture was washed with water, dried over sodiumsulfate, filtered and then concentrated under reduced pressure toprovide a residue. This residue was purified using flash chromatography(eluent of 1% methanol in methylene chloride) to provide 82 mg of awhite solid (m.p. 92°-95° C.).

Yield: 63%. ¹ H NMR (CDCl₃): δ 8.35 (br.s, 1H), 7.95-7.68 (m, 7H),7.62-7.30 (m, 10H), 6.71 (d, J=8.9 Hz, 1H), 6.10 (d, 6.2 Hz, 1H), 5.89(s, 1H), 4.61 (m, 1H), 4.26 (m, 1H), 3.51 (d, J=8.9 Hz, 2H), 3.0 (m,2H), 1.51 (s, 9H). Analysis for C₃₆ H₃₆ N₂ O₃ S; Calcd: C, 74.97; H,6.29; N, 4.86; Found: C, 75.13; H, 6.45; N, 4.49.

EXAMPLE 62

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(indol-4"-yl)pentyl!benzamide

The titled compound was prepared and substantially in accordance withthe procedure detailed in Example 61, using 100 mg (0.23 mmol) of thesubtitled compound of Preparation 25E, 42 mg (0.26 mmol) of the titledcompound of Preparation 32, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol)of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL ofdimethylformamide. The crude residue was purified using flashchromatography (eluent of 1% methanol in methylene chloride) to provide43 mg of a white solid (m.p. 109°-110° C.).

Yield: 35%. ¹ H NMR (CDCl₃): δ 8.45 (br.s, 1H), 7.90 (s, 1H), 7.76 (m,3H), 7.57-7.23 (m, 10H), 7.19-6.89 (m, 3H), 6.24 (d, J=6.24 Hz, 1H),5.97 (s, 1H), 4.63 (m, 1H), 4.13 (m, 1H), 3.51 (m, 2H), 3.01 (m, 2H),1.49 (s, 9H), Analysis for C₃₄ H₃₆ N₃ O₃ S: Calcd: C, 72.18; H, 6.24; N,7.43; Found: C, 72.31; H, 6.37; N, 7.22.

EXAMPLE 63

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(quinolin-5"-yl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 57, using 0.060 g (0.15 mmol) of thesubtitled compound of Preparation 25E, 42 μL(0.38 mmol) ofN-methylmorpholine, and 0.074 g (0.38 mmol) of the titled compound ofPreparation 31 in 2 mL of tetrahydrofuran to provide 0.045 g of thewhite solid.

Yield: 54%. ¹ H NMR (CDCl₃): δ 8.85 (m, 1H), 8.75 (m, 1H), 8.75 (d,J=8.21 Hz, 1H), 8.07 (m, 2H), 7.95 (s, 1H), 7.76 (m, 3H), 7.64 (m, 2H),7.54 (m, 2H), 7.44 (m, 2H), 7.38 (m, 3H), 7.25 (m, 1H), 4.88 (s, 2H),4.45 (m, 1H), 4.05 (m, 1H), 3.69 (dd, J=14, 3.09 Hz, 1H) 3.23 (m, 1H),3.05 (m, 2H), 1.32 (s, 9H). IR (KBr): 3485, 3429, 3279, 3061, 2964,1638, 1543, 1454, 1364, 1319, 1219, 1072, 806, 746 cm⁻¹. HR MS for C₃₅H₃₆ N₃ O₃ S (MH⁺): Calcd: 578.2477; Found: 578.2491. Analysis for C₃₅H₃₅ N₃ O₃ S.0.6H₂ O: Calcd: C, 71.42; H, 6.20; N, 7.14; S, 5.45; Found:C, 71.44; H, 6.16; N, 7.19; S, 5.41.

EXAMPLE 64

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(1",2",3",4"-tetrahydroquinolin-5"-yl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 58, using 0.023 g (0.36 mmol) of sodiumcyanoborohydride, 0.041 g (0.07 mmol) of the titled compound of Example63, and 2 mL of acetic acid to provide 0.024 g of a white amorphoussolid.

Yield: 60%. ¹ H NMR (CDCl₃): δ 7.88 (s, 1H), 7.75 (m, 3H), 7.42 (m, 6H),6.79 (t, J=7.73 Hz, 1H), 6.54 (d, J=7.28 Hz, 1H), 6.44 (d, J=8.15 Hz,2H), 6.10 (br. 1H), 5.91 (br.s, 1H), 4.45 (m, 1H), 4.05 (m, 1H), 3.48(m, 2H), 3.24 (t, J=5.50 Hz, 2H), 2.89 (m, 4H) 1.85 (m, 2H), 1.46 (s,9H). IR (KBr): 3450 , 2972, 4138, 1638, 1591, 1512, 1454 1309, 1119,1134, 1086, 814, 698, 621cm⁻¹. HR MS for C₃₅ H₄₀ N₃ O₃ S (MH⁺): Calcd:582.2790; Found: 582.2792.

EXAMPLE 65

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-Hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(indolin-4"-yl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 61, using 100 mg (0.23 mmol) of thesubtitled compound of Preparation 25E, 42 mg (0.26 mmol) of the titledcompound of Preparation 32, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol)of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL ofdimethylformamide. The crude residue was purified using flashchromatography (eluent of 1.5% methanol in methylene chloride) toprovide 12 mg of a white solid (m.p. 83°-84° C.).

Yield: 9%. ¹ H NMR (CDCl₃): δ 7.99 (s, 1H), 7.76 (m, 3H), 7.69-7.23 (m,10H), 7.10 (d, J=8.8 Hz, 1H), 6.60 (d, J=8.9 Hz, 1H), 5.99 (d, J6.2 Hz,1H), 5.89 (s, 1H), 4.53 (m, 1H), 4.11 (m, 1H), 3.44 (m, 6H), 3.01 (m,2H), 1.49 (s, 9H). Analysis for C₃₄ H₃₇ N₃ O₃ S: Calcd: C, 71.92; H,6.57; N, 7.40; Found: C, 72.21; H, 6.72; N, 7.26.

EXAMPLE 66

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-quinolin-4"-yl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure derailed in Example 61, using 100 mg (0.23 mmol) of thesubtitled compound of Preparation 25E, 45 mg (0.26 mmol) ofquinoline-4-carboxylic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL ofdimethylformamide. The crude residue was purified using flashchromatography (eluent of 1.5% methanol in methylene chloride) toprovide 42 mg of a white solid (m.p. 89°-92° C.).

Yield: 32%. ¹ H NMR (CDCl₃): δ 8.59 (s, 1H), 8.33 (d, J=7.9 Hz, 1H),8.09 (d, J=8.4 Hz, 1H), 7.93 (s, 1H), 7.80-7.71 (m, 4H), 7.69-7.25 (m,8H), 7.15 (s, 1H), 6.88 (d, J=8.4 Hz, 1H), 5.99 (s, 1H), 5.85 (s, 1H),4.63 (m, 1H), 4.21 (m, 1H), 3.51 (d, 6.2 Hz, 2H), 3.02 (m, 2H), 1.39 (s,9H). Analysis for C₃₅ H₃₅ N₃ O₃ S: Calcd: C, 72.76; H, 6.11; N, 7.27;Found: C, 72.91; H, 6.33; N, 7.36.

EXAMPLE 67

2'R-(2'R*,3'R*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-hiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-nitrophenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 61, using 100 mg (0.23 mmol) of thesubtitled compound of Preparation 25E, 47 mg (0.26 mmol) of2-methyl-3-nitrobenzoic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL ofdimethylformamide. The crude residue was purified using flashchromatography (eluent of 1% methanol in methylene chloride) to provide100 mg of a white solid (m.p. 80°-81° C.).

Yield: 74%. ¹ H NMR (CDCl₃): δ 7.89 (s, 1H), 7.75 (m, 3H), 7.65-7.25 (m,9H), 7.10 (d, J=7.9 Hz, 1H), 6.63 (d, J=8.9 Hz, 1H), 5.97 (d, J=6.0 Hz,1H), 5.87 (s, 1H), 4.53 (m, 1H), 4.11 (m, 1H), 3.44 (m, J=6.3 Hz, 2H),3.03 (dd, J=13.3, 10.2 Hz, 1H), 2.28 (dd, J=13.5, 2.8 Hz, 1H), 2.53 (s,3H), 1.47 (s, 9H). Analysis for C₃₃ H₃₅ N₃ O₅ S: Calcd: C, 67.67; H,6.02; N, 7.17; Found: C, 67.83; H, 5.93; N, 7.05.

EXAMPLE 68

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(3"-nitro-6"-methylphenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 61, using 100 mg (0.23 mmol) of thesubtitled compound of Preparation 25E, 47 mg (0.26 mmol) of2-methyl-5-nitrobenzoic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL ofdimethylformamide. The crude residue was purified using flashchromatography (eluent of 1% methanol in methylene chloride) to provide102 mg of a white solid (m.p. 85°-88° C.).

Yield: 75%. ¹ H NMR (CDCl₃): δ 8.17 (s, 1H), 8.07 (d, J=8.4 Hz, 1H),7.78 (m, 2H), 7.59-7.22 (m, 10H), 6.71 (d, J=8.9 Hz, 1H), 6.03 (d, J=6.1Hz, 1H), 5.9 (s, 1H), 4.52 (m, 1H), 4.13 (m, 1H), 3.45 (d, J=6.2 Hz,2H), 3.03 (dd, J=13.3, 9.61 Hz, 1H), 2.9 (dd, J=13.3, 3.72 Hz, 1H), 2.55(s, 3H), 1.43 (s, 9H). Analysis for C₃₃ H₃₅ N₃ O₅ S: Calcd: C, 67.67; H,6.02; N, 7.17; Found: C, 67.92; H, 6.22; N, 7.02.

EXAMPLE 69

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(1"-N(methyl)indol-4"-yl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 61, using 100 mg (0.23 mmol) of thesubtitled compound of Preparation 25E, 46 mg (0.26 mmol) of1-N-methyl-4-carboxylic acid indoline, 32 mg (0.23 mmol) of HOBT, 45 mg(0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mLof dimethylformamide. The crude residue was purified using flashchromatography (eluent of 1% methanol in methylene chloride) to provide42 mg of a white solid (m.p. 86°-89° C.).

Yield: 31%. ¹ H NMR (CDCl₃): δ 7.88 (s, 1H), 7.79-7.65 (m, 3H),7.53-6.95 (m, 13H), 6.22 (d, J=6.3 Hz, 1H), 5.99 (s, 1H), 4.67 (m, 1H),4.13 (m, 1H), 3.75 (s, 3H), 3.51 (m, 2H), 3.03 (m, 2H), 1.49 (s, 9H).Analysis for C₃₅ H₃₅ N₃ O₃ S: Calcd: C, 72.51; H, 6.43; N, 7.25; Found:C, 72.83; H, 6.51; N, 7.15.

EXAMPLE 70

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3",4"-dihydroxyphenyl)pentyl!benzamide

The titled compound was prepared substantially in accordance with theprocedure detailed in Example 61, using 100 mg (0.23 mmol) of thesubtitled compound of Preparation 25E, 44 mg (0.26 mmol) of thesubtitled compound of Preparation 33C, 32 mg (0.23 mmol) of HOBT, 45 mg(0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mLof dimethylformamide. The crude residue was purified using flashchromatography (eluent of 2.5% methanol in methylene chloride) toprovide 76 mg of a white solid (m.p. 121°-123° C.).

Yield: 58%. ¹ H NMR (CDCl₃): δ 7.89 (s, 1H), 7.75 (m, 2H), 7.55-7.22 (m,10H), 6.85 (t, J=7.9 Hz, 1H), 6.72 (m, 2H), 6.61 (d, J=5.7 Hz, 1H), 6.50(d, J=9.4 Hz, 1H), 6.13 (s, 1H), 5.92 (s, 1H), 4.51 (m, 1H), 4.09 (m,1H), 3.51 (m, 2H), 3.12 (dd, J=13.1, 10 Hz, 1H), 2.87 (dd, J=13.1, 3.1Hz, 1H), 2.13 (s, 3H), 1.46 (s, 9H). Analysis for C₃₃ H₃₆ N₂ O₅ S:Calcd: C, 69.21; H, 6.34; N, 4.89; Found: C, 69.43; H, 6.72; N, 4.72.

EXAMPLE 71

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-chloro-4"-aminophenyl)pentyl!benzamide

The desired title compound was prepared substantially in accordance withthe procedure detailed in Example 61, using 100 mg (0.23 mmol) of thesubtitled compound of Preparation 25E, 45 mg (0.26 mmol) of2-chloro-4-aminobenzoic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL ofdimethylformamide. The crude residue was purified using flashchromatography (eluent of 2% methanol in methylene chloride) to provide92 mg of a white solid (m.p. 102°-104° C.).

Yield: 69%. ¹ H NMR (CDCl₃): δ 7.88 (s, 1H), 7.77 (m, 2H), 7.61-7.23 (m,9H), 6.95 (t, J=7.7 Hz, 1H), 6.75 (m, 1H), 6.51 (d, J=7.8 Hz, 1H), 6.06(d, J=6.1 Hz, 1H). 5.90 (s, 1H), 4.51 (m, 1H), 4.20 (m, 2H), 4.12 (m,1H), 3.50 (m, 2H), 3.01 (m, 3H), 1.48 (s, 9H). Analysis for C₃₂ H₃₄ ClN₃O₃ S: Calcd: C, 66.71; H, 5.95; N, 7.29; Found: C, 66.92; H, 5.97; N,7.16.

EXAMPLE 72

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-5"-hydroxyphenyl)pentyl!benzamide

The desired titled compound was prepared substantially in accordancewith the procedure detailed in Example 61, using 100 mg (0.23 mmol) ofthe subtitled compound of Preparation 25E, 47 mg (0.26 mmol) of thesubtitled compound of Preparation 29B, 32 mg (0.23 mmol) of HOBT, 40 mg(0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mLof dimethylformamide. The crude residue was purified using flashchromatography (eluent of 3% methanol in methylene chloride) to provide86 mg of a white solid (m.p. 104°-106° C.).

Yield: 67%. ¹ H NMR (CDCl₃): δ 7.85 (s, 1H), 7.72 (m, 3H), 7.60-7.22 (m,9H), 6.92 (t, J=7.5 Hz, 1H), 6.72 (m, 1H), 6.50 (d, J=7.6 Hz, 1H), 5.96(s, 1H), 5.90 (s, 1H), 4.50 (m, 1H), 4.15 (m, 1H). 4.02 (m, 1H), 2.51(m, 2H), 3.01 (m, 3H), 2.36 (s, 3H), 1.45 (s, 9H). Analysis for C₃₃ H₃₇N₃ O₃ S: Calcd: C, 71.32; H, 6.71; N, 7.56; Found: C, 71.56; H, 5.76; N,7.52.

EXAMPLE 73

2'R-(2'R*,3'S*)!-N-t-Butyl-2-2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(3"-hydroxy-4"-aminophenyl)pentyl!benzamide

The desired titled compound was prepared substantially in accordancewith the procedure detailed in Example 61, using 100 mg (0.23 mmol) ofthe subtitled compound of Preparation 25E, 40 mg (0.26 mmol) of3-hydroxy-4-aminobenzoic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL ofdimethylformamide. The crude residue was purified using flashchromatography (eluent of 3% methanol in methylene chloride) to provide43 mg of a white solid (m.p. 119°-122° C.).

Yield: 34%. ¹ H NMR (CDCl₃): δ 7.91 (s, 1H), 7.75 (m, 2H), 7.60-7.20 (m,10H), 6.96 (t, J=77.9 Hz, 1H), 6.75 (m, 1H), 6.55 (d, J=7.8 Hz, 1H), 6.1(s, 1H), 5.95 (s, 1H), 4.51 (m, 1H), 4.23 (s, 2H), 4.12 (m, 1H). 3.52(m, 2H), 3.00 (m, 3H), 1.48 (s, 9H). Analysis for C₃₂ H₃₅ N₃ O₄ S:Calcd: C, 68.92; H, 6.33; N, 7.53; Found: C, 69.12; H, 6.57; N, 7.32.

Reaction Scheme III shows the structures of compounds in Examples 74 Athrough L below. ##STR63##

EXAMPLE 74 Example A

N-(Benzyloxycarbonyl)-3-(2-thienyl)-D,L-alanine

Into a 500 ml flask was placed 3.0 g of 3-(2-Thienyl)-D,L-alanine(optically active material in the L-form is available 4from Aldrich orSIGMA and could be used to obtain an optically active product) in 75 mlH₂ O/60 ml dioxane, and 5.6 g K₂ CO₃ was added, followed by 2.85 ml ofcarbobenzyloxy chloride. The mixture was stirred rapidly for 1 hour. TLC(21/7/7/9, EtoAc/AcOH/CH₃ CN/H₂ O) showed that the starting material wasgone. A new higher Rf product was seen. The dioxane was concentrated offand the aqueous layer was washed with Et₂ O (75 ml). The aqueous layerwas mixed with CH₂ Cl₂ (150 ml) and acidified to pH=2.0 with 5N HCl. Thedesired N-(Benzyloxycarbonyl)-3-(2-thienyl)-D,L-alanine was extractedwith CH₂ Cl₂. The organic layer was separated and dried with Na₂ SO₄,filtered, and concentrated to give 5.05 g of desiredN-(Benzyloxycarbonyl)-3-(2-thienyl)-D,L-alanine (98% yield).

¹ H NMR (300 MHz, CDCl₃): δ 7.37 (m, 5H); 7.18 (d, J=4 Hz, 1H); 6.95 (m,1H); 6.83 (m, 1H); 5.35 (d, J=8 Hz, 1M); 5.15 (s, 2H); 4.7 (m, 1H); and3.4 (m, 2H).

Example B

N-(Benzyloxycarbonyl)-3-(2-thienyl)-L-alanine tert-butyl amide

Into a 500 ml flask was placed 8.06 g of the subtitled compound ofExample A, N-(Benzyloxycarbonyl)-3-(2-thienyl)-L-alanine, in 130 ml ofTHF. The compound was cooled to 0° C. N-Methylmorpholine (4.23 ml) wasadded, followed by isobutylchloroformate (4.04 ml) over two minutes. Themixture was stirred for 15-20 minutes, and 3.74 ml of t-butylamine wasadded. The bath was removed, and the mixture was stirred at roomtemperature for two hours. The mixture was concentrated on rotovap, andthe residue was taken up in ethyl acetate. The residue was washedsuccessively with H₂ O, HCl, and saturated NaHCO₃ solution. The organicswere separated and dried with Na₂ SO₄, filtered, and concentrated to anoil. The oil was dissolved in 100 ml hot hexane and cooled in arefrigerator overnight to give a solid. The hexane was decanted,followed by drying to yield a solid of 9.25 gN-(carbobenzyloxy)-3-(2-thienyl)-L-alanine-tert-butylamide (97% yield).

¹ H NMR (300 MHz, CDCl₃): δ 7.37 (s, 5H); 7.2 (d, J-4 Hz, 1H); 6.95 (dd,J=4 Hz, 8 Hz, 1H); 6.87 (d, J=4 Hz, 1H); 5.52 (m, 2H); 5.12 (s, 2H);4.27 (m, 1H); 3.27 (m, 2H), and 1.23 (s, 9H).

Example C

N-t-butyl-5-benzyloxycarbonyl-(4, 5, 6, 7)-tetrahydro-thieno 3,2-c!pyridine-6S-N-t-butyl carboxamide

Into a 50 ml flask was placed 500 mg of the subtitled compound ofExample B, N-(Benzyloxycarbonyl)-3-(2-thienyl)-L-alanine tert-butylamide, in 12 ml of 1,1,2 trichloroethane. 2 ml of TFA was added,followed by 2 ml dimethoxymethane. The mixture was heated to reflux,followed by TLC every five minutes. After 15 minutes, TLC showed thatthe starting material was gone. Mostly, the desired product wasobtained, removed from heat and poured into 30 ml of H₂ O containing 3.5g K₂ CO₃ and 40 ml CH₂ Cl₂. The desired product was transferred to aseparatory funnel, and the organics were separated and dried with Na₂SO₄, filtered, and concentrated to oil. The product was purified byflash chromatography through 25 g (SiO₂) with 3% EtOAc/CH₂ Cl₂. 357 mgof N-t-butyl-5-benzyloxycarbonyl-(4, 5, 6, 7) -tetrahydro-thieno3,2-c!pyridine-6S-N-t-butyl carboxamide (69% yield) was obtained.

A period of fifteen minutes from time of reflux to removal of heatingsource and immediate work-up are very important to avoid side reactions.

¹ H NMR (300 MHz, d₆ DMSO): δ 7.35 (m, 7H); 6.83 (m, 1H); 5.15 (m, 2H);4.98 (m, 1H); 4.35 (m, 2H); 3.10 (m, 2H); and 1.10 (s, 9H). MS: m/e 372(M⁺)

Example D

6S-(6R*, 3aS*, 7aR*)!-N-(Benzyloxycarbonyl)-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide

Into a high pressure hydrogenation vessel was placed the subtitledcompound of Example C, N-t-butyl-5-benzyloxycarbonyl-(3, 5, 6,7)-tetrahydro-thieno 3,2-c!pyridine-6S-N-t-butyl carboxamide, (10.5 g)and 105 g of 5% Pd on carbon in 1100 ml of THF and 525 ml of ETOH. Themixture was placed under H₂ (3000 psi) at 80° C. for 24 hours. Thereaction mixture was cooled and the catalyst was filtered and washedwith 20% MeOH/CHCl₃. The organic filtrate was combined and concentratedto a crude oil. The oil was taken up in CH₂ Cl₂ and flashchromatographed on 250 g of (SiO₂) eluted with 2% MeOH/CH₂ Cl₂. Thedesired cis isomer (major) came through contaminated with a small amountof a minor isomer. This mixture was recrystallized by dissolving in 1.5ml of MeOH, adding 20 ml of Et ₂ O, followed by adding 120 ml of hexane,and the mixture was placed in a refrigerator overnight. The crystalsobtained were filtered, washed with cold hexane and dried under vacuumto give 2.54 g of the cis isomer 6S-(6R*, 3aS*,7aR*)!-N-(benzyloxycarbonyl)octahydrothieno 3,2-c!pyridine-6-N-t-butylcarboxamide (24% yield).

₁ H NMR (300 MHz, CDCl₃): δ 7.37 (s, 5H); 6.0 and 5.5 (br.s, 1H); 5.18(br.s, 2H); 4.22 (m, 2H); 3.40 (m, 1H); 2.87 (m, 3H); 2.48 (m, 1H); 2.15(m, 2H); 1.70 (m, 1H); and 1.15 (br.s, 9H). MS: m/e 377 (M⁺ +1).

Example E

6S-(6R*, 3aS*, 7aR*)!-Octahydrothieno 3,2-c!pyridine-6-N-t-butylcarboxamide

Into a 100 ml flask was placed 2.41 g of the subtitled compound ofExample D, 6S-(6R*, 3aS*, 7aR*) !-N-(Benzyloxycarbonyl)-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide, in 12 ml of 1:1 CH₃ CN/CH₂ Cl₂.The first portion of trimethylsilyl iodide (TMSI) (1.9 ml) was added andstirred for 10 minutes. A second portion of TMSI (0.94 ml) was added andstirred for 10 minutes. A third portion of TMSI (0.48 ml) was added andstirred for 30 minutes. The TLC (5% EtOAc/CH₂ Cl₂) showed that thestarting material was gone. The reaction mixture was diluted with 30 mlof diethylether and 40 ml of H₂ O and 6 ml of 1N HCl. The ether layerwas separated and washed with 15 ml of 0.1N HCl. The combined etherlayers were discarded, and aqueous washes were combined. SaturatedNaHCO₃ was added to adjust the pH of the aqueous layer to 8. The aqueouslayer was extracted twice with 200 ml CH₂ Cl₂, and the organic layerswere combined and dried over Na₂ SO₄. The solution was filtered andconcentrated to give 1.3 g (84% yield) of desired 6S-(6R*, 3aS*,7aR*)!-octahydrothieno 3,2-c!pyridine-6-N-t-butyl carboxamide.

¹ NMR (300 MHz, CDCl₃): δ 6.43 (s, 1H) ; 3.22 (m, 2H) 2.95 (m, 4H); 2.17(m, 3H); 2.0 (m, 1H); 1.55 (m, 2H); and 1.32 (s, 9H). α!_(D)(EtOH)=-179.1° (at 25° C.).

Example F

6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)!-5-2-Hydroxy-4-phenylthio-3-(benzoxycarbonyl)-aminobutyl!-octahydrothieno3,2-c)pyridine-6-N-t-butyl carboxamide

Into a 100 ml flask was placed 1.45 g of 1'R-(1'R*,1S*)!-1-1'-N-(Benzyloxycarbonyl)amino-2'-(phenylthio)ethyl) oxirane (obtainedfollowing Preparation 8E ( 1'R-(1'R*,1S*)!-1-1'-N-(Benzyloxycarbonyl)amino-2'-(phenylthio)ethyl! oxirane may also beobtained as set forth in Example M below)) and 1.07 g of the subtitledcompound of Example 74 E, !6S-(6R*, 3aS*, 7aR*)!-Octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide, in 30 ml of EtOH, and themixture was heated to 65° C. for 60 hours. The reaction mixture wasconcentrated to a foam and purified on chromatotron (4000 micron plate),eluted with 1% MeOH/CH₂ Cl₂. The desired fractions were concentrated togive 1.8 g of desired 6S-(6R*, 3aS*, 7aR*, 2'S*,3'S*)!-5-(2-Hydroxy-4-phenylthio-3-(benzoxycarbonyl)-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide. Some mixed fractions at thebeginning were combined to give 326 mg of a mixture, which was againsubmitted to the same chromatographic conditions on a 2000 micron plate.An additional 228 mg of desired 6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)) -5-2-Hydroxy-4-phenylthio-3-(benzoxycarbonyl)-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide was obtained. The total yield of6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*) !-5-2-Hydroxy-4-phenylthio-3-(benzoxycarbonyl)-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide obtained was (80.5% yield).

¹ H NMR (300 MHz, CDCl₃): δ 7.30 (m, 10H); 5.80 (m, 2H); 5.08 (AB, 2H);3.95 (m, 2H); 3.42 (m, 2H); 3.17 (m, 3H); 2.90 (m, 2H); 2.67 (m, 1H);2.58 (m, 1H); 2.48 (m, 1H); 2.35 (m, 2H); 1.98 (m, 4H); and 1.30 (s,9H).

Example G

6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)!-5-2-Hydroxy-4-phenylthio-3-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide

Into a 100 ml flask was placed 1.8 g of the subtitled compound ofExample F, 6S-(6R*, 3aS*, 7aR*, 2'S*,3'S*)!-5-!2-Hydroxy-4-phenylthio-3-(benzoxycarbonyl)-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide, in 10 ml each of CH₂ cl₂ and CH₃CN. A first portion of TMSI (1.14 ml) was added and stirred for 10minutes. A second portion of TMSI (0.72 ml) was added and stirred for 10minutes. A third portion of TMSI (0.24 ml) was added and stirred for 15minutes. The reaction mixture was diluted with 40 ml of Et₂ O and pouredinto 30 ml of 0.1N HCl and 60 ml of Et₂ O. The Et₂ O layer was separatedand the organics were discarded. The aqueous layer was made basic withsaturated NaHCO₃ solution and extracted with CH₂ Cl₂ (2×100 ml). Theorganics were separated, dried with Na₂ SO₄, filtered, and concentratedto afford 1.18 g of 6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)!-5-2-Hydroxy-4-phenylthio-3-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide (86% yield) as a white solid.

¹ H NMR (300 MHz, CDCl₃): δ 7.38 (m, 2H) ; 7.28 (m, 2H) 7.20 (m, 1H);6.23 (s, 2H); 3.65 (s, 1H); 3.28 (m, 3H); 2.90 (m, 4H); 2.70 (m, 2H);2.58 (m, 1H); 2.43 (m, 1H); 2.34 (m, 1H); 2.05 (m, 4H); 1.80 (m, 3H);and 1.32 (s, 9H). IR (CHCl₃): 3430; 3005; 2973; 1670; 1514; 1456; 1366;and 1090 cm⁻¹. MS: m/e 437 (M⁺).

Example H

!6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)!-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydrothieno3,2-c! pyridine-6-N-t-butyl carboxamide

Into a 25 ml flask was placed 40 mg of the subtitled compound of ExampleG, 6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)!-5-2-Hydroxy-4-phenylthio-3-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide, 14 mg of 3-hydroxy-2-methylbenzoic acid, and 12.6 mg of HOBT in 2 ml of THF, and the reactionmixture was cooled to -10° C. DCC (18.7 mg) was added, and the mixturewas warmed co room temperature and stirred for 85 hours. The reactionmixture was diluted with 2 ml of Et₂ O and filtered through a cottonplug, the filtrate was concentrated, and the residue was eluted onchromatotron (2000 micron plate) with 3% MeOH/CHCl₃. The desiredfractions were concentrated to give 44 mg of 6S-(6R*, 3aS*, 7aR*, 2'S*,3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide (85% yield).

Example I

(6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydrothieno 3,2-c!pyridine-6-N-t-butylcarboxamide methanesulfonic acid salt

Into a 50 ml flask was placed 330 mg of the subtitled compound ofExample H, 6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide, in CH₂ Cl₂ /CH₃ CN (4 ml/2 ml),and 37.5 ml of MeSo₃ H was added via a microliter-syringe. The mixturebecame cloudy. The reaction mixture was diluted with 1 ml of CH₂ Cl₂,and Et₂ O and hexane were added and concentrated. The residue wassonicated with hexane and concentrated two times to obtain 385 mg ofdesired 6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide methanesulfonic acid salt (100%yield).

Example J

(6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)!-5-2-Hydroxy-4-phenyl-3-(benzoxycarbonyl)-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide

Into a 50 ml flask was placed 145 mg of 1'S-(1'R*,1R*)!-1-1'-N-(Benzyloxycarbonyl)amino-2'-(phenyl)ethyl! oxirane (obtainable asin Reaction Scheme A (steps 1 through 5) below, and 118 mg of thesubtitled compound of Example E, 6S-(6R*, 3aS*, 7aR*)!-Octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide, as a mixture of enantiomers in 3ml of EtOH. The mixture was heated to 65° C. and was maintained at thistemperature for 20 hours. The reaction mixture was concentrated, and thecrude residue was purified by chromatotron on a 2000 micron plate,eluted with 1% MeOH/CHCl₃ to afford 98 mg of 6S-(6R*, 3aS*, 7aR*, 2'S*,3'R*)!-5-2-Hydroxy-4-phenyl-3(benzoxycarbonyl)-aminobutyl!-octahydrothieno 3,2-cpyridine-6-N-t-butyl carboxamide (37% yield) and 109 mg of adiastereomer of 6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)!5-2-Hydroxy-4-phenyl-3-(benzoxycarbonyl)-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide.

If substantially enantiomerically pure (6S-(6R*, 3aS*,7aR*)!-Octahydrothieno 3,2-c!pyridine-6-N-t-butyl carboxamide is usedinstead of 6S-(6R*, 3aS*, 7aR*)!-Octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide as a mixture of enantiomers, ahigher yield of 6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)!-5-2-Hydroxy-4-phenyl-3-(benzoxycarbonyl)-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide should result. (See, e.g.,Example F above.)

Example K

6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)!-5-2-Hydroxy-4-phenyl-3-aminobutyl!-octahydrothieno 3,2-c!pyridine-6-N-t-butyl carboxamide

Into a 25 ml flask was placed 85 mg of the subtitled compound of ExampleJ, 6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)!-5-2-Hydroxy-4-phenyl-3-(benzoxycarbonyl)-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide, in CH₃ CN/CH₂ Cl₂. TMSI wasadded in portions of 56 microliters, 34 microliters and 11 microliters,respectively, every ten minutes and stirred for 1 1/2 hours. The mixturewas diluted with Et₂ O (5 ml) and poured into 15 ml of 1N HCl and Et ₂ O(20 ml). The organics were separated and discarded. The aqueous layerwas treated with 30 ml of saturated NaHCO₃ solution and extracted withCH₂ CL₂ (2×50 ml). The organics were dried with Na₂ SO₄, filtered, andconcentrated to an oil that crystallized to give 64 mg 6S-(6R*, 3aS*,7aR*, 2'S*, 3'R*)!-5- 2-Hydroxy-4-phenyl-3-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide (100% yield).

¹ H NMR (300 MHz, CDCl₃): δ 7.28 (m, 5H) ; 6.38 (s, 1H) 3.75 (m, 1H) ;3.32 (m, 2H); 3.12 (m, 1H); 2.93 (m, 2H); 2.78 (m, 2H); 2.58 (m, 3H);2.38 (m, 1H); 2.12 (m, 5H); 1.83 (m, 2H); and 1.35 (s, 9H).

Example L

6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydrothieno(3,2-c!pyridine-6-N-t-butylcarboxamide

Into a 25 ml flask was placed 64 mg of the subtitled compound of ExampleK, 6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)!-5-2-Hydroxy-4-phenyl-3-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide, 24 mg of 3-hydroxy-2-methylbenzoic acid (obtained by the method disclosed in Preparation 23C), and22 mg of HOBT.H₂ O in 2 ml of THF, and the mixture was cooled to -10° C.DCC (32 mg) was added, and the mixture was warmed to room temperatureand stirred for 60 hours. The reaction mixture was diluted with 2 ml ofEt₂ O, filtered through a cotton plug, and the filtrate wasconcentrated, and the residue was eluted on chromatotron (2000 micronplate) with 1.5% MeOH/CHCl₃ to 4% MeOH/CHCl₃ gradient. The desiredfractions were concentrated to give 72 mg of 6S-(6R*, 3aS*, 7aR*, 2'S*,3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide (85% yield).

EXAMPLE 75

3S-(3R*, 4aR*, 8aR*, 2'S*, 3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide methanesulfonic acid salt This compound was prepared as inExample 23, with the exception that Preparation Steps 8A and 8D werechanged as set forth in step (1) below, and the salt formation step (2)below was added.

(1) To a 2 L flask was added Ph₃ P (109.6 g) in 500 ml of CH₂ Cl₂, andthe mixture was cooled to -70° C. To the mixture was added a solution ofdiethylazidodicarboxylate (66 ml) in 60 ml of THF dropwise over 25minutes. After 25 minutes, a solution of N-carbobenzyloxy-L-serine (100g) in 400 ml of THF was added dropwise over 45 minutes and allowed towarm to room temperature in a water bath over two hours. 150 ml of THFwas added to the mixture. In another flask, a solution of thiophenol (46g) in 1 L of THF was cooled in an ice bath to 0° C. and treatedportionwise with an NaH dispersion (10 g) to give a thick solution.After one hour, the crude lactone solution was added to the thiolatesolution dropwise via an addition funnel over 30 minutes. After 12hours, a white precipitate was filtered off, and the filter cake washedwith THE. The solid was taken up in 0.4N NaHSO₄ and EtOAc, separated,and the organic layer was washed with brine, dried, and evaporated toafford 85 g of 2-2-N-(benzyloxycarbonyl)amino-3-phenylthio propanoicacid as a viscous oil.

The original solid is believed to be the sodium salt of the desiredproduct. Thus, the yield and ease of isolation may be improved byisolation of the sodium salt directly.

The crude chloroketone3R-1-Chloro-2-oxo-3-N-(benzyloxycarbonyl)amino-4-phenylthio butane(16.87 g, 46.4 mmol) was added to 1 L absolute EtOH and 200 mL THF, andthe solution was cooled in a CO₂ -acetone bath (-78° T_(int)), and NaBH₄(2.63 g, 69.5 mmol) in 200 ml absolute EtOH was added dropwise over 1 h(T_(int) <-75° C.). TLC analysis after the addition showed that thereaction was complete. The reaction was diluted with 300 mL ether andwas quenched by the slow addition of 0.4N NaHSO₃ with stirring, whichproduced the evolution of gas. This mixture was concentrated underreduced pressure to remove most of the EtOH and additional water wasadded. The mixture was extracted with ether, and the combined organiclayers were washed with saturated aqueous NaHCO₃ and brine, dried (Na₂SO₄), and concentrated to afford 15.7 g of an off white solid. Thismaterial was triturated with boiling hexane (300 mL), and the hexane wascarefully decanted while hot. This was repeated 10 times (300 mL each)to provide 10.35 g of an off white solid (one pure isomer by TLC). Thehexane filtrate was concentrated to give 6 g of white solid which wasset aside. The triturated solid was heated with 50 mL CH₂ Cl₂ and about6 mL hexane and filtered hot. The clear solution was allowed to cool to25° C. and was then placed in the freezer. The resulting solid wasfiltered and washed with hexanes to give 7.157 g of a white solid. Thefiltrate was combined with the hexane filtrated from above and withcrude reaction product from two small scale experiments (500 mg startingketone each), and the combined material was chromatographed on SiO₂ (2:1hexanes-ether→1:1 hexanes-ether, loaded with CH₂ Cl₂) to afford 2.62 gof additional product. A total of 10.31 g pure isomer of 2S-(2R*,3S*)!-1-chloro-2-hydroxy-3-N-(benzyloxycarbonyl)amino-4-phenylthiobutane (50% yield from acid) was obtained. alpha_(D) =-63.6° (c=1, MeOH)

(2) Salt formation (3S-(3R*,4aR*,8aR*,2'S*,3'S*)1-2-2'Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide (3.34 g) was dissolved in30 ml of MeOH and 30 ml of CH₂ Cl₂, and a solution of methanesulfonicacid (596 mg) in 10 ml of CH₂ Cl₂ was added dropwise. After 10 minutes ,the reaction mixture was concentrated to foam. The crude salt was takenup in 5 ml of THF and added slowly to a mixture of 175 ml of ethyl etherand 25 ml of hexanes with stirring until a fine suspension resulted.This was cooled in a freezer, filtered cold and washed several timeswith ethyl ether, followed by drying in a vacuum oven to afford 3.75 g(96%) of 3S-(3R*, 4aR*, 8aR*, 2'S*, 3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide methanesulfonic acid salt as a white powder.

EXAMPLE 76

3-(Bisbenzoxyphosphinyl)oxy-2-methyl Benzoic Acid ##STR64##

To a cooled (0° C.), stirred solution of 706 mg (4.67 mmol) of3-hydroxy-2-methylbenzoic Acid in 30 mL of pyridine was added dropwise10.3 mL (10.21 mmol) of a 1.0M solution of lithium hexamethyldisilazideover 5 minutes. After stirring for 5 minutes, 3.0 g (5.57 mmol) oftetrabenzylpyrophosphate was added in one portion, and the reactionmixture was warmed to room temperature over 30 minutes. The reactionmixture was concentrated, and the residue was partitioned between 2.5NHCL (200 mL) and a 50/50 mixture of ethyl acetate/hexane (200 mL). Thelayers were separated, and the aqueous layer was extracted twice with a50/50 solution of ethyl acetate/hexane. The organic layers werecombined, washed with brine and dried over sodium sulfate. Purificationof the crude product by flash chromatography (gradient eluent of 50-70%ethyl acetate/hexane/ 2% Acetic acid) gave 910 mg of a light yellow oil,which is 3-(bisbenzoxyphosphinyl)oxy-2-methyl benzoic acid.

Yield: 47% ¹ H NMR (CDCl₃): d 2.49 (s, 3H), 5.14 (d, J=8.60 Hz, 4H),7.10-7.40 (m, 11H), 7.48 (d, J=8.09 Hz, 1H), 7.81 (d, J=7.80 Hz, 1H). IR(CHCl3): 3700-2350 (br), 1700, 1457, 1382, 1273, 1240, 1179, 1082, 1034,1023, 1001, 966, 881, 851 cm⁻¹. MS (FD): m/e 413 (M⁺, 100).

EXAMPLE 77

3S-(3R*, 4aR*, 8aR*,2'S*,3'R*)!-2-(2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxa-5'-(2"-methyl-3"-(bisbenzoxyphosphinyl)oxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butylcarboxamide ##STR65##

To a cooled (-10° C.) solution of 95 mg (0.23 mmol) of the subtitledcompound of Example 76, 3-(Bisbenzoxyphosphinyl)oxy-2-methyl benzoicacid, 92 mg (0.23 mmol) of 3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)!-2-3'-Amino-2'-hydroxy-4'-phenyl!butyl decahydroisoquinoline-3-N-t-butylcarboxamide and 31 mg (0.23 mmol) of HOBt in 5 mL of anhydrous THF, wasadded 48 mg (0.23 mmol) of DCC in one portion. After stirring for 3 daysat room temperature, the reaction mixture was diluted with ethyl acetateand filtered through a plug of cotton. The resulting filtrate wasextracted twice with saturated sodium carbonate, washed with brine, anddried over sodium sulfate. Purification of the crude product by radialchromatography (2 mm plate; gradient eluent of 2.5-5% methanol/methylenechloride) gave 100 mg of a white foam, which is 3S-(3R*, 4aR*, 8aR*,2'S*, 3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-(Bisbenzoxyphosphinyl)oxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide.

Yield: 52% ¹ H NMR (CDCl₃): d 1.13 (s, 9H), 1.14-2.10 (m, 15H)5,2.23-2.36 (m, 2H), 2.50-2.70 (m, 2H), 2.92-3.05 (m, 2H), 3.39-3.50 (m,1H), 3.80-4.10 (m, 2H), 4.52-4.62 (m, 1H), 5.03-5.13 (m, 4H), 5.65 (s,1H), 6.62 (d, J=8.51 Hz, 1H), 6.83 (d, J=7.60 Hz, 1H), 7.02 (t, J=8.10Hz, 1H). IR (CHCl3): 3690, 3600-3100 (br), 3009, 2929, 2866, 1672, 1603,1513, 1456, 1368, 1277, 1239, 1182, 1037, 1023, 1001, 967, 880 cm⁻¹. MS(FD): m/e 796 (M⁺, 100). Analysis for C₄₆ H₅₈ N₃ O₇ P₁ : Calcd: C,69.41; H, 7.34; N, 5.28. Found: C, 69.57; H, 7.33; N, 5.20.

EXAMPLE 78

3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxa-5'-(2"-methyl-3"-Hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butyl carboxamide 3"-dihydrogen phosphate##STR66##

A mixture of 86 mg (0.108 mmol) of the subtitled compounds of Example77, 3S-(3R*, 4aR*, 8aR*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-(bisbenzoxyphosphinyl)oxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide, and 23 mg of 10% Palladium on carbon in 16 mL of methanolwas stirred under one atmosphere of hydrogen for 1 hour. The reactionmixture was filtered through celite and concentrated to give 61 mg of awhite solid, which is 3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3",-hydroxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide 3"-dihydrogen phosphate.

Yield: 96% ¹ NMR (Methanol-d₄): d 1.32 (s, 9H), 1.33-2.21 (m, 14H),2.60-2.75 (m, 1H), 3.18-3.49 (m, 5H), 3.56-3.70 (m, 1H), 3.95-4.35 (m,3H) , 5.47 (s, 1H), 6.71 (d, J=7.26 Hz, 1H), 7.02 (t, J=8.24 Hz, 1H),7.15-7.35 (m, 5H), 7.40 (d, J=8.18 Hz, 1H). IR (KBr): 3800-2400 (br),1673, 1545, 1456, 1395, 1368, 1222, 1185, 1077, 942, 857, 792 cm⁻¹. MS(FAB): m/e 616.3 (M⁺, 100).

EXAMPLE 79

3S-(3R*, 4aR*, 8aR*, 2'S*, 3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxa-5'-(2"-methyl-3"-(bisbenzoxyphosphinyl)oxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butyl carboxamide ##STR67##

To a cooled (0° C.), stirred solution of 478 mg (1.16 mmol) of thesubtitled compound of Example 76, 3-(bisbenzoxyphosphinyl)oxy-2-methylbenzoic acid, 500 mg (1.16 mmol) of (3S-(3R*, 4aR*, 8aR*, 2'S*,3'S*)!-2- 3'-amino-2'-hydroxy-4'(phenyl)thio!butyldecahydroisoquinoline-3-N-t-butyl carboxamide, 352 mg (3.48 mmol) oftriethyl amine, and 166 mg (1.23 mmol) of HOBt in 8 mL of anhydrous THFwas added 254 mg (1.23 mmol) of DCC in one portion. After stirringovernight at room temperature, the reaction mixture was concentrated,the residue was taken up in ethyl acetate and filtered through a plug ofcotton. The resulting filtrate was extracted twice with saturated sodiumcarbonate, washed with brine, and dried over sodium sulfate.Purification of the crude product by radial chromatography (6 mm plate;gradient eluent of 30% ethyl acetate/hexane) gave 644 mg of a whitefoam, which is 3S-(3R*, 4aR*, 8aR*, 2'S*, 3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-(Bisbenzoxyphosphinyl)oxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butyl carboxamide.

Yield: 67%¹ H NMR (CDCl₃): 2.89-3.00 (m, 1H), 3.39-3.50 (m, 1H), 3.67(s, 1H), 3.75-3.85 (m, 1H), 4.03-4.15 (m, 1H) , 4.43-4.58 (m, 1H),5.00-5.20 (m, 4H), 5.47 (s, 1H), 7.10-7.55 (m, 19H). IR (CHCl₃):3600-3150 (br), 3010, 2975, 2929, 2867, 1670, 1517, 1457, 1440, 1368,1277, 1239, 1082, 1035, 1025, 1001, 968, 879 cm⁻¹. MS (FAB): 828.4 (M⁺,100). Analysis for C₄₆ H₅₈ N₃ O₇ S₁ P₁ : Calcd: C, 66.73; H, 7.06; N,5.07; S, 3.87. Found: C, 66.56; H, 7.29; N, 4.82; S, 3.62.

EXAMPLE 80

3S-(3R*, 4aR*, 8aR*, 2'S*, 3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxa-5'-2"-methyl-3'-Hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butyl carboxamide 3"-Dihydrogen PhosphateHydrochloride ##STR68##

A mixture of 505 mg (0.61 mmol) of the subtitled compound of Example 79,3S-(3R*, 4aR*, 8aR*, 2'S*,3'S*)!2-!2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3-(Bisbenzoxyphosphinyl)oxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide, and 500 mg of 10% Palladium on carbon in 20 mL of methanolwas stirred under one atmosphere of hydrogen for 24 hours. The reactionmixture was filtered through celite and concentrated to give 380 mg ofthe crude product which was purified by HPLC (Waters Nova Pack C18 RCMColumn (40×10 cm); Flow rate of 40 mL/minute; Eluent of 45% (1% HCl)water, 15% acetonitrile, 40% methanol), to give 230 mg of a white foam,which is 3S-(3R*, 4aR*, 8aR*, 2'S*, 3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-hydroxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide 3'-dihydrogen phosphate.

Yield: 58% ¹ H NMR (Methanol-d₄) d 1.10-2.30 (m, 25H), 2.39 (s, 3H),2.95-3.65 (m, 4H), 3.90-4.25 (m, 3H), 7.15-7.50 (m, 8H), 7.99 (s, 1H).IR (KBr): 3700-2100 (br), 1674, 1547, 1458, 1440, 1395, 1368, 1241,1182, 1074, 1025, 966, 867 cm⁻¹. MS (FAB): m/e 648.3 (M⁺ +1, 100).Analysis for C₃₂ H₄₁ N₃ O₉ S₁ Cl₁ P₁ : Calcd: C, 53.37; H, 7.14; N,5.83. Found: C, 53.44; H, 6.76; N, 5.84.

EXAMPLE 81

3-(Acetyl)hydroxy-2-methylbenzoic acid ##STR69##

To a heterogeneous solution of 3.06 g (30 mmol) of acetic anhydride and1.53 g (10 mmol) of 3-hydroxy-2-methylbenzoic acid was added one drop ofconcentrated sulfuric acid. The mixture was heated with a heat gun for 2min. and then poured into 14 mL of cold water. The resulting precipitatewas collected by vacuum filtration, washed twice with water and driedovernight in a vacuum oven. Recrystallization from 20% ethylacetate/hexane (7 mL) gave 595 mg of a white solid, which is3-(Acetyl)hydroxy-2-methyl benzoic acid.

Yield: 31% IR (CHCl3): 3700-2300 (br), 1765, 1698, 1460, 1404, 1372,1299, 1273, 1172, 1081, 1041, 1012, 933, 913, 865, 823 cm ⁻¹ . MS (FD):m/e 194 (M⁺, 100).

EXAMPLE 82

3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxa-5'-(2"-methyl-3"-(acetyl)hydroxyphenyl)pentyl!decahydroisoquinoline-3-N-t-butyl carboxamide ##STR70##

To a cooled (-10° C.) stirred solution of 34 mg (0.174 mmol) of thesubtitled compound of Example 81, 3-(Acetyl)hydroxy-2-methyl benzoicacid, 70 mg (0.174 mmol) of 3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)!-2-3'-Amino-2'-hydroxy-4'-phenyl!butyl decahydroisoquinoline-3-N-t-butylcarboxamide and 24 mg (0.174 mmol) of HOBt in 3 mL of anhydrous THF wasadded 36 mg (0.174 mmol) of DCC in one portion. After stirring for 2days at room temperature, the reaction mixture was diluted with ethylacetate and filtered through a plug of cotton. The resulting filtratewas extracted once with saturated sodium carbonate, once with brine, anddried over sodium sulfate. Purification of the crude product by radialchromatography (1 mm plate; gradient eluent of 0%-5% methanol/methylenechloride) gave 65 mg of a white foam, which is 3S-(3R*, 4aR*, 8aR*,2'S*, 3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-(acetyl)hydroxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butyl carboxamide.

Yield: 65% ¹ H NMR (CDCl₃): d 1.15 (s, 9H) , 1.16-2.37 (m, 21H) ,2.50-2.70 (m, 2H), 2.93-3.05 (m, 2H), 3.39-3.50 (m, 1H), 3.99-4.10 (m,1H), 4.53-4.64 (m, 1H) , 3.99-4.10 (m, 1H) , 4.53-4.64 (m, 1H) , 5.69(s, 1H) , 6.64 (d, J=8.45 Hz, 1H) , 6.91 (d, J=7.47 Hz, 1H) , 7.00 (d,J=7.57 Hz, 1H) , 7.11 (t, J=7.75 Hz, 1H) , 7.19-7.40 (m, 5H).

IR (CHCl₃): 3700-3100 (br), 3008, 2929, 2865, 1762, 1671, 1604, 1514,1455, 1394, 1368, 1303, 1277, 1175, 1121, 1082, 1047, 910 cm⁻¹.

MS (FD): m/e 578 (M⁺, 100).

EXAMPLE 83 ##STR71##

To a cold (0° C.) solution of 35 mg (0.061 mmol) of the subtitledcompound of Example 82, 3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-(acetyl)hydroxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide in 2 mL of anhydrous methylene chloride, was added dropwise128 microliters (0.064 mmol) of a 0.5M solution of methanesulfonic acidin methylene chloride. The resulting reaction was reduced to drynessunder reduced pressure (0.2-0.1 Torr) to provide 40.5 mg (crude) of alight yellow foam, which is 3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2"-methyl-3"-(acetyl)hydroxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide methanesulfonic acid salt.

Yield: 98%

EXAMPLE 84 ##STR72##

N-Boc-4-thio-L-proline (available from Sigma) (1.5 g) was dissolved in 3ml of methanol and cooled to 0° C. in an ice bath. In a separate flask,5.8 g of "OXONE" was dissolved in 5 ml of H₂ O and added dropwise to thereaction mixture. After 30 minutes, the reaction mixture was allowed towarm to room temperature and stirred overnight, followed by dilutionwith CHCl₃ /H₂ O, separation, and extraction with CHCl₃ (3×100 ml). Theorganic layers were combined, dried over Na₂ SO₄, and concentrated invacuo to afford the compound of the formula shown above (700 mg, 41%yield) as a white solid.

EXAMPLE 85 ##STR73##

The compound of the formula shown in Example 84 and 3S-(3R*, 4aR*, 8aR*,2'S*, 3'S*)!-2- 3'-amino-2'-hydroxy-4'(phenyl)thio!butyldecahydroisoquinoline-3-N-t-butyl carboxamide were coupled together by aprocedure similar to that shown in Example 79 above. The crude materialwas purified by flash chromatography (3% MeOH/CH₂ Cl₂) to afford 40 mg(51% yield) of a compound of the formula shown above.

EXAMPLE 86 ##STR74##

The compound of the formula shown in Example 85 (20 mg) was dissolved in1 ml of CH₂ Cl₂ and treated with 1 ml of trifluoroacetic acid. After 30minutes at room temperature, the reaction product was concentrated invacuo to give the compound of the formula shown above, which is 3S-(3R*,4aR*, 8aR*, 2'S*, 3'S*, 4"S)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(thiazolino-4"-yl-1",1"-dioxide)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide.

Pandex IC₅₀ =244 ng/ml

EXAMPLE 87 ##STR75##

3-Carboxylic acid thiophene (available from Aldrich) and 3S-(3R*, 4aR*,8aR*, 2'S*, 3'R*)!-2- 3'-Amino-2'-hydroxy-4'-phenyl!butyldecahydroisoquinoline-3-N-t-butyl carboxamide were coupled together by aprocedure similar to Example 77 above. The crude material was purifiedby flash chromatography (2% MeOH/CH₂ Cl₂) to afford 70 mg (63% yield) ofthe compound of the formula shown above, which is 3S-(3R*, 4aR*, 8aR*,2'S*, 3'R*)!-2- 2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(thieno-3"-yl)pentyl!-decahydroisoquinoline-3-N-t-butyl carboxamide.

Pandex IC₅₀ =25% at 1,000 ng/ml

EXAMPLE 88 ##STR76##

3-Carboxylic acid tetrahydrothiophene-1,1-dioxide and 3S-(3R*, 4aR*,8aR*, 2'S*, 3'R*)!-2- 3'-Amino-2'-hydroxy-4'-phenyl!butyldecahydroisoquinoline-3-N-t-butyl carboxamide were coupled together by aprocedure similar to that described in Example 77 above. The crudematerial was purified by flash chromatography (3% MeOH/CH₂ Cl₂) toafford 50 mg (42% yield) of the compound of the formula shown above,3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)!-2-2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(tetrahydrothieno-3"-yl-1",1"-dioxide)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide, as a mixture of diastereoisomers.

Pandex IC₅₀ =28% at 20 ng/ml.

EXAMPLE 89 ##STR77##

3-Carboxylic acid tetrahydrothiophene-1,1-dioxide and 6S-(6R*, 3aS*,7aR*, 2'S*, 3'R*)!-5-2-Hydroxy-4-phenyl-3-(benzoxycarbonyl)-aminobutyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide were coupled together by aprocedure similar to that of Example 74 H above. The crude material waspurified by flash chromatography (3-4% MeOH/CH₂ Cl₂) to afford 30 mg(57% yield) of 6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)!-2-2-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(tetrahydrothieno-3''-yl-1'',1''-dioxide)pentyl!-octahydrothieno 3,2-c!pyridine-6-N-t-butylcarboxamide, as a mixture of diastereoisomers.

CEM IC₉₅ =98 nM

Pandex IC₅₀ =0.5 ng/ml (0.9)

EXAMPLE 90 ##STR78##

3-Methyl-2-carboxylic acid thiophene and (3S-(3R*, 4aR*, 8aR*, 2'S*,3'S*)!-2- 3'-amino-2'-hydroxy-4'(phenyl)thio)butyldecahydroisoquinoline-3-N-t-butyl carboxamide were coupled together by aprocedure similar to that of Example 79 above, which afforded 39 mg (76%yield) of a compound of the above formula, which is 3S-(3R*, 4aR*, 8aR*,2'S*, 3'S*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(3''-methyl-thieno-2''-yl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide.

EXAMPLE 91 ##STR79##

6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)!-2- 2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl!-octahydrothieno3,2-c!pyridine-6-N-t-butyl carboxamide (30.5 mg) was dissolved in 2 mlof MeOH. In another flask, "OXONE" (51 mg) was dissolved in 1 ml ofwater and added to the first flask. After 6 hours of stirring, anotherportion of "OXONE" (17 mg) was added, and the reaction mixture wasstirred for 42 hours. The reaction mixture was diluted with CH₂ C₂ andwashed with water. The organic layer was dried with Na₂ SO₄, filteredand concentrated. The crude residue was purified by radialchromatography (1000 micron plate; 3-9; MeOH/CH₂ Cl₂) to afford 5 mg of6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)!-2-2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl!-octahydrothieno3,2-c!pyridine-1,1-dioxide-6-N-t-butyl carboxamide.

EXAMPLE 92 ##STR80##

The compound shown above, 3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)!-2-2'-Hydroxy-3'-(4'''-fluoro)phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide was prepared using analogous procedures as set forth inExample 23, with the exception that thiophenol was replaced by4-fluorothiophenol in Preparation 8A.

The resulting product is used in an analogous manner as the product ofPreparation 8A in the subsequent preparation protocol of Example 23.

EXAMPLE 93 ##STR81##

The compound shown above, 3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)!-2-2'-Hydroxy-3'-(4'''-fluoro)phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl!-decahydroisoquinoline-3-N-t-butylcarboxamide methanesulfonic acid salt was prepared by a method analogousto Example 75 (step 2) above.

As noted above, the compounds of the present invention are useful forinhibiting HIV protease, which is an enzyme associated with viralcomponent production and assembly. An embodiment of the presentinvention is a method of treating HIV infection comprising administeringto a host or patient, such as a primate, an effective amount of acompound of formula (1) or a Pharmaceutically acceptable salt thereof.Another embodiment of the present invention is a method of treating AIDScomprising administering to a host or patient an effective amount of acompound of formula (1) or a pharmaceutically acceptable salt thereof. Afurther embodiment of the present invention is a method of inhibitingHIV protease comprising administering to an HIV infected cell or a hostor patient, such as a primate, infected with HIV, an effective amount ofa compound of formula (1) or a pharmaceutically acceptable salt thereof.

The term "effective amount" means an amount of a compound of formula (1)or its pharmaceutically acceptable salt that is effective to inhibit theHIV protease mediated viral component production and assembly. Thespecific dose of compound administered according to this invention toobtain therapeutic or inhibitory effects will, of course, be determinedby the particular circumstances surrounding the case, including, forexample, the compound administered, the route of administration, thecondition being treated and the individual host or patient beingtreated. An exemplary daily dose (administered in single or divideddoses) contains a dosage level of from about 0.01 mg/kg to about 50mg/kg of body weight of a compound of this invention. Preferred dailydoses generally are from about 0.05 mg/kg to about 20 mg/kg and, morepreferably, from about 0.1 mg/kg to about 10 mg/kg.

The compounds of the invention may be administered by a variety ofroutes, including oral, rectal, transdermal, subcutaneous, intravenous,intramuscular and intranasal routes. The compounds of the presentinvention are preferably formulated prior to administration. Therefore,another embodiment of the present invention is a pharmaceuticalcomposition or formulation comprising an effective amount of a compoundof formula (1) or a pharmaceutically acceptable salt thereof and apharmaceutically acceptable carrier, such as a diluent or excipienttherefor.

The active ingredient preferably comprises from 0.1§ to 99.9% by weightof the formulation. By "pharmaceutically accertable" is meant that thecarrier, such as the diluent or excipient, is compatible with the otheringredients of the formulation and not deleterious to the host orpatient.

Pharmaceutical formulations may be prepared from the compounds of theinvention by known procedures using known and readily availableingredients. In making the compositions of the present invention, theactive ingredient will usually be admixed with a carrier, or diluted bya carrier, or enclosed within a carrier, which may be in the form of acapsule, sachet, paper or other suitable container. When the carrierserves as a diluent, it may be a solid, semi-solid or liquid materialwhich acts as a vehicle, excipient or medium for the active ingredient.Thus, the compositions can be in the form of tablets, pills, powders,lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions,syrups, aerosols (as a solid or in a liquid medium), ointments(containing, for example, up to 10% by weight of the active compound),soft and hard gelatin capsules, suppositories, sterile injectablesolutions, sterile packaged powders and the like.

The following formulation examples are illustrative only and are notintended to limit the scope of the invention. The term "activeingredient" represents a compound of formula (1) or a pharmaceuticallyacceptable salt thereof.

Formulation 1

Hard gelatin capsules are prepared using the following ingredients:

    ______________________________________                                                            Quantity                                                                      (mg/capsule)                                              ______________________________________                                        Active ingredient     250                                                     Starch, dried         200                                                     Magnesium stearate    10                                                      Total                 460    mg                                               ______________________________________                                    

Formulation 2

A tablet is prepared using the ingredients below:

    ______________________________________                                                             Quantity                                                                      (mg/capsule)                                             ______________________________________                                        Active ingredient      250                                                    Cellulose, microcrystalline                                                                          400                                                    Silicon dioxide, fumed 10                                                     Stearic acid           5                                                      Total                  665    mg                                              ______________________________________                                    

The components are blended and compressed to form tablets each weighing665 mg.

Formulation 3

An aerosol solution is prepared containing the following components:

    ______________________________________                                                        Weight                                                        ______________________________________                                        Active ingredient 0.25                                                        Methanol          25.75                                                       Propellant 22     74.00                                                       (Chlorodifluoromethane)                                                       Total             100.00                                                      ______________________________________                                    

The active compound is mixed with ethanol and the mixture added to aportion of the propellant 22, cooled to -30° C. and transferred to afilling device. The required amount is then fed to a stainless steelcontainer and diluted with the remainder of the propellant. The valveunits are then fitted to the container.

Formulation 4

Tablets, each containing 60 mg of active ingredient, are made asfollows:

    ______________________________________                                                         Quantity                                                                      (mg/tablet)                                                  ______________________________________                                        Active ingredient  60                                                         Starch             45                                                         Microcrystalline cellulose                                                                       35                                                         Polyvinylpyrrolidone                                                          (as 10% solution in water)                                                                       4                                                          Sodium carboxymethyl starch                                                                      4.5                                                        Magnesium stearate 0.5                                                        Talc               1                                                          Total              150                                                        ______________________________________                                    

The active ingredient, starch and cellulose are passed through a No. 45mesh U.S. sieve and mixed thoroughly. The aqueous solution containingpolyvinylpyrrolidone is mixed with the resultant powder, and the mixturethen is passed through a No. 14 mesh U.S. sieve. The granules soproduced are dried at 50° C. and passed through a No. 18 mesh U.S.sieve. The sodium carboxymethyl starch, magnesium stearate and talc,previously passed through a No. 60 mesh U.S. sieve, are then added tothe granules which after mixing, are compressed on a tablet machine toyield tablets each weighing 150 mg.

Formulation 5

Capsules, each containing 80 mg of active ingredient, are made asfollows:

    ______________________________________                                                        Quantity                                                                      (mg/capsule)                                                  ______________________________________                                        Active ingredient 60 mg                                                       Starch            59 mg                                                       Microcrystalline cellulose                                                                      59 mg                                                       Magnesium stearate                                                                               2 mg                                                       Total             200 mg                                                      ______________________________________                                    

The active ingredient, cellulose, starch and magnesium stearate areblended, passed through a No. 45 mesh U.S. sieve, and filled into hardgelatin capsules in 200 mg quantities.

Formulation 6

Suppositories, each containing 225 mg of active ingredient, are made asfollows:

    ______________________________________                                        Active ingredient    225 mg                                                   Saturated fatty acid glycerides                                                                  2,000 mg                                                   Total              2,225 mg                                                   ______________________________________                                    

The active ingredient is passed through a No. 60 mesh U.S. sieve andsuspended in the saturated fatty acid glycerides previously melted usingthe minimum heat necessary. The mixture is then poured into asuppository mold of nominal 2 g capacity and allowed to cool.

Formulation 7

Suspensions, each containing 50 mg of active ingredient per 5 ml dose,are made as follows:

    ______________________________________                                        Active ingredient      50     mg                                              Sodium carboxymethyl cellulose                                                                       50     mg                                              Syrup                  1.25   ml                                              Benzoic acid solution  0.10   ml                                              Flavor                 q.v.                                                   Color                  q.v.                                                   Purified water to total                                                                              5      ml                                              ______________________________________                                    

The active ingredient is passed through a No. 45 mesh U.S. sieve andmixed with the sodium carboxymethylcellulose and syrup to form a smoothpaste. The benzoic acid solution, flavor and color are diluted with aportion of the water and added, with stirring. Sufficient water is thenadded to produce the required volume.

Formulation 8

An intravenous formulation is prepared as follows:

    ______________________________________                                        Active ingredient                                                                               100 mg                                                      Isotonic saline 1,000 mL                                                      ______________________________________                                    

The solution of the above ingredients generally is administeredintravenously to a subject at a rate of 1 ml per minute.

ACTIVITY SCREENING

A number of tests were used to test the biological activity of HIVprotease inhibitory compounds. For example, tests were used to analyzeproteolytic inhibition rates and antiviral effects on HIV-infected celllines. The procedures for these experiments are described below. Theresults from these assays are summarized in Table 1 below or aresummarized in the examples above.

I. Primary Drug Screening of Anti-HIV Compounds at Southern ResearchInstitute (SRI) (Results recorded in Table 1 are designated "SRI CEM(ng/ml)" or "SRI MT2 (ng/ml)")

A. Principle of MTT Assay:

SRI has an established program for the primary antiviral analysis ofcompounds in microtiter assays which measures the ability of a selectedcompound to inhibit HIV-induced cell killing. This assay involves theconversion of the tetrazolium dye MTT to a colored formazan product bymitochondrial enzymes 4. metabolically active cells. This assay systemis used at SRI to screen over 30,000 compounds per year. Briefly, theassay involves the infection of CEM or MT2 cells in round bottom 96-wellplates. The compound of interest is added just prior to infection.Following 6 days of incubation at 37° C. the plates are stained withMTT. The results of the assay are quantitated spectrophotometrically ona Molecular Devices Vmax plate reader. The data are analyzed by linearregression utilizing an in-house software program to calculate antiviralactivity (IC₂₅, IC₅₀, IC₉₅) and toxicity (TC₂₅, TC₅₀, TC₉₅) as well asother values.

Primary antiviral assays are routinely performed in CEM or MT-2 cells.SRI has found that all active compounds have been identified in CEMcells, while experiments performed in the MT-2 cell line miss a smallproportion of the active compounds.

B. Standard Screening Assays in CEM and MT-2 Cells

1. Compound dilution and delivery to the plates

Drugs are solubilized in the appropriate vehicle such as distilled wateror DMSO if necessary. Latex gloves, lab coats and masks are used duringall phases of the handling process to prevent exposure to potentiallyharmful agents. The drug prepared at the appropriate concentration andstored at -200° C. until used by the screening laboratory. The firstdilution of each compound is made in a dilution tube with medium toyield a concentration two-fold that of the highest test concentration.Sterile titer tubes are then used to make serial one half-log dilutionsof each compound. Following drug dilution, the diluted compound is addedco the appropriate well of a 96-well microtiter plate. Up to 12dilutions can be assayed conveniently in triplicate on a single platewith all appropriate controls including cell control, virus control,toxicity control, drug color control, medium control and plastic(background) control. When testing includes only six dilutions, twodrugs can be assayed on a single microtiter plate. The drugs are addedto the plate in a final volume of 100 microliters.

2. Cells and virus

During the time the drug dilutions are prepared, cells are washed andcounted. Viability is monitored by trypan blue dye exclusion and assaysare not performed if the viability falls below 90%. Cells are maintainedin an exponential growth phase and are split 1:2 on the day prior toassay to assure exponential growth rate.

For the primary screen, the cell lines utilized are CEM and MT-2. Unlessotherwise indicated, the medium used is RPMI 1640 with 10%heat-inactivated fetal calf serum (FBS), glutamine and antibiotics.

Cells are propagated at 37° C. in an atmosphere of 5% CO₂ n air. Thevirus employed for this work is HIV-1 isolates IIIB and/or RF, which areprepared by an acute infection process.

Briefly, virus-infected cells are pelleted on a daily basis beginning atthree days post-infection until the virus has killed all of the cells inthe culture. Reverse transcriptase activity and p24 ELISA are used toidentify pools with the greatest amount of virus.

These 24-hour harvests are pooled, filtered and frozen at -90° C. Priorto use in the assay, the infectious pool of virus is titered on allavailable cell lines in order to determine the amount of virus requiredin the antiviral assay.

In general, pools produced by the acute infection method require theaddition of one microliter of infectious virus per well resulting in thescreening of drugs at a multiplicity of infection of 0.01. In thismanner, enough virus is prepared and frozen to complete over onethousand microtiter plates, allowing the testing of up to two thousandcompounds from a single stock of infectious virus. The use of a singlestock of virus for a long period of testing has very favorable effectson the repeatability of the assay systems.

Virus infection of the CEM and MT-2 cells for the antiviral assay iscarried out in a bulk infection process. The appropriate number of cellsrequired to complete the assay is mixed with infectious virus in aconical centrifuge tube in a small total volume of 1-2 milliliters.

Following a 4-hour incubation the infected cells are brought to theappropriate final concentration of 5×10⁴ cells per milliliter with freshtissue culture medium and 100 microliters are added to the appropriateexperimental and virus control wells. Uninfected cells at the sameconcentration are plated for the toxicity controls and for the cellcontrols. Assays can also be performed using an in-well infectionmethod. In this case, drug, cells and virus are added to the wellindividually. In each case the MOI is adjusted to give complete cellkilling in the virus control wells by Day 6.

3. Evaluation of CPE-inhibition

Following the addition of cells and drugs to the microtiter plate, theplate is incubated for 6 days at 37° C. Experience has determined thatincubation for longer periods of time (7-8 days) or the use of higherinput cell numbers (1×10⁴) results in significant decreases in cellcontrol viability and a narrowing in the differential in optical densitybetween cell and virus controls upon staining with MTT.

The method of evaluating the antiviral assay involves the addition of 20microliters of the tetrazolium salt MTT at 5mg/ml to each well of theplate for 4-8 hours. After this incubation period, the cells aredisrupted by the addition of 50 microliters of 20% SDS in 0.01N HCL.

The metabolic activity of the viable cells in the culture result in acolored reaction product which is measured spectropotometrically in aMolecular Devices Vmax plate reader at 570 nm. The optical density(O.D.) value is a function of the amount of formazan product which isproportional to the number of viable cells.

The plate reader is on line to the screening laboratory microcomputerwhich evaluates the plate data and calculates place data. The platereport provides a rundown of all pertinent information including the rawO.D. values, the calculated mean O.D.'s and the percent reduction inviral CPE as well as calculations including TC₅₀, IC₅₀ and antiviral andspecificity indices. Finally, the results include a plot which visuallydepicts the effect of the compound on uninfected cells (toxicity) andthe protective or nonprotective effect of the compound on the infectedcells.

II. Whole Cell Screening of Anti-HIV Compounds at Eli Lilly (ResultsRecorded in Table 1 Are Designated "Whole Cell IC₅₀ nM" or "Whole CellIC₉₀ nM"

A. Purpose and Materials

Purpose: To determine IC₅₀ and CC₅₀ for compounds:

Reagents and Materials

Media A

Media A 1% DMSO! (100 microliters DMSO +9.9 ml media A)

SN 123 used to infect cells (15 ml for 6 plates) (10 ml for 4 plates)

CEM cells @ 1×10⁴ ! cells/ml (4 plate=40 ml) (6 plate=60 ml)

DMSO (need 5 ml)

35B at 10 mM! (need 70 microliters of each)

A-D at 10 mM! in 100% DMSO

4 or 6 u-bottom 96-well plates

4 flat bottom 96-well plates for dilutions

8-10 boxes of sterile costar tips

Approximately 10 reagent trays

Costar 12-pette

Relevant formation:

1000 cells/well=1×10⁴ cells/ml=1000 cells/100 microliters

200 microliters=total volume in a well

Final concentration of DMSO=0.25%

Final dilution of Sn123=1:64

Serially diluted compounds 35B, A-D, 1:3

B. Procedure

1. Cell Preparation and Plating of Cells, Media A Media A (1% DMSO)

Number a 96-well tissue culture plate for each compound tested, one fora control plate, and one for control compound.

    ______________________________________                                        Plate #          Description                                                  ______________________________________                                        1                Controls Neg. and Pos.                                       2                35B                                                          3                A                                                            4                B                                                            5                C                                                            6                D                                                            ______________________________________                                    

Count cells on hemacytometer and resuspend them in 40 ml or 80 ml ofMedia A at a concentration of 1×10⁴ !cells/ml.

Counting Cells on a Hemacytomer:

Label two 1.8 ml nunc tubes 1 and 2.

Put 0.5 ml of well mixed CEM cells (in growth phase) in tube 1.

Put 50 micoliters PBS and 40 microliters of trypan blue into tube 2.

Mix up the cells in tube 1 then remove 10 microliters of cells and putthem into tube 2.

Mix well in tube 2, then remove 10 microliters of the stained cells andput them on the hemacytometer.

Count the number of cells in the center square of the hemacytometer withthe microscope set on 10×.

The concentration of the stock CEM's in cells/ml is as follows:

Cells counted×1×10⁵ =Conentration of CEM's in cells/ml!.

c. Add 200 microliters Media A to: Al of plates 2-6. These are Blanks.A4-H4 of plate 1. These are Blanks.

d. Add 5 microliters Media A to all wells of Rows A-D of plates 2-6except Al (the top half of each plate).

e. Add 50 microliters of Media A to wells Al-D3 of Plate 1 (the top halfof the plate).

f. Add 50 microliters Media A 1% DMSO! to all wells of Columns 1-3 ofplate 1.

g. Add 100 microliters of 1×10⁴ ! cells/ml to all wells of Columns 1-3of plate 1 and to all wells (except A1 which is the blank) of the otherplates. This puts 1000 cells/well.

h. Put plates in an incubator while doing drug dilutions.

2. Preparation Control and Test Drugs

(a) Preparation of (35B, A-D) 1:3 serial dilutions in plate with 100%DMSO.

(1) Put 60 microliters of DMSO into all wells of Columns 2-12, Rows A-E.

(2) Put 70 microliters of 35B 10 mM! at 100% DMSO into well A1.

(3) Put 70 microliters of A 10 mM! at 100% DMSO into well B1.

(4) Put 70 microliters of B 10 mM! at 100% DMSO into well C1.

(5) Put 70 microliters of C 10 mM! at 100% DMSO into well D1.

(6) Put 70 microliters of D 10 mM! at 100% DMSO into well E1.

(7) Serially dilute (35B, A-D) 1:3 down through Column 12 bytransferring 30 microliters from Column 1 to Column 2, then from Column2 to Column 3, etc., down through Column 12. Change tips before eachdilution.

Preparation of 1:10 Dilution plate in Media A:

(1) In rows A-E of another plate make a row for the first 1:10 dilutionto correspond to each compound's 100% DMSO row. 35B into Row A for thefirst 1:10 dilution. A into Row B for the first 1:10 dilution. B intoRow C for the first 1:10 dilution. C into Row D for the first 1:10dilution. D into Row E for the first 1:10 dilution.

(2) Put 180 microliters of media A into all wells of rows A-Ecorresponding to the 100% DMSO rows. 2.5 ml needed per row.

3) Remove 20 microliters from all wells of each row of the 100% DMSOrows and transfer it to the corresponding 1:10 row.

C. Preparation of 1:100 Dilution plate in Media A:

1) Make a plate for every 3 compounds to be tested.

2) Put 225 microliters of media A into all wells of rows A, B, D, E, G.and H, leaving rows C and F empty. Use 20 ml of media A per plate.

3) Transfer 25 microliters of each compound from the row in the 1:10dilution to the corresponding two rows on the 1:100 dilution platechanging tips before each transfer.

    ______________________________________                                                     Drug      Drug                                                   Column No.   Conc.  nM!                                                                              Conc.  microliters!                                    ______________________________________                                        1            25000     25.00000                                               2            8333      8.33333                                                3            2778      2.77778                                                4             926      0.92593                                                5             309      0.30864                                                6             103      0.10288                                                7             34       0.03429                                                8             11       0.01143                                                9            3.81      0.00381                                                10           1.27      0.00127                                                11           0.42      0.00042                                                12           0.14      0.00014                                                ______________________________________                                    

3. Addition of Vital SN123 to Plates

a. Thaw Sn123 in 37° C. water bath for approximately 10 minutes.

b. Dilute Sn123 1:16 by adding 1 ml of Sn123 to 15 ml of media A.

c. Add 50 microliters of Sn123 1:16! to wells E1-H12 of plates 2-6 andto wells E1-H3 of plate 1.

4. Addition of Drugs to Plates

a. Add 50 microliters of the control and test drugs from the rows in the1:100 dilution plates to the appropriate rows in the final plates(changing tips before each transfer). One row in the 1:100 plate will do4 rows in the final plate. Leave A1 blank.

b. Incubate all plates 7 days at 37° C. 5% CO₂.

c. Do Xtt protocol on day 7 as follows:

    ______________________________________                                        d.    Preparation of Xtt/PMS Solution:                                                                   (4 plate = 20 ml)                                                             (6 plate = 30 ml)                                  ______________________________________                                    

(1) Recipe for 2 mM PMS: 15.3 mg PMS+0.5 ml PBS=PMS at 100 mM! 100microliters 100 mM! PMS+4.9 ml PBS=PMS at 2 mM!

(2) Heat 500 ml of H₂ O in microwave for 5 minutes on high.

(3) Put 20 or 30 ml of phenol red RPMI in a 50 ml centrifuge tube.

(4) Put the RPMI in the beaker of hot water.

(5) Add 20 or 30 mg of XTT to the warmed up RPMI.

Final concentration of XTT= 1 mg/ml!.

(6) Wait for XTT to dissolve, then add 200 microliters of 2 mM! PMS per10 ml of XTT solution.

e. Addition of Xtt/PMS to plate:

(1) Add 50 microliters of XTT/PMS solution To all wells of all plates.

(2) Cover plates and incubate 4 hours at 37° C. at 5% CO₂.

(3) Remove places from incubator and replace covers with plastic platesealers.

(4) Mix contents of plates.

(5) Read plates at test wavelength 450 nM and reference wavelength 650nM.

III Fluorescence HIV-1 Protease inhibitor Assay To Screen for Inhibitionof HIV Protease (Results Recorded in Table 1 Are Designated "Pandex(ng/ml)")

As used herein, the abbreviations are defined as follows:

SA--bovine serum albumin

BOC--t-butoxycarbonyl

BrZ--2-bromobenzyloxycarbonyl

2-ClZ--2-chlorobenzyloxycarbonyl

DCC--dicyclohexylcarbodiimide

DIEA--diioisopropylethylamine

DTT--dithiothreitol

EDTA--ethylenediaminetetraacetic acid

FITC--fluorescein isothiocarbamyl

HEPES--4- (2-hydroxyethyl)-1-piperazine-ethanesulfonic acid

MES--4 morpholineethanesulfonic acid

PAM--phenylacetimidomethyl

TAPS--3- tris(hydroxymethyl)methyl!amino-1-sulfonic acid

TRIS--tris(hydroxymethyl)aminomethane

TOS--p-toluenesulfonyl (tosyl)

A. Preparation of Protease and Gag Fractions

1. Culture of E. coli K12 L507/pHP10D

Lyophils of E. coli K12 L507/pHP10D were obtained from the NorthernRegional Research Laboratory, Peoria, Ill. 61604, under the accessionnumber NRRL B-18560 (deposited Nov. 14, 1989). The lyophils weredecanted into tubes containing 10 ml LB medium (10 g Bacto-tryptone, 5 gBacto-yeast extract, and 10 g aqueous sodium chloride per liter; the pHwas adjusted to 7.5 and incubated at 32° C. overnight).

A small portion of the overnight culture was placed on LB-agar (LBmedium with 15 g/L Bacto-agar) plates containing 12.5 micrograms/mltetracycline in a manner so as to obtain a single colony isolate of E.coli K12 L507/pHP10D. The single colony obtained was inoculated into 10ml of LB medium containing 12.5 micrograms/ml tetracycline and incubatedovernight at 32° C. with vigorous shaking. The 10 ml overnight culturewas inoculated into LB medium containing 12.5 micrograms/ml tetracyclineand incubated at 32° C. with vigorous shaking until the culture reachedmid-log phase.

2. Culture of E. coli K12 L507/pHGAG

Lyophils of E. coli K12 L507/pHGAG were obtained from the NRRL under theaccession number NRRL B-18561 (deposited Nov. 14, 1989). A purifiedcolony of E. coli K12 L507/pHGAG was isolated, and used as an inoculumfor a culture which was grown to mid-log phase in substantial accordancewith the teaching of Step A, above, for E. Coli K12 L507/pHP10D.

3 Preparation of Protease Fraction

A culture of E. coli K12 L507/pHP10D was grown to mid-log phase at 32°C. in LB media containing 12.5 micrograms/ml tetracycline. Thecultivation temperature was quickly elevated to 40° C. to induce geneexpression, and the cells were allowed to grow for 2.5 hours at thistemperature before the culture was quickly chilled on ice. The cellswere centrifuged and the cell pellet was resuspended in 20 ml of 50 mmolMES buffer (pH 6.0) containing 1 mmol EDTA, 1 mmol DTT, 1 mmol PMSF and10% glycerol ("Buffer A"). Cells were lysed by sonication using aFischer Model 300 Dismembrator and a microtip probe. Followingcentrifugation at 27,000×g, the supernatant was diluted to a totalvolume of 60 ml with Buffer A and loaded onto a 2.0×19 cm QAE-Sepharosecolumn (1 ml/min, 4° C.), that had been equilibrated in Buffer A. Thecolumn was washed isocratically for 180 min and then eluted with agradient eluent of 0-1.0M aqueous sodium chloride in Buffer A over 120min. Enzymatic activity was measured by HPLC using the synthetic peptideSer-Gln-Asn-Tyr-Pro-Ile-Val as described in Margolin et al., Biochem.Biophys. Res. Commun., 167, 554-560 (1990); the production of the pipeptide (Ser-Gln-Asn-Tyr) was measured.

The active fractions were combined, adjusted to pH 1.2M in ammoniumsulfate, and applied to a 2.0×18 cm hexyl agarose column that had beenequilibrated in Buffer A containing 1.2M ammonium sulfate. The samplewas loaded at a flow rate of 1 ml/min at 4° C., washed with theequilibration buffer for 240 min (1 ml/min) and then eluted using areverse linear gradient of 1.2-0M ammonium sulfate in Buffer A for 120min at the same flow rate. The was then washed isocratically in Buffer Afor 120 min.

The active fractions were combined, concentrated to 10 ml using anAmicon stirred cell with a YM-10 membrane and then applied to a MonoScation exchange column (1.0×10 cm) that had been equilibrated in BufferA. The sample was loaded at a flow rate of 1 ml/min at 25° C. Afterwashing isocratically for 30 min, the protease was eluted using a lineargradient of 0-0.45M aqueous sodium chloride in Buffer A over 40 min. Thecolumn was washed isocratically in Buffer A containing 0.45M aqueoussodium chlorine for 30 minutes.

The active fractions were combined and concentrated to 200 microlitersusing an Amicon stirred cell and a YM-10 membrane and then the proteasewas applied to a Superose 6 size exclusion column equilibrated in BufferA containing 0.1M aqueous sodium chloride. The column was washedisocratically in this buffer at a flow rate of 0.5 ml/min, followingwhich the HIV protease was eluted as a single peak.

QAE-Sepharose and hexyl agarose were purchased from Sigma ChemicalCompany. Superose 6 and MonoS were were purchased from Pharmacia.Buffers and reagents were obtained from Sigma.

4. Preparation of Gag Fraction

In an analogous manner, a culture of E. coli K12 507/pHGAG was grown tomid-log phase at 32° C. then shifted to 40° C. for about 4 to 5 hours.The culture was chilled on ice and centrifuged, then the pellet wasresuspended in 8 ml lysis buffer containing 5 mg/ml lysozyme. Lysisbuffer was comprised of 50 mM Tris-HCl (pH 7.8), 5 mM EDTA, 1 mM DTT,100 mM NaCl, 1 microgram/ml 4 and 2 micrograms/ml aprotinin. The culturewas incubated about 30 to 60 minutes at 4° C., then briefly sonicated ina Branson™ Cell Disrupter at 60% power for three 20 second bursts withchilling between each burst. The culture was then centrifuged at15,000×g. The supernatant, which contains the unprocessed gag protein,was partially purified by size exclusion chromatography on a SephadexG-50 column and stored at -20° C. in 50% glycerol and lysis buffer.

B. Preparation of Substrate: N^(a)-Biotin-Gly-Ser-Gln-Asn-Tyr-Pro-Tle-val-Gly-Lys(N^(e) -FITC)--OH(a=Alpha, e=Epsilon)

1. Preparation of the amino-terminal biotinylated peptide

The protected peptide-resin N^(a)-Boc-Gly-Ser-Gln-Asn-Tyr(BrZ)-Pro-Ile-Val-Gly-Lys(2-ClZ)--OCH₂-PAM-resin was synthesized on an Advanced Chemtech Model 200 peptidesynthesizer at 1.5 mmol scale using the standard double-couple protocol.The amino terminal t-Boc group was removed with 50% trifluoroacetic acidin methylene chloride and the resulting resin neutralized with 5%diisopropylethylamine (DIEA) in methylene chloride. Then, 1.1 g (4.5mmol) of biotin in 20 ml of dimethylsulfoxide was added to the peptideresin, followed by 4.5 mmol of dicyclohexylcarbodiimide (DCC) in 9 ml ofmethylene chloride. The resulting reaction mixture was diluted to 40 mltotal volume using 11 ml of methylene chloride, and then allowed toreact for approximately 5 hours. The reaction solution was concentrated,the resin washed sequentially with dimethylsulfoxide, dimethylformamideand methylene chloride and then neutralized with 5% DIEA in methylenechloride. This reaction was repeated twice with the reaction time beingex-ended to 12 hours per reaction. Ninhydrin analysis of the resinindicated complete reaction of the biotin with the glycine amine group.The final peptide resin was washed extensively with dimethylformamideand methylene chloride and dried to provide 4.3 g (98%) yield.

2. Deprotection

The peptide was deprotected and cleaved from the resin using 50 ml of ahydrofluoric acid/m-cresol solution, 0° C., 1 hour. After removal of thehydrofluoric acid by vacuum distillation, the m-cresol was extractedfrom the reaction mixture using 100 ml of diethylether. The peptide wasthen solubilized in 50 aqueous acetic acid, frozen and lyophilized toprovide 2.14 g.

3. Purification

The crude peptide, biotinylated at the amino terminal, was dissolved in200 ml of a 5% acetonitrile in water solution containing 0.1%trifluoroacetic acid and then filtered through a 0.22 micron filter. Theresulting solution was applied to a 2.2×25 cm reverse phase column ofoctadecyl-silica (Vydac C-18) which had been equilibrated with the samebuffer. The peptide was eluted using an 855 minute linear gradient of7.5-25% acetonitrile, at 2 ml/minute, with collection of fractions.These fractions were analyzed using Analytical HPLC was performed on a6×250 mm Vydac C-18 column using similar buffer conditions. Thefractions containing the desired material were combined, frozen andlyophilized to provide 1.206 g (62% yield).

Amino acid analysis of the isolated biotinylated peptide gave thefollowing ratios in agreement with theoretical: Asn 1.1; Ser 0.96; Gln1.1; Pro 1.1; Gly 2.1; Val 0.80; lie 0.78; Tyr 1.1; Lys 1.1. Fast-atombombardment mass spectrometry gave a molecular ion mass peak of 1288, inagreement with theoretical.

4. Labeling

The purified biotinylated peptide was then labeled with a fluorescentmarker at the C-terminal end for use in the Pandex assay. First, thebiotinylate peptide (1.206 g, 0.936 mmol) was dissolved on a 100 ml of0.1M sodium borate, pH 9.5. Then, a solution of 3 g (7.7 mmol) offluorescein isothiocyanate in 15 ml of dimethylsulfoxide was added to2the reaction mixture in 10 equal portions over two hours. The resultingmixture was allowed to react for one hour after the final addition. Thesolution was adjusted to pH 3 using 5N hydrochloric acid, resulting inthe formation of a precipitate which was removed by centrifugation.

The peptide solution was then adjusted to pH 7.8 using 5N sodiumhydroxide and then diluted to 200 ml by the addition of 0.1M ammoniumacetate, pH 7.5. The resulting solution was then filtered through a 0.22micron filter and loaded onto a 2.2×25 cm column of Vydac C-18 which hadbeen equilibrated with of 5% acetonitrile in 0.1M ammonium acetate (pH7.5). The peptide was eluted from the column using an 855 minute lineargradient of 5-25% acetonitrile, at 2 ml/minute, with collection offractions. Analytical HPLC was used to analyze the fractions. Thefractions containing the desired product were then combined, frozen andlyophilized to provide 190.2 mg (12%).

Amino acid analysis of the purified peptide gave the following inagreement with theory: Asn 1.1; Ser 1.0; Gin 1.1: Pro 1.1; Gly 2.1; Val0.8; Ile 0.8; Tyr 1.1; Lys 1.0. Fast-atom bombardment mass spectrometrygave a molecular ion mass peak of 1678, in agreement with theory.

5. Fluorescence HIV-1 Protease Inhibitor Assay

The following buffers and solutions are used in the Fluorescence HIV-lProtease Inhibitor Assay:

    ______________________________________                                        MES-ALB Buffer: 0.05M 4-morpholine ethane                                                     sulfonic acid, pH 5.5                                                         0.02M NaCl                                                                    0.002M EDTA                                                                   0.001M DTT                                                                    1.0 mg/ml BSA                                                 TBSA Buffer:    0.02M TRIS                                                                    0.15M NaCl                                                                    1.0 mg/ml BSA                                                 Avidin Coated   0.1% solution of Fluoricon                                    Beads Solution: Avidin Assay Particles                                                        (Avidin conjugated to solid                                                   polystyrene beads, 0.6-0.8                                                    microns in diameter in TBSA                                                   Buffer                                                                        Enzyme Solution:                                                              27 IU/ml of purified HIV-1                                                    protease in MES-ALB buffer (1                                                 IU equals the amount of                                                       enzyme required to hydrolyze                                                  1 micromole of substrate per                                                  minute at 37° C.)                                      ______________________________________                                    

To each well of a round bottom, 96-well plate is added 20 microliters ofthe Enzyme Solution followed by 10 microliters of the compound to beevaluated in a 20% aqueous dimethylsulfoxide solution. Purified HIV-1protease was obtained as described above. The resulting solution isincubated for one hour at room temperature and then 20 microliters of asolution containing the substrate, prepared above, in MES-ALB buffer(1.5 microliters/ml) is added to each well. The solutions are thenincubated for 16 hours at room temperature and then each well is dilutedwith 150 microliters of MES-ALB buffer.

To each well of a second round bottom, 96-well Pandex plate is added 25microliters of the Avidin Coated Beads Solution. Then, to each well isadded 25 microliters of the diluted incubation solutions, preparedabove. The solutions are mixed thoroughly and the plates are loaded intoa Pandex® machine, washed, evacuated and read. Sample detection wasperformed by excitation at 485 nm, reading the resulting epifluorescenceat 535 nm.

The IC₅₀ results obtained in the Fluorescence Assay for the compounds ofthe present invention are set forth below in Tables 1, 2, and 3. Allvalues have been normalized to a positive control which is 1S-(1R*, 4R*,5S*)!-N-(1-(2-amino-2-oxoethyl)-2-oxo-3-aza-4-phenylmethyl-5-hydroxy-6-(2-(1-t-butylamino-1-oxomethyl)phenyl)hexyl)-2-quinolinylcarboxamide.

Activity data for exemplary compounds emcompassed by the presentinvention is provided in Tables 1, 2, and 3 below and in the preceedingExamples. Results in Parentheses are for Example 1 of Published EuropeanPatent Application 0 526 009 Al=35B in same assay.

                  TABLE 1                                                         ______________________________________                                        Results in Parentheses are for Example 1 of                                   Published European Patent Application 0 526 009 A1 - 35B                      in same assay                                                                 ______________________________________                                                Whole    Whole    SRI    SRI                                                  cell     cell     CEM    MT2    Pandex                                Example IC.sub.50 nM                                                                           IC.sub.90 nM                                                                           ng/ml  ng/ml  ng/ml                                 ______________________________________                                        12      15                16.5   24.3   9.4.sup.a                                     (69)                            11.4.sup.b                            28      *35.7*   *91.8*                                                               (41.17)  (76.45)                                                       3      96.1     286.3    15.2   21.3   11.6.sup.d                                    (70.0)   (237.3)                                                      22      399.9    798      136     53    70.sup.c                                      (74.8)   (257.8)                                                      21      414.28   886.16   443    427    7.9.sup.e                                     (41.17)  (76.45)                                                      20      186.11   671.15   153    144    85.sup.f                                      (43.96)  (92.17)                                                      37                                      33.sup.g                              ______________________________________                                         .sup.a 35B 3.1 ng/ml; .sup.b 35B 2.7 ng/ml; .sup.c 35B 9.6 ng/ml; .sup.d      35B 0.48 ng/ml; .sup.e 35B 0.7 ng/ml; .sup.f 35B 1.3 ng/ml; .sup.g 35B 1.     ng/ml;                                                                        **tested as the mesylate salt                                            

            Whole    Whole    SRI    SRI                                                  cell     cell     CEM    MT2    Pandex                                Example IC.sub.50 nM                                                                           IC.sub.90 nM                                                                           ng/ml  ng/ml  ng/ml                                 ______________________________________                                        25                        7 211  169    2.0.sup.b                                                                     14.3.sup.d                            26      56       165.7    49.7   49.0   2.0.sup.c                                     (70)     (237.3)                                                      ______________________________________                                         35B 0.63 ng/ml; .sup.d 35B 9.3 ng/ml; .sup.3 35B 0.65 ng/ml              

            Whole    Whole    SRI    SRI                                                  cell     cell     CEM    MT2    Pandex                                Example IC.sub.50 nM                                                                           IC.sub.90 nM                                                                           ng/ml  ng/ml  ng/ml                                 ______________________________________                                        12      15                16.5   24.3   28.sup.d                                      (69)                            11.4.sup.b                            23      2.39     19.0      8.62   6.27  0.2.sup.c                                     (9.93)   (53.5)                 0.16.sup.d                            92      2.01     57.02                  <0.16.sup.f                           24      25                67     41.4   2.8.sup.e                                     (19)              (74.8) 46.4   84%/20.sup.d                          ______________________________________                                         .sup.b 35B 2.7 ng/ml; .sup.c 35B 9.3 ng/ml; .sup.d 35B 0.63 ng/ml; .sup.e     35B 0.48 ng/ml; .sup.f 35B 1.24 ng/ml; .sup.f 35B 1.24 ng/ml             

            Whole    Whole    SRI    SRI                                                  cell     cell     CEM    MT2    Pandex                                Example IC.sub.50 nM                                                                           IC.sub.90 nM                                                                           ng/ml  ng/ml  ng/ml                                 ______________________________________                                        29      1587.6   4455.7                 2.0.sup.a                             23      2.39     19.0      8.62   6.27  0.2.sup.b                                     (9.93)   (53.5)                 0.16.sup.d                            31      430.05   884.09                 3.5.sup.c                             32      539.47   2307.2                 1.5.sup.c                             38                                      35.sup.e                              39                                      8.sup.f                               90                                      27.sup.g                              30      366.63   735.75                 5.0.sup.a                             ______________________________________                                         .sup.a 35B 1.2 ng/ml; .sup.b 35B 2.7 ng/ml; .sup.c 35B 2.9 ng/ml; .sup.d      35B 0.63 ng/ml; .sup.e 35B 2.3 ng/ml; .sup.f 35B 1.5 ng/ml; .sup.g 35B        1.24 ng/ml                                                               

                              SRI    SRI                                                  Whole    Whole    CEM    MT2                                                  cell.sup.i                                                                             cell.sup.i                                                                             IC.sub.50                                                                            IC.sub.50                                                                            Pandex                                Example IC.sub.90 nM                                                                           IC.sub.50 nM                                                                           ng/ml  ng/ml  ng/ml                                 ______________________________________                                        12      47.77    15       16.5   24.3   9.4.sup.a                                     (??)     (69)     11.8   10.0   11.4.sup.b                                    91.80*   35.71*                                                               (76.45)  (41.17)                                                              73.15    22.28                                                                (78.01)  (31.33)                                                       3      286.3    96.1     15.2   21.3   11.6.sup.d                                    (165.7)  (70)     11.3   21.5                                         11               114      420    649    13.7.sup.b                                              (9)     338    387                                          ______________________________________                                         .sup.a 35B 3.1 ng/ml; .sup.b 35B 2.7 ng/ml; .sup.c 35B 0.38 ng/ml; .sup.d     35B 0.48 ng/ml; .sup.e 35B 1.5 ng/ml; .sup.f 35B 1.5 ng/ml; .sup.g 35B 1.     ng/ml; .sup.h 35B 0.65 ng/ml; .sup.i Results in parentheses are for 35B i     same assay; .sup.k 35B 1.4 ng/ml; .sup.l 35B 2.1 ng/ml                        *Tested as mesylate salt                                                 

                              SRI    SRI                                                  Whole    Whole    CEM    MT2                                                  cell.sup.i                                                                             cell.sup.i                                                                             IC.sub.50                                                                            IC.sub.50                                                                            Pandex                                Example IC.sub.90 nM                                                                           IC.sub.50 nM                                                                           ng/ml  ng/ml  ng/ml                                 ______________________________________                                         1                        1000   1310   462.sup.d                                                       1380   1500                                         18               738.75   256    254    9.6.sup.e                                              (70.67)  231    232                                           7               323      617    2330   18.5.sup.c                                             (19)     1330   970    221.sup.d                             14                        2550   1610   48.7.sup.d                                                      1240   1290                                         ______________________________________                                         .sup.a 35B 3.1 ng/ml; .sup.b 35B 2.7 ng/ml; .sup.c 35B 0.38 ng/ml; .sup.d     35B 0.48 ng/ml; .sup.e 35B 1.5 ng/ml; .sup.f 35B 1.5 ng/ml; .sup.g 35B 1.     ng/ml; .sup.h 35B 0.65 ng/ml; Results in parentheses are for 35B in same      assay; .sup.k 35B 1.4 ng/ml; .sup.l 35B 2.1 ng/ml                             *Tested as mesylate salt                                                 

                              SRI    SRI                                                  Whole    Whole    CEM    MT2                                                  cell     cell     IC.sub.50                                                                            IC.sub.50                                                                            Pandex                                Example IC.sub.90 nM                                                                           IC.sub.50 nM                                                                           ng/ml  ng/ml  ng/ml                                 ______________________________________                                         5                        4970   7800   1000.sup.c                                                      4430   5030                                         17                        2900   8990   346.sup.b                                                       2500   5390                                          9                                      52.7.sup.a                             8                                      5.80.sup.a                            ______________________________________                                         .sup.a 35B 3.1 ng/ml; .sup.b 35B 2.7 ng/ml; .sup.c 35B 0.38 ng/ml; .sup.d     35B 0.48 ng/ml; .sup.e 35B 1.5 ng/ml; .sup.f 35B 1.5 ng/ml; .sup.g 35B 1.     ng/ml; .sup.h 35B 0.65 ng/ml; .sup.i Results in parentheses are for 35B i     same assay; .sup.k 35B 1.4 ng/ml; .sup.l 35B 2.1 ng/ml                        *Tested as mesylate salt                                                 

                              SRI    SRI                                                  Whole    Whole    CEM    MT2                                                  cell.sup.i                                                                             cell.sup.i                                                                             IC.sub.50                                                                            IC.sub.50                                                                            Pandex                                Example IC.sub.90 nM                                                                           IC.sub.50 nM                                                                           ng/ml  ng/ml  ng/ml                                 ______________________________________                                        16                                      125.sup.c                             15                        1430   1680   181.sup.d                                                       1590   1470                                         36                        2430   1870   93.sup.e                                                        1730   2300                                         82                                      158.sup.f                             ______________________________________                                         .sup.a 35B 3.1 ng/ml; .sup.b 35B 2.7 ng/ml; .sup.c 35B 0.38 ng/ml; .sup.d     35B 0.48 ng/ml; .sup.e 35B 1.5 ng/ml; .sup.f 35B 1.5 ng/ml; .sup.g 35B 1.     ng/ml; .sup.h 35B 0.65 ng/ml; .sup.i Results in parentheses are for 35B i     same assay; .sup.k 35B 1.4 ng/ml; .sup.l 35B 2.1 ng/ml                        *Tested as mesylate salt                                                 

                              SRI    SRI                                                  Whole    Whole    CEM    MT2                                                  cell.sup.i                                                                             cell.sup.i                                                                             IC.sub.50                                                                            IC.sub.50                                                                            Pandex                                Example IC.sub.90 nM                                                                           IC.sub.50 nM                                                                           ng/ml  ng/ml  ng/ml                                 ______________________________________                                        80      27.94    8.99                   0.3%                                                                          at 20.sup.k                                                                   4.sup.1                               78      66.48    8.64     2040   1640   1993.sup.g                                    (73.81)  (19.96)  34.1   80.0                                                                   45.8   80.0                                          2                        1380   1580   520.sup.d                                                       1580   1630                                         ______________________________________                                         .sup.a 35B 3.1 ng/ml; .sup.b 35B 2.7 ng/ml; .sup.c 35B 0.38 ng/ml; .sup.d     35B 0.48 ng/ml; .sup.e 35B 1.5 ng/ml .sup.f 35B 1.5 ng/ml; .sup.g 35B 1.2     ng/ml; .sup.h 35B 0.65 ng/ml; .sup.i Results in parentheses are for 35B i     same assay; .sup.k 35B 1.4 ng/ml; .sup.i 35B 2.1 ng/ml                        *Tested as mesylate salt                                                 

                              SRI    SRI                                                  Whole    Whole    CEM    MT2                                                  cell.sup.i                                                                             cell.sup.i                                                                             IC.sub.50                                                                            IC.sub.50                                                                            Pandex                                Example IC.sub.50 nM                                                                           IC.sub.90 nM                                                                           ng/ml  ng/ml  ng/ml                                 ______________________________________                                        19      16.10    41.96                  0.42.sup.a                                    (52.77)  (101.17)                                                     33      39.54    200.15                 2.sup.b                                       (22.02)  (80.07)                                                      34      149.05   564.04                 5.4.sup.b                                     (22.80)  (80.07)                                                      35                        501    519    73.sup.c                                                        156    368                                          ______________________________________                                         .sup.a 35B 1.5 ng/ml; .sup.b 35B 1.2 ng/ml; .sup.c 35B 2.3 ng/ml; .sup.d      35B 1.9 ng/ml; .sup.e Results in parentheses are for 35B in same assay        *Tested as the mesylate salt                                             

Table 2

Example 74 I

IC₅₀ =0.3 nM (Pandex)

IC₅₀ =4.06 nM (Whole Cell)

IC₉₀ =9.74 nM (Whole Cell)

Example 75

IC₅₀ =14.5 nM (Whole Cell)

IC₉₀ =56.1 nM (Whole Cell)

                  TABLE 3                                                         ______________________________________                                        Inhibitory Activity                                                                               Fluorescence                                                                  Assay IC.sub.50                                           Example No.         in ng/mL                                                  ______________________________________                                        Control             1.0                                                        1                  962                                                        2                  1083                                                       3                  24.2                                                       4                  1425*                                                      5                  2631*                                                      6                  513*                                                       7                  255*                                                       8                  16.4                                                       9                  17                                                        10                  N.T.                                                      11                  5.1                                                       12                  8.3*                                                      13                  346                                                       14                  101                                                       15                  377                                                       16                  329                                                       17                  269*                                                      18                  67.2*                                                     19                  0.32                                                      20                  6.5                                                       21                  9.4                                                       22                  0.73                                                      23                  0.25                                                      24                  5.8                                                       25                  3.2                                                       26                  3.1                                                       27                  N.T.                                                      28                  N.T.                                                      29                  1.7                                                       30                  4.2                                                       31                  1.2                                                       32                  0.52                                                      33                  1.7                                                       34                  4.5                                                       35                  31.7                                                      36                  62                                                        37                  27.5                                                      38                  15.2                                                      39                  5.3                                                       40                  10                                                        41                  6                                                         42                  106                                                       43                  540                                                       44                  70                                                        45                  133                                                       46                  63                                                        47                  91                                                        48                  177                                                       49                  86                                                        50                  120                                                       51                  500                                                       52                  281                                                       53                  55                                                        54                  77                                                        55                  112                                                       56                  94                                                        57                  800                                                       58                  180                                                       59                  350                                                       60                  400                                                       61                  1600                                                      62                  198                                                       63                  250                                                       64                  113                                                       65                  390                                                       66                  274                                                       67                  543.1                                                     68                  10000                                                     69                  IC.sub.35 (15000)**                                       70                  105                                                       71                  180                                                       72                  630                                                       73                  1940                                                      ______________________________________                                         N.T. No tested.                                                               *A calculated average.                                                        **The concentration of the inhibitor was not increased above 15 μg/mL.

Exemplary structures of compounds encompassed by the present inventionare shown in Table 4 below.

                  TABLE 4                                                         ______________________________________                                         ##STR82##                                                                     ##STR83##                                                                     ##STR84##                                                                     ##STR85##                                                                     ##STR86##                                                                     ##STR87##                                                                     ##STR88##                                                                     ##STR89##                                                                     ##STR90##                                                                     ##STR91##                                                                     ##STR92##                                                                     ##STR93##                                                                     ##STR94##                                                                     ##STR95##                                                                     ##STR96##                                                                     ##STR97##                                                                     ##STR98##                                                                     ##STR99##                                                                     ##STR100##                                                                    ##STR101##                                                                    ##STR102##                                                                    ##STR103##                                                                    ##STR104##                                                                    ##STR105##                                                                    ##STR106##                                                                    ##STR107##                                                                    ##STR108##                                                                    ##STR109##                                                                    ##STR110##                                                                    ##STR111##                                                                    ##STR112##                                                                    ##STR113##                                                                    ##STR114##                                                                    ##STR115##                                                                    ##STR116##                                                                    ##STR117##                                                                    ##STR118##                                                                    ##STR119##                                                                    ##STR120##                                                                    ##STR121##                                                                    ##STR122##                                                                    ##STR123##                                                                    ##STR124##                                                                    ##STR125##                                                                    ##STR126##                                                                    ##STR127##                                                                    ##STR128##                                                                    ##STR129##                                                                    ##STR130##                                                                    ##STR131##                                                                   ______________________________________                                    

We claim:
 1. A compound of the formula: ##STR132## wherein: Q₁ and Q₂are each independently selected from hydrogen and substituted andunsubstituted alkyl and aryl;Q₃ is selected from mercapto andsubstituted and unsubstituted alkoxyl, aryloxyl, thioether, amino,alkyl, cycloalkyl, saturated and partially saturated heterocycle, andaryl; Q₄, Q₅, Q₆, Q₇, and Q₈ are each independently selected fromhydrogen, hydroxyl, mercapto, nitro, halogen, --O--J, where J is asubstituted or unsubstituted hydrolyzable group, and substituted andunsubstituted alkoxyl, aryloxyl, thioether, sulfinyl, sulfonyl, amino,alkyl, cycloalkyl, saturated and partially saturated heterocycle, aryl,and L₆ C(O)L₄, where L₆ is a single bond, --O or --N, and further whereL₄ is alkyl, hydroxyl, alkoxyl or hydrogen; and further wherein any oneor more of Q₄, Q₅, Q₆, Q₇, and Q₈ may be a member of a spiro ring, andany two of Q₄, Q₅, Q₆, Q₇, and Q₈ may together be members of a ring; Eis carbon or nitrogen; Q₉ is selected from hydrogen, halogen, hydroxyl,mercapto, and substituted and unsubstituted alkoxyl, aryloxyl,thioether, amino, alkyl, and aryl, where Q₉ may form part of a ring;##STR133## is a monocyclic or polycyclic carbocycle or heterocycle,which is optionally further substituted, and when ##STR134## isheterocycle, each heterocyclic ring has one to three heteroatomsindependently selected from nitrogen, oxygen, and sulfur; and ##STR135##is a 6-membered monocyclic carbocycle or heterocycle, which isoptionally further substituted, and when ##STR136## is heterocycle, thering has one to three heteroatoms independently selected from nitrogen,oxygen and sulfur, which is optionally further substituted; wherein atleast one of ##STR137## is a heterocycle; or a prodrug orpharmaceutically acceptable salt of said compound.
 2. A compound,prodrug, or pharmaceutically acceptable salt according to claim 1,wherein E is carbon.
 3. A compound, prodrug, or pharmaceuticallyacceptable salt according to claim 1, wherein Q₃ is substituted orunsubstituted aryl or thioether.
 4. A compound, prodrug, orpharmaceutically acceptable salt according to claim 3, wherein E iscarbon.
 5. A compound, prodrug, or pharmaceutically acceptable saltaccording to claim 1, wherein Q₁ is hydrogen and Q₂ is substituted orunsubstituted alkyl.
 6. A compound, prodrug, or pharmaceuticallyacceptable salt according to claim 1, wherein ##STR138## is phenyl.
 7. Apharmaceutical composition comprising:(a) an active ingredient thatis:(i) a compound of the formula: ##STR139## wherein: Q₁ and Q₂ are eachindependently selected from hydrogen and substituted and unsubstitutedalkyl and aryl;Q₃ is selected from mercapto and substituted andunsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl, cycloalkyl,saturated and partially saturated heterocycle, and aryl; Q₄, Q₅, Q₆, Q₇,and Q8 are each independently selected from hydrogen, hydroxyl,mercapto, nitro, halogen, --O--J, where J is a substituted orunsubstituted hydrolyzable group, and substituted and unsubstitutedalkoxyl, aryloxyl, thioether, sulfinyl, sulfonyl, amino, alkyl,cycloalkyl, saturated and partially saturated heterocycle, aryl, and L₆C(O)L₄, where L₆ is a single bond, --O or --N, and further where L₄ isalkyl, hydroxyl, alkoxyl or hydrogen; and further wherein any one ormore of Q₄, Q₅, Q₆, Q₇, and Q₈ may be a member of a Spiro ring, and anytwo of Q₄, Q₅, Q₆, Q₇, and Q₈ may together be members of a ring; E iscarbon or nitrogen; Q₉ is selected from hydrogen, halogen, hydroxyl,mercapto, and substituted and unsubstituted alkoxyl, aryloxyl,thioether, amino, alkyl, and aryl, where Q₉ may form part of a ring;##STR140## is a monocyclic or polycyclic carbocycle or heterocycle,which is optionally further substituted, and when ##STR141## isheterocycle, each heterocyclic ring has one to three heteroatomsindependently selected from nitrogen, oxygen, and sulfur; and ##STR142##is a 6-membered monocyclic carbocycle or heterocycle, which isoptionally further substituted, and when ##STR143## is heterocycle, thering has one to three heteroatoms independently selected from nitrogen,oxygen and sulfur, which is optionally further substituted; wherein atleast one of ##STR144## is a heterocycle; or (ii) a prodrug orpharmaceutically acceptable salt of said compound; and (b) apharmaceutically acceptable carrier.
 8. A pharmaceutical compositionaccording to claim 7, wherein E is carbon.
 9. A pharmaceuticalcomposition according to claim 7, wherein Q₃ is substituted orunsubstituted aryl or thioether.
 10. A pharmaceutical compositionaccording to claim 9, wherein E is carbon.
 11. A pharmaceuticalcomposition according to claim 7, wherein Q₁ is hydrogen and Q₂ issubstituted or unsubstituted alkyl.
 12. A pharmaceutical compositionaccording to claim 7, wherein ##STR145## is phenyl.
 13. A method ofinhibiting HIV protease, comprising administering to a host an effectiveamount of:a compound of the formula: ##STR146## wherein: Q₁ and Q₂ areeach independently selected from hydrogen and substituted andunsubstituted alkyl and aryl; Q₃ is selected from mercapto andsubstituted and unsubstituted alkoxyl, aryloxyl, thioether, amino,alkyl, cycloalkyl, saturated and partially saturated heterocycle, andaryl; Q₄, Q₅, Q₆, Q₇, and Q₈ are each independently selected fromhydrogen, hydroxyl, mercapto, nitro, halogen, --O--J, where J is asubstituted or unsubstituted hydrolyzable group, and substituted andunsubstituted alkoxyl, aryloxyl, thioether, sulfinyl, sulfonyl, amino,alkyl, cycloalkyl, saturated and partially saturated heterocycle, aryl,and L₆ C(O)L₄, where L₆ is a single bond, --O or --N, and further whereL₄ is alkyl, hydroxyl, alkoxyl or hydrogen; and further wherein any oneor more of Q₄, Q₅, Q₆, Q₇, and Q₈ may be a member of a spiro ring, andany two of Q₄, Q₅, Q₆, Q₇, and Q₈ may together be members of a ring; Eis carbon or nitrogen; Q₉ is selected from hydrogen, halogen, hydroxyl,mercapto, and substituted and unsubstituted alkoxyl, aryloxyl,thioether, amino, alkyl, and aryl, where Q₉ may form part of a ring;##STR147## is a monocyclic or polycyclic carbocycle or heterocycle,which is optionally further substituted, and when ##STR148## isheterocycle, each heterocyclic ring has one to three heteroatomsindependently selected from nitrogen, oxygen, and sulfur; and ##STR149##is a 6-membered monocyclic carbocycle or heterocycle, which isoptionally further substituted, and when ##STR150## is heterocycle, thering has one to three heteroatoms independently selected from nitrogen,oxygen and sulfur, which is optionally further substituted; wherein atleast one of ##STR151## is a heterocycle; or a prodrug orpharmaceutically acceptable salt of said compound.
 14. A methodaccording to claim 13, wherein E is carbon.
 15. A method according toclaim 13, wherein Q₃ is substituted or unsubstituted aryl or thioether.16. A method according to claim 15, wherein E is carbon.
 17. A methodaccording to claim 13, wherein Q₁ is hydrogen and Q₂ is substituted orunsubstituted alkyl.
 18. A method according to claim 13, wherein##STR152## is phenyl.